PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
20530751-4	2010	CFTR blockade gave an ~50% reduction in lipoxin A(4) (LXA(4)) formation during PLT/polymorphonuclear leukocytes (PMN) coincubations by inhibiting the lipoxin synthase activity of PLT 12-lipoxygenase.	lipoxin A4	40-52	CF transmembrane conductance regulator	Homo sapiens	0-4
20530751-4	2010	CFTR blockade gave an ~50% reduction in lipoxin A(4) (LXA(4)) formation during PLT/polymorphonuclear leukocytes (PMN) coincubations by inhibiting the lipoxin synthase activity of PLT 12-lipoxygenase.	lipoxin A4	54-60	CF transmembrane conductance regulator	Homo sapiens	0-4
19675173-2	2009	Leukocyte-type 12/15-lipoxygenase (12/15-LO) represents a major enzyme involved in the generation of a subclass of eicosanoids, including the anti-inflammatory lipoxin A(4) (LXA(4)).	lipoxin A4	160-169	arachidonate 15-lipoxygenase	Mus musculus	15-33
20094061-0	2010	Lipoxin A4 impairment of apoptotic signaling in macrophages: implication of the PI3K/Akt and the ERK/Nrf-2 defense pathways.	lipoxin A4	0-10	AKT serine/threonine kinase 1	Homo sapiens	85-88
20094061-0	2010	Lipoxin A4 impairment of apoptotic signaling in macrophages: implication of the PI3K/Akt and the ERK/Nrf-2 defense pathways.	lipoxin A4	0-10	mitogen-activated protein kinase 1	Homo sapiens	97-100
20094061-0	2010	Lipoxin A4 impairment of apoptotic signaling in macrophages: implication of the PI3K/Akt and the ERK/Nrf-2 defense pathways.	lipoxin A4	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	101-106
20094061-4	2010	Our data show that pretreatment of human or murine macrophages with LXA(4) at the concentrations prevailing in the course of resolution of inflammation (nanomolar range) significantly inhibits the apoptosis induced by staurosporine, etoposide and S-nitrosoglutathione or by more pathophysiological stimuli, such as LPS/IFNgamma challenge.	lipoxin A4	68-74	interferon gamma	Mus musculus	319-327
20979801-10	2010	CONCLUSION: The reversed changes of 15-lipoxygenase product LXA4 and 5-lipoxygenase product LTC4 in children with asthma of mild, moderate and severe degree suggests that insufficiency of LXA4, an physiological antagonist to leukotrienes, and an overproduction of LTC4, may be involved in the pathogenesis of worsening of asthma in children.	lipoxin A4	60-64	arachidonate 15-lipoxygenase	Homo sapiens	36-51
20979801-10	2010	CONCLUSION: The reversed changes of 15-lipoxygenase product LXA4 and 5-lipoxygenase product LTC4 in children with asthma of mild, moderate and severe degree suggests that insufficiency of LXA4, an physiological antagonist to leukotrienes, and an overproduction of LTC4, may be involved in the pathogenesis of worsening of asthma in children.	lipoxin A4	60-64	arachidonate 5-lipoxygenase	Homo sapiens	37-51
19846590-0	2010	Lipoxin A(4) reduces lipopolysaccharide-induced inflammation in macrophages and intestinal epithelial cells through inhibition of nuclear factor-kappaB activation.	lipoxin A4	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	130-151
20714129-1	2010	BACKGROUND: Previous studies showed that connective tissue growth factor (CTGF)-induced proliferation of lung fibroblasts and production of chemokines in mesangial cells could be inhibited by lipoxin A(4) (LXA(4)).	lipoxin A4	192-201	cellular communication network factor 2	Homo sapiens	41-72
20714129-1	2010	BACKGROUND: Previous studies showed that connective tissue growth factor (CTGF)-induced proliferation of lung fibroblasts and production of chemokines in mesangial cells could be inhibited by lipoxin A(4) (LXA(4)).	lipoxin A4	192-201	cellular communication network factor 2	Homo sapiens	74-78
20714129-8	2010	CONCLUSION: LXA(4) inhibits the tubular epithelial to mesenchymal transition, initiated by CTGF but not by TGF-beta(1), via downregulation of ILK, Ras/MEK/ERK1/2 and PI3-K/Akt-dependent signal pathway stimulated by CTGF.	lipoxin A4	12-18	cellular communication network factor 2	Homo sapiens	91-95
20714129-8	2010	CONCLUSION: LXA(4) inhibits the tubular epithelial to mesenchymal transition, initiated by CTGF but not by TGF-beta(1), via downregulation of ILK, Ras/MEK/ERK1/2 and PI3-K/Akt-dependent signal pathway stimulated by CTGF.	lipoxin A4	12-18	integrin linked kinase	Homo sapiens	142-145
20714129-8	2010	CONCLUSION: LXA(4) inhibits the tubular epithelial to mesenchymal transition, initiated by CTGF but not by TGF-beta(1), via downregulation of ILK, Ras/MEK/ERK1/2 and PI3-K/Akt-dependent signal pathway stimulated by CTGF.	lipoxin A4	12-18	mitogen-activated protein kinase kinase 7	Homo sapiens	151-154
20714129-8	2010	CONCLUSION: LXA(4) inhibits the tubular epithelial to mesenchymal transition, initiated by CTGF but not by TGF-beta(1), via downregulation of ILK, Ras/MEK/ERK1/2 and PI3-K/Akt-dependent signal pathway stimulated by CTGF.	lipoxin A4	12-18	mitogen-activated protein kinase 3	Homo sapiens	155-161
20714129-8	2010	CONCLUSION: LXA(4) inhibits the tubular epithelial to mesenchymal transition, initiated by CTGF but not by TGF-beta(1), via downregulation of ILK, Ras/MEK/ERK1/2 and PI3-K/Akt-dependent signal pathway stimulated by CTGF.	lipoxin A4	12-18	AKT serine/threonine kinase 1	Homo sapiens	172-175
20714129-8	2010	CONCLUSION: LXA(4) inhibits the tubular epithelial to mesenchymal transition, initiated by CTGF but not by TGF-beta(1), via downregulation of ILK, Ras/MEK/ERK1/2 and PI3-K/Akt-dependent signal pathway stimulated by CTGF.	lipoxin A4	12-18	cellular communication network factor 2	Homo sapiens	215-219
20860668-0	2010	Lipoxin A(4) attenuates zymosan-induced arthritis by modulating endothelin-1 and its effects.	lipoxin A4	0-9	endothelin 1	Mus musculus	64-76
20107188-6	2010	In vivo, the antimigratory properties of compound 43, lipoxin A(4), annexin A1, and dexamethasone were reduced notably in Fpr2(-/-) mice compared with those in wild-type littermates.	lipoxin A4	54-63	formyl peptide receptor 2	Mus musculus	122-126
20004734-0	2010	A synthetic analog of 15-epi-lipoxin A4 inhibits human monocyte apoptosis: involvement of ERK-2 and PI3-kinase.	lipoxin A4	22-39	mitogen-activated protein kinase 1	Homo sapiens	90-95
19751275-1	2009	The eicosanoid lipoxin A(4) (LXA(4)) is a potent anti-inflammatory mediator in many in vivo experimental models, and it has been proposed that the effects of this molecule are mediated through binding to FPR2 (also termed FPRL1 or ALXR), a member of the formyl peptide receptor family.	lipoxin A4	15-24	formyl peptide receptor 2	Homo sapiens	204-208
19751275-1	2009	The eicosanoid lipoxin A(4) (LXA(4)) is a potent anti-inflammatory mediator in many in vivo experimental models, and it has been proposed that the effects of this molecule are mediated through binding to FPR2 (also termed FPRL1 or ALXR), a member of the formyl peptide receptor family.	lipoxin A4	15-24	formyl peptide receptor 2	Homo sapiens	222-227
19751275-1	2009	The eicosanoid lipoxin A(4) (LXA(4)) is a potent anti-inflammatory mediator in many in vivo experimental models, and it has been proposed that the effects of this molecule are mediated through binding to FPR2 (also termed FPRL1 or ALXR), a member of the formyl peptide receptor family.	lipoxin A4	15-24	formyl peptide receptor 2	Homo sapiens	231-235
19751275-1	2009	The eicosanoid lipoxin A(4) (LXA(4)) is a potent anti-inflammatory mediator in many in vivo experimental models, and it has been proposed that the effects of this molecule are mediated through binding to FPR2 (also termed FPRL1 or ALXR), a member of the formyl peptide receptor family.	lipoxin A4	29-35	formyl peptide receptor 2	Homo sapiens	204-208
19751275-1	2009	The eicosanoid lipoxin A(4) (LXA(4)) is a potent anti-inflammatory mediator in many in vivo experimental models, and it has been proposed that the effects of this molecule are mediated through binding to FPR2 (also termed FPRL1 or ALXR), a member of the formyl peptide receptor family.	lipoxin A4	29-35	formyl peptide receptor 2	Homo sapiens	222-227
19751275-1	2009	The eicosanoid lipoxin A(4) (LXA(4)) is a potent anti-inflammatory mediator in many in vivo experimental models, and it has been proposed that the effects of this molecule are mediated through binding to FPR2 (also termed FPRL1 or ALXR), a member of the formyl peptide receptor family.	lipoxin A4	29-35	formyl peptide receptor 2	Homo sapiens	231-235
19456898-3	2009	Recently, it was reported that LXA(4) repressed the expression and activity of cyclooxygenase-2 (COX-2), which is essential for invasion.	lipoxin A4	31-37	prostaglandin-endoperoxide synthase 2	Homo sapiens	79-95
19456898-3	2009	Recently, it was reported that LXA(4) repressed the expression and activity of cyclooxygenase-2 (COX-2), which is essential for invasion.	lipoxin A4	31-37	prostaglandin-endoperoxide synthase 2	Homo sapiens	97-102
19357230-0	2009	Lipoxin A4 inhibits IL-1beta-induced IL-8 and ICAM-1 expression in 1321N1 human astrocytoma cells.	lipoxin A4	0-10	interleukin 1 beta	Homo sapiens	20-28
19483113-0	2009	15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury.	lipoxin A4	0-17	myeloperoxidase	Homo sapiens	27-42
19498085-7	2009	Surprisingly, the endogenous anti-inflammatory peptide annexin 1 and its N-terminal fragments also bind human FPR1 and FPR2/ALX, and the anti-inflammatory eicosanoid lipoxin A4 is an agonist at FPR2/ALX.	lipoxin A4	166-176	annexin A1	Homo sapiens	55-64
19498085-7	2009	Surprisingly, the endogenous anti-inflammatory peptide annexin 1 and its N-terminal fragments also bind human FPR1 and FPR2/ALX, and the anti-inflammatory eicosanoid lipoxin A4 is an agonist at FPR2/ALX.	lipoxin A4	166-176	formyl peptide receptor 2	Homo sapiens	194-198
19498085-7	2009	Surprisingly, the endogenous anti-inflammatory peptide annexin 1 and its N-terminal fragments also bind human FPR1 and FPR2/ALX, and the anti-inflammatory eicosanoid lipoxin A4 is an agonist at FPR2/ALX.	lipoxin A4	166-176	hematopoietic SH2 domain containing	Homo sapiens	199-202
19124557-1	2009	Ajulemic acid (AjA), a synthetic nonpsychoactive cannabinoid, and lipoxin A(4) (LXA(4)), an eicosanoid formed from sequential actions of 5- and 15-lipoxygenases (LOX), facilitate resolution of inflammation.	lipoxin A4	66-75	arachidonate 5-lipoxygenase	Homo sapiens	137-160
19357230-0	2009	Lipoxin A4 inhibits IL-1beta-induced IL-8 and ICAM-1 expression in 1321N1 human astrocytoma cells.	lipoxin A4	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	37-41
19357230-0	2009	Lipoxin A4 inhibits IL-1beta-induced IL-8 and ICAM-1 expression in 1321N1 human astrocytoma cells.	lipoxin A4	0-10	intercellular adhesion molecule 1	Homo sapiens	46-52
19357230-8	2009	Furthermore, LXA(4) (10 nM) decreased the expression of IL-1beta-induced IL-8 protein levels (P < 0.05).	lipoxin A4	13-19	interleukin 1 beta	Homo sapiens	56-64
19357230-8	2009	Furthermore, LXA(4) (10 nM) decreased the expression of IL-1beta-induced IL-8 protein levels (P < 0.05).	lipoxin A4	13-19	C-X-C motif chemokine ligand 8	Homo sapiens	73-77
19321784-0	2009	Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke.	lipoxin A4	13-23	arachidonate 5-lipoxygenase	Rattus norvegicus	27-41
19570467-10	2009	(3) The level of vWF: The expression of vWF was decreased with the increasing concentrations of LXA(4) added into culture medium, the gray values were 203.9 +/- 0.7 in 1 nmol/L, 204.6 +/- 0.9 in 10 nmol/L, 191.8 +/- 0.5 in 100 nmol/L respectively, which reached statistical difference in comparison with that of hypoxia groups (P < 0.05).	lipoxin A4	96-102	von Willebrand factor	Homo sapiens	17-20
19570467-10	2009	(3) The level of vWF: The expression of vWF was decreased with the increasing concentrations of LXA(4) added into culture medium, the gray values were 203.9 +/- 0.7 in 1 nmol/L, 204.6 +/- 0.9 in 10 nmol/L, 191.8 +/- 0.5 in 100 nmol/L respectively, which reached statistical difference in comparison with that of hypoxia groups (P < 0.05).	lipoxin A4	96-102	von Willebrand factor	Homo sapiens	40-43
19570467-12	2009	CONCLUSIONS: LXA(4) plays an important role in keeping the normal shape of HUVEC under hypoxia, can enhance survival of hypoxial HUVEC and decrease the level of vWF in cytoplasm.	lipoxin A4	13-19	von Willebrand factor	Homo sapiens	161-164
19321784-0	2009	Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke.	lipoxin A4	13-23	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	51-60
19095947-1	2009	Anti-inflammatory effects of the 15-lipoxygenase (15-LO) derivatives lipoxin A(4) (LXA(4)) and 15-S-hydroxyeicosatetraenoic acid (15-S-HETE) have been documented in many experimental models of acute inflammation.	lipoxin A4	69-78	arachidonate 15-lipoxygenase	Homo sapiens	33-48
18849442-5	2009	LXA(4) (100 nM) stimulated the daily increase of the 16HBE14o- cell monolayer TER, and this effect was inhibited by boc-2 (LXA(4) receptor antagonist).	lipoxin A4	0-6	formyl peptide receptor 2	Homo sapiens	123-138
19095947-1	2009	Anti-inflammatory effects of the 15-lipoxygenase (15-LO) derivatives lipoxin A(4) (LXA(4)) and 15-S-hydroxyeicosatetraenoic acid (15-S-HETE) have been documented in many experimental models of acute inflammation.	lipoxin A4	69-78	arachidonate 15-lipoxygenase	Homo sapiens	50-55
18777114-6	2008	CONCLUSIONS: LXA(4) inhibits synthesis of IL-1beta, IL-6 and IL-8 in PMVEC and this antagonism is related to PI3-K, p38 and p42/44 MAPK, NF-kappaB and AP-1 pathway-dependent signal transduction.	lipoxin A4	13-19	interleukin 1 beta	Rattus norvegicus	42-50
19050289-0	2008	Lipoxin A4 counterregulates GM-CSF signaling in eosinophilic granulocytes.	lipoxin A4	0-10	colony stimulating factor 2	Homo sapiens	28-34
18802107-8	2008	Interestingly, treatment with an ALX/FPRL-1 agonist, 15-epi-lipoxin A4 reversed the enhanced sensitivity of AnxA1 (-/-) mice to DSS colitis.	lipoxin A4	53-70	formyl peptide receptor 3	Mus musculus	33-36
18802107-8	2008	Interestingly, treatment with an ALX/FPRL-1 agonist, 15-epi-lipoxin A4 reversed the enhanced sensitivity of AnxA1 (-/-) mice to DSS colitis.	lipoxin A4	53-70	formyl peptide receptor 3	Mus musculus	37-43
18802107-8	2008	Interestingly, treatment with an ALX/FPRL-1 agonist, 15-epi-lipoxin A4 reversed the enhanced sensitivity of AnxA1 (-/-) mice to DSS colitis.	lipoxin A4	53-70	annexin A1	Mus musculus	108-113
18535486-8	2008	Moreover, whereas treatment of adult neutrophils with lipoxin A4 increased PPAR-gamma expression, no effects were observed in neonatal cells.	lipoxin A4	54-64	peroxisome proliferator activated receptor gamma	Homo sapiens	75-85
18535486-9	2008	5- and 15-lipoxygenase, enzymes required for the synthesis of lipoxin A4, were also reduced in neonatal neutrophils.	lipoxin A4	62-72	arachidonate 5-lipoxygenase	Homo sapiens	0-22
18535486-10	2008	These findings suggest that the anti-inflammatory activity of lipoxin A4 is impaired in neonatal neutrophils and that this is due, in part, to reduced PPAR-gamma signaling.	lipoxin A4	62-72	peroxisome proliferator activated receptor gamma	Homo sapiens	151-161
19844131-3	2009	It was found that both types of gastroprotection were antagonized by the lipoxygenase inhibitors and the lipoxin A(4)/annexin-1 antagonist in doses that have no direct damaging effect on gastric mucosa.	lipoxin A4	105-114	annexin A1	Rattus norvegicus	118-127
18559988-7	2008	Results from these indicate that 12/15-lipoxygenase expression protects mice against atherosclerosis via its role in the local biosynthesis of lipid mediators, including lipoxin A(4), resolvin D1, and protectin D1.	lipoxin A4	170-179	arachidonate 15-lipoxygenase	Mus musculus	33-51
18777114-6	2008	CONCLUSIONS: LXA(4) inhibits synthesis of IL-1beta, IL-6 and IL-8 in PMVEC and this antagonism is related to PI3-K, p38 and p42/44 MAPK, NF-kappaB and AP-1 pathway-dependent signal transduction.	lipoxin A4	13-19	interleukin 6	Rattus norvegicus	52-56
18777114-6	2008	CONCLUSIONS: LXA(4) inhibits synthesis of IL-1beta, IL-6 and IL-8 in PMVEC and this antagonism is related to PI3-K, p38 and p42/44 MAPK, NF-kappaB and AP-1 pathway-dependent signal transduction.	lipoxin A4	13-19	mitogen activated protein kinase 14	Rattus norvegicus	116-119
18777114-6	2008	CONCLUSIONS: LXA(4) inhibits synthesis of IL-1beta, IL-6 and IL-8 in PMVEC and this antagonism is related to PI3-K, p38 and p42/44 MAPK, NF-kappaB and AP-1 pathway-dependent signal transduction.	lipoxin A4	13-19	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	151-155
17625069-4	2007	A 15-epi-LXA4 analog (ATLa) and a 3-oxa-15-epi-LXA4 analog (ZK-994) prevented excessive eosinophil and T lymphocyte accumulation and activation after mice were sensitized and aerosol-challenged with ovalbumin.	lipoxin A4	2-13	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	199-208
18056401-0	2007	The required role of endogenously produced lipoxin A4 and annexin-1 for the production of IL-10 and inflammatory hyporesponsiveness in mice.	lipoxin A4	43-53	interleukin 10	Mus musculus	90-95
18056401-4	2007	In this study, we investigated the role of lipoxin A4 and annexin-1 for the IL-10-dependent inflammatory hyporesponsiveness observed in germfree mice.	lipoxin A4	43-53	interleukin 10	Mus musculus	76-81
18056401-5	2007	Administration of a 15-epi-lipoxin A4 analog or an annexin-1-derived peptide to conventional mice prevented tissue injury, TNF-alpha production, and lethality after intestinal ischemia/reperfusion.	lipoxin A4	20-37	tumor necrosis factor	Mus musculus	123-132
18056401-9	2007	Blockade of lipoxin A4 synthesis with a 5-lipoxygenase inhibitor or Abs against annexin-1 partially prevented IL-10 production and this was accompanied by partial reversion of inflammatory hyporesponsiveness in germfree mice.	lipoxin A4	12-22	arachidonate 5-lipoxygenase	Mus musculus	40-54
18056401-9	2007	Blockade of lipoxin A4 synthesis with a 5-lipoxygenase inhibitor or Abs against annexin-1 partially prevented IL-10 production and this was accompanied by partial reversion of inflammatory hyporesponsiveness in germfree mice.	lipoxin A4	12-22	interleukin 10	Mus musculus	110-115
18714024-0	2008	Phosphorylation of 5-lipoxygenase at ser523 by protein kinase A determines whether pioglitazone and atorvastatin induce proinflammatory leukotriene B4 or anti-inflammatory 15-epi-lipoxin a4 production.	lipoxin A4	172-189	arachidonate 5-lipoxygenase	Rattus norvegicus	19-33
18714024-0	2008	Phosphorylation of 5-lipoxygenase at ser523 by protein kinase A determines whether pioglitazone and atorvastatin induce proinflammatory leukotriene B4 or anti-inflammatory 15-epi-lipoxin a4 production.	lipoxin A4	172-189	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	47-63
18193074-0	2008	ATL-1, an analogue of aspirin-triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor.	lipoxin A4	40-50	atlastin GTPase 1	Homo sapiens	0-5
18193074-0	2008	ATL-1, an analogue of aspirin-triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor.	lipoxin A4	40-50	vascular endothelial growth factor A	Homo sapiens	118-152
18193074-2	2008	We have demonstrated that ATL-1, a synthetic analogue of aspirin-triggered lipoxin A(4), inhibits VEGF-induced endothelial cell (EC) migration.	lipoxin A4	75-84	atlastin GTPase 1	Homo sapiens	26-31
18193074-2	2008	We have demonstrated that ATL-1, a synthetic analogue of aspirin-triggered lipoxin A(4), inhibits VEGF-induced endothelial cell (EC) migration.	lipoxin A4	75-84	vascular endothelial growth factor A	Homo sapiens	98-102
17384141-5	2007	In vivo deletion of 12/15-LOX correlated with exacerbated inflammation and impaired wound healing in 12/15-LOX(-/-) mice, a phenotype that was rescued by treatment with LXA4.	lipoxin A4	169-173	arachidonate 15-lipoxygenase	Homo sapiens	26-29
17687517-0	2007	Effects of lipoxin A(4) on lipopolysaccharide induced proliferation and reactive oxygen species production in RAW264.7 macrophages through modulation of G-CSF secretion.	lipoxin A4	11-20	colony stimulating factor 3 (granulocyte)	Mus musculus	153-158
17687517-12	2007	CONCLUSIONS: LXA(4) inhibited LPS-induced proliferation and reactive oxygen species production in RAW264.7 macrophages partially through modulation of G-CSF secretion.	lipoxin A4	13-19	colony stimulating factor 3 (granulocyte)	Mus musculus	151-156
17384141-5	2007	In vivo deletion of 12/15-LOX correlated with exacerbated inflammation and impaired wound healing in 12/15-LOX(-/-) mice, a phenotype that was rescued by treatment with LXA4.	lipoxin A4	169-173	arachidonate 15-lipoxygenase	Homo sapiens	107-110
17384141-8	2007	HO-2(-/-) mice, which fail to induce HO-1, also demonstrated exacerbated inflammation in response to injury, a phenotype that, notably, correlated with a 50% reduction in endogenous LXA4 formation.	lipoxin A4	182-186	heme oxygenase 2	Mus musculus	0-4
17624266-10	2007	These alterations of LPS+LXA(4)-treated cells were associated with a marked inhibition of IkappaB degradation, NF-kappaB translocation and then the transcriptional activity of NF-kappaB.	lipoxin A4	25-31	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	111-120
17624266-10	2007	These alterations of LPS+LXA(4)-treated cells were associated with a marked inhibition of IkappaB degradation, NF-kappaB translocation and then the transcriptional activity of NF-kappaB.	lipoxin A4	25-31	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	176-185
17403678-7	2007	We demonstrate that association of the PDGFRbeta with lipid raft microdomains renders it susceptible to LXA(4)-mediated dephosphorylation by possible reactivation of oxidatively inactivated SHP-2.	lipoxin A4	104-110	platelet derived growth factor receptor beta	Homo sapiens	39-48
17403678-7	2007	We demonstrate that association of the PDGFRbeta with lipid raft microdomains renders it susceptible to LXA(4)-mediated dephosphorylation by possible reactivation of oxidatively inactivated SHP-2.	lipoxin A4	104-110	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	190-195
17397313-10	2007	LXA(4) levels were significantly higher in PRP compared to WB.	lipoxin A4	0-6	complement component 4 binding protein alpha	Homo sapiens	43-46
17218541-7	2007	However, lipoxin A4 (LXA4, 0.02-2 microM, a lipid mediator with high affinity for Fpr-rs1) mimicked the inhibitory effects of ANXA1 on ACTH release as also did fMLF in high (1-100 microM) but not lower (10-100 nM) concentrations.	lipoxin A4	21-25	formyl peptide receptor 3	Mus musculus	82-89
17218541-7	2007	However, lipoxin A4 (LXA4, 0.02-2 microM, a lipid mediator with high affinity for Fpr-rs1) mimicked the inhibitory effects of ANXA1 on ACTH release as also did fMLF in high (1-100 microM) but not lower (10-100 nM) concentrations.	lipoxin A4	21-25	annexin A1	Mus musculus	126-131
17218541-7	2007	However, lipoxin A4 (LXA4, 0.02-2 microM, a lipid mediator with high affinity for Fpr-rs1) mimicked the inhibitory effects of ANXA1 on ACTH release as also did fMLF in high (1-100 microM) but not lower (10-100 nM) concentrations.	lipoxin A4	21-25	pro-opiomelanocortin-alpha	Mus musculus	135-139
17329090-1	2007	Studies have shown that lipoxin A(4) (LXA(4)) inhibited proliferation of mesangial cells in vitro induced by platelet-derived growth factor, epidermal growth factor, leukotriene D(4) or tumor necrosis factor-alpha.	lipoxin A4	24-33	tumor necrosis factor	Rattus norvegicus	166-213
17242094-0	2007	Posttreatment with aspirin-triggered lipoxin A4 analog attenuates lipopolysaccharide-induced acute lung injury in mice: the role of heme oxygenase-1.	lipoxin A4	37-47	heme oxygenase 1	Mus musculus	132-148
17130543-4	2006	Deficient LXA4 production is not due to deficient lipoxygenase (LO) activity, but is related to increased soluble epoxide hydrolase (sEH), involved in metabolism of anti-inflammatory epoxyeicosatrienoic acids (EET).	lipoxin A4	10-14	epoxide hydrolase 2, cytoplasmic	Mus musculus	106-131
17218541-7	2007	However, lipoxin A4 (LXA4, 0.02-2 microM, a lipid mediator with high affinity for Fpr-rs1) mimicked the inhibitory effects of ANXA1 on ACTH release as also did fMLF in high (1-100 microM) but not lower (10-100 nM) concentrations.	lipoxin A4	9-19	formyl peptide receptor 3	Mus musculus	82-89
17218541-7	2007	However, lipoxin A4 (LXA4, 0.02-2 microM, a lipid mediator with high affinity for Fpr-rs1) mimicked the inhibitory effects of ANXA1 on ACTH release as also did fMLF in high (1-100 microM) but not lower (10-100 nM) concentrations.	lipoxin A4	9-19	annexin A1	Mus musculus	126-131
17218541-7	2007	However, lipoxin A4 (LXA4, 0.02-2 microM, a lipid mediator with high affinity for Fpr-rs1) mimicked the inhibitory effects of ANXA1 on ACTH release as also did fMLF in high (1-100 microM) but not lower (10-100 nM) concentrations.	lipoxin A4	9-19	pro-opiomelanocortin-alpha	Mus musculus	135-139
17200775-4	2007	In this study, we have examined whether an aspirin-triggered lipoxin A (4) analog (ATL-1) modulates ROS generation in endothelial cells (EC).	lipoxin A4	61-70	atlastin GTPase 1	Homo sapiens	83-88
17130543-4	2006	Deficient LXA4 production is not due to deficient lipoxygenase (LO) activity, but is related to increased soluble epoxide hydrolase (sEH), involved in metabolism of anti-inflammatory epoxyeicosatrienoic acids (EET).	lipoxin A4	10-14	epoxide hydrolase 2, cytoplasmic	Mus musculus	133-136
16968948-3	2006	Lipoxin A(4) (LXA(4)), ATL, and their metabolic stable analogs elicit cellular responses and regulate leukocyte trafficking in vivo by activating the specific receptor, ALX.	lipoxin A4	0-9	hematopoietic SH2 domain containing	Homo sapiens	169-172
16968948-6	2006	Although LXA(4) is the endogenous potent ligand for ALX activation, a number of peptides can also activate this receptor to stimulate calcium mobilization and chemotaxis in vitro.	lipoxin A4	9-15	hematopoietic SH2 domain containing	Homo sapiens	52-55
16613568-1	2006	Lipoxin A4 (LXA4) and lipoxin B4 (LXB4) were first identified in 1984 by Serhan and colleagues as 5- and 15-lipoxygenase interaction products of activated leukocytes.	lipoxin A4	0-10	arachidonate 5-lipoxygenase	Homo sapiens	98-120
16550298-10	2006	SEB effects on platelet metabolism were investigated using high performance liquid chromatography showing up to a 2-fold increase of active metabolites lipoxin A4 and 12-HETE, as compared to control.	lipoxin A4	152-162	SET binding protein 1	Homo sapiens	0-3
16613568-3	2006	Acetylation of cyclooxygenase-2 (COX-2) by aspirin can trigger 15-epi-LXA4 (ATL) biosynthesis.	lipoxin A4	63-74	prostaglandin-endoperoxide synthase 2	Homo sapiens	15-31
16613568-3	2006	Acetylation of cyclooxygenase-2 (COX-2) by aspirin can trigger 15-epi-LXA4 (ATL) biosynthesis.	lipoxin A4	63-74	prostaglandin-endoperoxide synthase 2	Homo sapiens	33-38
16127149-2	2005	We investigated the potential of LXA(4) (1 to 10 nmol/L) to modify the effects of platelet-derived growth factor (PDGF)-induced gene expression in human renal mesangial cells (hMCs).	lipoxin A4	33-39	Miles-Carpenter X-linked mental retardation syndrome	Homo sapiens	176-180
16424219-0	2006	Lipoxin A4 redistributes myosin IIA and Cdc42 in macrophages: implications for phagocytosis of apoptotic leukocytes.	lipoxin A4	0-10	cell division cycle 42	Homo sapiens	40-45
16424219-6	2006	THP-1 cells treated with LXA4 adopt a polarized morphology with activated Cdc42 localized toward the leading edge and MYH9 localized at the cell posterior.	lipoxin A4	25-29	cell division cycle 42	Homo sapiens	74-79
16424219-6	2006	THP-1 cells treated with LXA4 adopt a polarized morphology with activated Cdc42 localized toward the leading edge and MYH9 localized at the cell posterior.	lipoxin A4	25-29	myosin heavy chain 9	Homo sapiens	118-122
15901601-0	2005	Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells.	lipoxin A4	39-49	heme oxygenase 1	Homo sapiens	58-74
16141446-0	2006	Lipoxin A4 inhibits proliferation of human lung fibroblasts induced by connective tissue growth factor.	lipoxin A4	0-10	cellular communication network factor 2	Homo sapiens	71-102
16408113-0	2006	Lipoxin A4 inhibits connective tissue growth factor-induced production of chemokines in rat mesangial cells.	lipoxin A4	0-10	cellular communication network factor 2	Rattus norvegicus	20-51
16408113-3	2006	The present studies investigate the regulatory role of CTGF in the production of fractalkine, monocyte chemoattractant protein-1 (MCP-1), and RANTES (regulated upon activation, normal T cell expressed and secreted) in cultured mesangial cells of rats, and the modulatory effects of lipoxin A(4) (LXA(4)) on actions of CTGF.	lipoxin A4	282-291	cellular communication network factor 2	Rattus norvegicus	55-59
16024242-2	2005	In recent years, lipoxin A4 and its epimeric counterpart, which is synthesized via aspirin-acetylated cyclooxygenase-2, have been shown to exert very potent protective effects in the stomach.	lipoxin A4	17-27	prostaglandin-endoperoxide synthase 2	Homo sapiens	102-118
15936930-5	2005	Pretreatment of the cells with calcium inhibitor SK&F96365 inhibited the LXA4-induced apoptosis, levels of [Ca2+]i, expression of calpain 10 and Smac.	lipoxin A4	77-81	calpain 10	Rattus norvegicus	134-144
16034127-0	2005	Involvement of the Rho-kinase/myosin light chain kinase pathway on human monocyte chemotaxis induced by ATL-1, an aspirin-triggered lipoxin A4 synthetic analog.	lipoxin A4	132-142	myosin light chain kinase	Homo sapiens	30-55
16034127-0	2005	Involvement of the Rho-kinase/myosin light chain kinase pathway on human monocyte chemotaxis induced by ATL-1, an aspirin-triggered lipoxin A4 synthetic analog.	lipoxin A4	132-142	atlastin GTPase 1	Homo sapiens	104-109
16034127-3	2005	In this study, we have investigated the mechanisms associated with human monocyte activation in response to 15-epi-16-(para-fluoro)-phenoxy-LXA4 (ATL-1), a stable 15-epi-LXA4 analog.	lipoxin A4	163-174	atlastin GTPase 1	Homo sapiens	146-151
15936930-1	2005	Studies have implicated that lipoxinA4 (LXA4) inhibited nuclear factor-kappaB (NF-kappaB), Akt/PKB and PI 3-kinase activity and proliferation of glomerular mesangial cells.	lipoxin A4	29-38	AKT serine/threonine kinase 1	Rattus norvegicus	91-98
15954894-0	2005	Lipoxin A4 inhibits TNF-alpha-induced production of interleukins and proliferation of rat mesangial cells.	lipoxin A4	0-10	tumor necrosis factor	Rattus norvegicus	20-29
15954894-1	2005	BACKGROUND: Studies have shown that lipoxin A(4) (LXA(4)) and its analogues inhibited proliferation of glomerular mesangial cells induced by leukotriene D(4) (LTD(4)) or platelet-derived growth factor (PDGF), reduced the production of proinflammatory cytokines such as interleukin (IL)-1beta and IL-6 in renal tissue of ischemic injury.	lipoxin A4	36-45	myotrophin	Rattus norvegicus	187-200
15954894-1	2005	BACKGROUND: Studies have shown that lipoxin A(4) (LXA(4)) and its analogues inhibited proliferation of glomerular mesangial cells induced by leukotriene D(4) (LTD(4)) or platelet-derived growth factor (PDGF), reduced the production of proinflammatory cytokines such as interleukin (IL)-1beta and IL-6 in renal tissue of ischemic injury.	lipoxin A4	36-45	interleukin 1 beta	Rattus norvegicus	269-291
15954894-1	2005	BACKGROUND: Studies have shown that lipoxin A(4) (LXA(4)) and its analogues inhibited proliferation of glomerular mesangial cells induced by leukotriene D(4) (LTD(4)) or platelet-derived growth factor (PDGF), reduced the production of proinflammatory cytokines such as interleukin (IL)-1beta and IL-6 in renal tissue of ischemic injury.	lipoxin A4	36-45	interleukin 6	Rattus norvegicus	296-300
15954894-12	2005	LXA(4) antagonized the phosphorylation of SHP-2 and activity of NF-kappaB induced by TNF-alpha.	lipoxin A4	0-5	protein tyrosine phosphatase, non-receptor type 11	Rattus norvegicus	42-47
15954894-12	2005	LXA(4) antagonized the phosphorylation of SHP-2 and activity of NF-kappaB induced by TNF-alpha.	lipoxin A4	0-5	tumor necrosis factor	Rattus norvegicus	85-94
15954894-17	2005	TNF-alpha-induced decrement in expression of p27(kip1) protein was ameliorated by LXA(4) in a dose-dependent manner.	lipoxin A4	82-88	tumor necrosis factor	Rattus norvegicus	0-9
15954894-17	2005	TNF-alpha-induced decrement in expression of p27(kip1) protein was ameliorated by LXA(4) in a dose-dependent manner.	lipoxin A4	82-88	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	45-48
15954894-17	2005	TNF-alpha-induced decrement in expression of p27(kip1) protein was ameliorated by LXA(4) in a dose-dependent manner.	lipoxin A4	82-88	cyclin-dependent kinase inhibitor 1B	Rattus norvegicus	49-53
15936930-5	2005	Pretreatment of the cells with calcium inhibitor SK&F96365 inhibited the LXA4-induced apoptosis, levels of [Ca2+]i, expression of calpain 10 and Smac.	lipoxin A4	77-81	diablo, IAP-binding mitochondrial protein	Rattus norvegicus	149-153
15814734-8	2005	COX-2-derived products increased levels of the proresolving lipid mediators lipoxin A4 (LXA4) and, in the presence of aspirin, 15-epi-LXA4.	lipoxin A4	76-86	prostaglandin-endoperoxide synthase 2	Mus musculus	0-5
15708862-3	2005	Lipoxin A(4) (LXA(4)) and docosahexaenoic acid-derived neuroprotectin D1 (NPD1) are lipid autacoids formed by 12/15-lipoxygenase (LOX) pathways that exhibit anti-inflammatory and neuroprotective properties.	lipoxin A4	0-9	arachidonate 15-lipoxygenase	Mus musculus	110-128
15708862-3	2005	Lipoxin A(4) (LXA(4)) and docosahexaenoic acid-derived neuroprotectin D1 (NPD1) are lipid autacoids formed by 12/15-lipoxygenase (LOX) pathways that exhibit anti-inflammatory and neuroprotective properties.	lipoxin A4	0-9	arachidonate 15-lipoxygenase	Mus musculus	130-133
15814734-8	2005	COX-2-derived products increased levels of the proresolving lipid mediators lipoxin A4 (LXA4) and, in the presence of aspirin, 15-epi-LXA4.	lipoxin A4	127-138	prostaglandin-endoperoxide synthase 2	Mus musculus	0-5
15924723-0	2005	[Transfection of Lipoxin A4 receptor-like protein gene enhanced the inhibitory effect of Lipoxin A4 on human lung fibroblasts proliferation induced by connective tissue growth factor].	lipoxin A4	17-27	cellular communication network factor 2	Homo sapiens	151-182
15778399-9	2005	Moreover, aspirin-triggered lipoxin A(4) analog evoked release of the antiphlogistic cytokine TGF-beta.	lipoxin A4	28-37	transforming growth factor, beta 1	Mus musculus	94-102
15924723-5	2005	The purpose of the study was to transfect LRLP gene into human lung fibroblasts and investigate the mechanism of its enhancing antagonistic effect of Lipoxin A(4) on human lung fibroblasts proliferation induced by connective tissue growth factor.	lipoxin A4	150-159	cellular communication network factor 2	Homo sapiens	214-245
15003994-6	2004	However, during resolution there is a switch to a sequential induction of first sPLA2 (types IIa and V) that mediates the release of PAF and lipoxin A4, which, in turn, are responsible for the subsequent induction of type IV cPLA2 that mediates the release of arachidonic acid for the synthesis of proresolving prostaglandins.	lipoxin A4	141-151	phospholipase A2 group IIA	Homo sapiens	80-85
15924723-15	2005	Pretreatment with 10 nm Lipoxin A(4) inhibited the proliferation of HLF and HLF/LRLP.	lipoxin A4	24-33	HLF transcription factor, PAR bZIP family member	Homo sapiens	68-71
15924723-15	2005	Pretreatment with 10 nm Lipoxin A(4) inhibited the proliferation of HLF and HLF/LRLP.	lipoxin A4	24-33	HLF transcription factor, PAR bZIP family member	Homo sapiens	76-79
15924723-17	2005	(3) The flow cytometry analysis showed that compared with HLF, more HLF/LRLP were arrested at G(0)/G(1) phase in the presence of pretreatment of Lipoxin A(4).	lipoxin A4	145-154	HLF transcription factor, PAR bZIP family member	Homo sapiens	58-61
15924723-17	2005	(3) The flow cytometry analysis showed that compared with HLF, more HLF/LRLP were arrested at G(0)/G(1) phase in the presence of pretreatment of Lipoxin A(4).	lipoxin A4	145-154	HLF transcription factor, PAR bZIP family member	Homo sapiens	68-71
15924723-21	2005	(5) Ten nmol/L Lipoxin A(4) antagonized CTGF induced increase of STAT(3) DNA binding activity, and its antagonistic effect on HLF/LRLP was more powerful than that on HLF (P < 0.05).	lipoxin A4	15-24	cellular communication network factor 2	Homo sapiens	40-44
15924723-21	2005	(5) Ten nmol/L Lipoxin A(4) antagonized CTGF induced increase of STAT(3) DNA binding activity, and its antagonistic effect on HLF/LRLP was more powerful than that on HLF (P < 0.05).	lipoxin A4	15-24	signal transducer and activator of transcription 3	Homo sapiens	65-71
15924723-21	2005	(5) Ten nmol/L Lipoxin A(4) antagonized CTGF induced increase of STAT(3) DNA binding activity, and its antagonistic effect on HLF/LRLP was more powerful than that on HLF (P < 0.05).	lipoxin A4	15-24	HLF transcription factor, PAR bZIP family member	Homo sapiens	126-129
15924723-22	2005	CONCLUSIONS: Transfection of Lipoxin A(4) receptor-like protein gene enhanced the inhibitory effect of Lipoxin A(4) on human lung fibroblasts proliferation induced by CTGF.	lipoxin A4	29-38	cellular communication network factor 2	Homo sapiens	167-171
15505205-0	2004	A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction.	lipoxin A4	27-37	amyloid beta (A4) precursor protein	Mus musculus	0-6
15265945-0	2004	A stable aspirin-triggered lipoxin A4 analog blocks phosphorylation of leukocyte-specific protein 1 in human neutrophils.	lipoxin A4	27-37	lymphocyte specific protein 1	Homo sapiens	71-99
15308762-1	2004	Formyl peptide receptor-like 1 (FPRL1) is a G protein-coupled receptor that binds natural and synthetic peptides as well as lipoxin A(4) and mediates important biological functions.	lipoxin A4	124-133	formyl peptide receptor 2	Rattus norvegicus	0-30
15308762-1	2004	Formyl peptide receptor-like 1 (FPRL1) is a G protein-coupled receptor that binds natural and synthetic peptides as well as lipoxin A(4) and mediates important biological functions.	lipoxin A4	124-133	formyl peptide receptor 2	Rattus norvegicus	32-37
15171815-1	2004	Lipoxin A4 (LXA4) is a potent eicosanoid that inhibits IL-1beta-induced activation of human fibroblast like synoviocytes (FLS) via the ALX4 receptor.	lipoxin A4	0-10	interleukin 1 beta	Homo sapiens	55-63
15171815-1	2004	Lipoxin A4 (LXA4) is a potent eicosanoid that inhibits IL-1beta-induced activation of human fibroblast like synoviocytes (FLS) via the ALX4 receptor.	lipoxin A4	12-16	interleukin 1 beta	Homo sapiens	55-63
14982847-6	2004	LXA4 (10 nmol/L) modulates PDGF-induced (10 ng/ml, 24 hours) decrements in the levels of cyclin kinase inhibitors p21Cip1 and p27Kip1.	lipoxin A4	0-4	cyclin dependent kinase inhibitor 1A	Homo sapiens	114-121
14982847-6	2004	LXA4 (10 nmol/L) modulates PDGF-induced (10 ng/ml, 24 hours) decrements in the levels of cyclin kinase inhibitors p21Cip1 and p27Kip1.	lipoxin A4	0-4	cyclin dependent kinase inhibitor 1B	Homo sapiens	126-133
15003994-6	2004	However, during resolution there is a switch to a sequential induction of first sPLA2 (types IIa and V) that mediates the release of PAF and lipoxin A4, which, in turn, are responsible for the subsequent induction of type IV cPLA2 that mediates the release of arachidonic acid for the synthesis of proresolving prostaglandins.	lipoxin A4	141-151	phospholipase A2 group IVA	Homo sapiens	225-230
15061569-10	2004	In agreement with in vitro results, ALX agonists, namely LXA4 and 15-epi-LXA4 and their stable analogs, regulate PMN during acute inflammation.	lipoxin A4	57-61	hematopoietic SH2 domain containing	Homo sapiens	36-39
15061569-10	2004	In agreement with in vitro results, ALX agonists, namely LXA4 and 15-epi-LXA4 and their stable analogs, regulate PMN during acute inflammation.	lipoxin A4	66-77	hematopoietic SH2 domain containing	Homo sapiens	36-39
12709408-2	2003	The acetylated COX-2 remains active, and upon cell activation, initiates the generation of 15R-HETE, a lipid substrate for 5-lipoxygenase (LOX) leading to the formation of 15-epi-LXA4 (also termed "aspirin-triggered lipoxin," or ATL).	lipoxin A4	172-183	arachidonate 5-lipoxygenase	Rattus norvegicus	123-137
12920210-0	2003	Differential signaling of formyl peptide receptor-like 1 by Trp-Lys-Tyr-Met-Val-Met-CONH2 or lipoxin A4 in human neutrophils.	lipoxin A4	93-103	formyl peptide receptor 2	Homo sapiens	26-56
12920210-3	2003	The formyl peptide receptor-like 1 (FPRL1) can be stimulated by two different ligands, Trp-Lys-Tyr-Met-Val-Met-CONH2 (WKYMVM) and lipoxin A4 (LXA4).	lipoxin A4	130-140	formyl peptide receptor 2	Homo sapiens	4-34
12920210-3	2003	The formyl peptide receptor-like 1 (FPRL1) can be stimulated by two different ligands, Trp-Lys-Tyr-Met-Val-Met-CONH2 (WKYMVM) and lipoxin A4 (LXA4).	lipoxin A4	130-140	formyl peptide receptor 2	Homo sapiens	36-41
12709408-2	2003	The acetylated COX-2 remains active, and upon cell activation, initiates the generation of 15R-HETE, a lipid substrate for 5-lipoxygenase (LOX) leading to the formation of 15-epi-LXA4 (also termed "aspirin-triggered lipoxin," or ATL).	lipoxin A4	172-183	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	15-20
12560218-1	2003	Recent investigations conducted with human neutrophils have indicated an involvement for the receptor for formylated peptides, termed FPR, and its analog FPRL1 (or ALXR because it is the receptor for the endogenous ligand lipoxin A(4)) in the in vitro inhibitory actions of the glucocorticoid-regulated protein annexin 1 and its peptidomimetics.	lipoxin A4	222-231	formyl peptide receptor 2	Homo sapiens	154-159
12560218-1	2003	Recent investigations conducted with human neutrophils have indicated an involvement for the receptor for formylated peptides, termed FPR, and its analog FPRL1 (or ALXR because it is the receptor for the endogenous ligand lipoxin A(4)) in the in vitro inhibitory actions of the glucocorticoid-regulated protein annexin 1 and its peptidomimetics.	lipoxin A4	222-231	formyl peptide receptor 2	Homo sapiens	164-168
12560218-1	2003	Recent investigations conducted with human neutrophils have indicated an involvement for the receptor for formylated peptides, termed FPR, and its analog FPRL1 (or ALXR because it is the receptor for the endogenous ligand lipoxin A(4)) in the in vitro inhibitory actions of the glucocorticoid-regulated protein annexin 1 and its peptidomimetics.	lipoxin A4	222-231	annexin A1	Homo sapiens	311-320
12560218-7	2003	Both ALXR agonists, lipoxin A(4) and peptide Ac2-26, provoked detachment of adherent leukocytes in naive as well as in FPR-deficient mice, whereas the CXC chemokine KC or fMLP were inactive.	lipoxin A4	20-29	formyl peptide receptor 2	Homo sapiens	5-9
12709408-2	2003	The acetylated COX-2 remains active, and upon cell activation, initiates the generation of 15R-HETE, a lipid substrate for 5-lipoxygenase (LOX) leading to the formation of 15-epi-LXA4 (also termed "aspirin-triggered lipoxin," or ATL).	lipoxin A4	172-183	arachidonate 5-lipoxygenase	Rattus norvegicus	139-142
12456400-7	2003	Thus LXA(4) generated in or near the paracellular space via neutrophil-epithelial interactions can rapidly act on epithelial LXA(4)R to downregulate epithelial promotion of intestinal inflammation.	lipoxin A4	5-11	formyl peptide receptor 2	Homo sapiens	125-132
12235371-0	2002	Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes.	lipoxin A4	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	120-124
12368230-6	2002	Interestingly, the endogenous antiinflammatory eicosanoids LXA4 and ASA-triggered 15-epi-LXA4, in addition to inhibiting macrophage 5-LO activity to a similar extent as PGE2, significantly reduced PPARalpha and CINC-1 levels in hepatocytes.	lipoxin A4	59-63	peroxisome proliferator activated receptor alpha	Rattus norvegicus	197-206
12368230-6	2002	Interestingly, the endogenous antiinflammatory eicosanoids LXA4 and ASA-triggered 15-epi-LXA4, in addition to inhibiting macrophage 5-LO activity to a similar extent as PGE2, significantly reduced PPARalpha and CINC-1 levels in hepatocytes.	lipoxin A4	59-63	C-X-C motif chemokine ligand 1	Rattus norvegicus	211-217
12368230-6	2002	Interestingly, the endogenous antiinflammatory eicosanoids LXA4 and ASA-triggered 15-epi-LXA4, in addition to inhibiting macrophage 5-LO activity to a similar extent as PGE2, significantly reduced PPARalpha and CINC-1 levels in hepatocytes.	lipoxin A4	82-93	peroxisome proliferator activated receptor alpha	Rattus norvegicus	197-206
12368230-6	2002	Interestingly, the endogenous antiinflammatory eicosanoids LXA4 and ASA-triggered 15-epi-LXA4, in addition to inhibiting macrophage 5-LO activity to a similar extent as PGE2, significantly reduced PPARalpha and CINC-1 levels in hepatocytes.	lipoxin A4	82-93	C-X-C motif chemokine ligand 1	Rattus norvegicus	211-217
12393391-9	2003	Collectively, these results indicate that the cytokine-like property of SAA is manifested through activation of the Gi-coupled FPRL1/LXA4R, which has been known to mediate the anti-inflammatory effects of lipoxin A4.	lipoxin A4	205-215	serum amyloid A1 cluster	Homo sapiens	72-75
12393391-9	2003	Collectively, these results indicate that the cytokine-like property of SAA is manifested through activation of the Gi-coupled FPRL1/LXA4R, which has been known to mediate the anti-inflammatory effects of lipoxin A4.	lipoxin A4	205-215	formyl peptide receptor 2	Homo sapiens	127-132
12393391-9	2003	Collectively, these results indicate that the cytokine-like property of SAA is manifested through activation of the Gi-coupled FPRL1/LXA4R, which has been known to mediate the anti-inflammatory effects of lipoxin A4.	lipoxin A4	205-215	formyl peptide receptor 2	Homo sapiens	133-138
12404234-0	2002	Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage.	lipoxin A4	25-35	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	0-16
12410796-1	2002	Lipoxin A4 (LXA4) has been shown to bind to the leucocyte formyl peptide receptor (FPR) homologue, FPRL1, without triggering the biological activities induced by other FPRL1 agonists.	lipoxin A4	0-10	formyl peptide receptor 2	Homo sapiens	99-104
12410796-1	2002	Lipoxin A4 (LXA4) has been shown to bind to the leucocyte formyl peptide receptor (FPR) homologue, FPRL1, without triggering the biological activities induced by other FPRL1 agonists.	lipoxin A4	0-10	formyl peptide receptor 2	Homo sapiens	168-173
12235371-0	2002	Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes.	lipoxin A4	33-50	C-X-C motif chemokine ligand 8	Homo sapiens	120-124
11688989-4	2001	The recombinant 15-PGDH that acts on both prostaglandin E(2) (PGE(2)) and lipoxin A(4) (LXA(4)) was not significantly inhibited by the NSAIDs tested.	lipoxin A4	74-83	carbonyl reductase 1	Homo sapiens	16-23
12045128-7	2002	Nanomolar concentrations of LXA4 and LXB4 inhibited the IL-8 released by peripheral blood mononuclear cells from the two groups of patients with asthma: a maximal inhibition of 29.4% (p < 0.01) was observed for patients with mild asthma, and 41.5% inhibition (p < 0.001) for patients with severe asthma at 1 nM and 100 nM LXA4 concentrations, respectively.	lipoxin A4	28-32	C-X-C motif chemokine ligand 8	Homo sapiens	56-60
12806051-6	2002	Among eicosanoids, ALXR is stereoselective for LXA4 (5S,6R,15S-trihydroxy-7,9,13- trans-11-cis-eicosatetraenoic acid).	lipoxin A4	47-51	formyl peptide receptor 2	Homo sapiens	19-23
11509622-0	2001	Lipoxin A(4) and aspirin-triggered 15-epi-lipoxin A(4) antagonize TNF-alpha-stimulated neutrophil-enterocyte interactions in vitro and attenuate TNF-alpha-induced chemokine release and colonocyte apoptosis in human intestinal mucosa ex vivo.	lipoxin A4	0-9	tumor necrosis factor	Homo sapiens	66-75
11509622-0	2001	Lipoxin A(4) and aspirin-triggered 15-epi-lipoxin A(4) antagonize TNF-alpha-stimulated neutrophil-enterocyte interactions in vitro and attenuate TNF-alpha-induced chemokine release and colonocyte apoptosis in human intestinal mucosa ex vivo.	lipoxin A4	0-9	tumor necrosis factor	Homo sapiens	145-154
11003574-11	2000	LXA(4)-stimulated TF expression was blunted by pertussis toxin and by GF-109203X, an inhibitor of protein kinase C, and was not associated with degradation of IkappaBalpha.	lipoxin A4	0-6	coagulation factor III, tissue factor	Homo sapiens	18-20
11141472-1	2001	Aspirin-triggered lipoxin A(4) (ATL, 15-epi-LXA(4)) and leukotriene D(4) (LTD(4)) possess opposing vascular actions mediated via receptors distinct from the LXA(4) receptor (ALX) that is involved in leukocyte trafficking.	lipoxin A4	18-27	hematopoietic SH2 domain containing	Homo sapiens	174-177
11185557-3	2000	The microsomes from yeast cells transfected with CYP4F14 expression vector showed 0.1 nmol P450/mg protein and catalyzed omega-hydroxylations of leukotriene B4, 6-trans-leukotriene B4, lipoxin A4, prostaglandin A1, and several hydroxyeicosatetraeonic acids (HETEs), with 8-HETE being the most active substrate.	lipoxin A4	185-195	cytochrome P450, family 4, subfamily f, polypeptide 14	Mus musculus	49-56
10837478-0	2000	Oxidoreductases in lipoxin A4 metabolic inactivation: a novel role for 15-onoprostaglandin 13-reductase/leukotriene B4 12-hydroxydehydrogenase in inflammation.	lipoxin A4	19-29	prostaglandin reductase 1	Homo sapiens	104-142
11003574-0	2000	Influence of lipoxin A(4) and other lipoxygenase-derived eicosanoids on tissue factor expression.	lipoxin A4	13-22	coagulation factor III, tissue factor	Homo sapiens	72-85
11003574-6	2000	LXA(4) stimulated TF activity in each cell type.	lipoxin A4	0-6	coagulation factor III, tissue factor	Homo sapiens	18-20
11003574-7	2000	The influence of LXA(4) on TF activity by ECV304 cells was studied further to explore the mechanism of induction of TF expression.	lipoxin A4	17-23	coagulation factor III, tissue factor	Homo sapiens	27-29
11003574-8	2000	LXA(4)-induced TF activity was dose dependent, cycloheximide sensitive, and associated with increased TF mRNA levels.	lipoxin A4	0-6	coagulation factor III, tissue factor	Homo sapiens	15-17
11003574-8	2000	LXA(4)-induced TF activity was dose dependent, cycloheximide sensitive, and associated with increased TF mRNA levels.	lipoxin A4	0-6	coagulation factor III, tissue factor	Homo sapiens	102-104
11003574-12	2000	Our results establish that LXA(4) induces TF activity via cell signaling pathways with different structural and receptor requirements from those described for inhibition of leukocyte-endothelial cell interactions.	lipoxin A4	27-33	coagulation factor III, tissue factor	Homo sapiens	42-44
10833273-5	2000	The preparation solubilized using n-octyl-beta-D-glucopyranoside from microsomes of CYP 4F2-expressing yeast cells catalyzes v- hydroxylation of LTB(4), 6-trans-LTB(4), lipoxin A(4), 8-hydroxyeicosatetraenoate, 12-hydroxyeicosatetraenoate, and 12-hydroxystearate in the presence of rabbit liver NADPH-P450 reductase.	lipoxin A4	169-178	cytochrome P450 family 4 subfamily F member 2	Homo sapiens	84-91
10872839-1	2000	FPRL1 is a seven-transmembrane (STM), G-protein coupled receptor which was originally identified as a low affinity receptor for the bacterial chemotactic formyl peptide and a high affinity receptor for the lipid metabolite lipoxin A4.	lipoxin A4	223-233	formyl peptide receptor 2	Homo sapiens	0-5
10688842-6	2000	Using transfected HL-60 cells expressing either the FPR or its neutrophil homologue FPRL1, also referred to as LXA(4)R because it has been shown to bind lipoxin A(4), we show that WKYMVm is about 300-fold more active at mobilizing intracellular calcium through FPRL1 than through FPR.	lipoxin A4	153-162	formyl peptide receptor 1	Homo sapiens	52-55
10818443-4	2000	Here, we determined the relationship between polyisoprenyl phosphate (PIPP) remodeling and PLD signaling and their impact in activation of PMN receptors by "pro-inflammatory" (leukotriene B4), and "anti-inflammatory" (aspirin-triggered lipoxinA4) ligands.	lipoxin A4	236-245	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	91-94
10688842-6	2000	Using transfected HL-60 cells expressing either the FPR or its neutrophil homologue FPRL1, also referred to as LXA(4)R because it has been shown to bind lipoxin A(4), we show that WKYMVm is about 300-fold more active at mobilizing intracellular calcium through FPRL1 than through FPR.	lipoxin A4	153-162	formyl peptide receptor 2	Homo sapiens	84-89
10688842-6	2000	Using transfected HL-60 cells expressing either the FPR or its neutrophil homologue FPRL1, also referred to as LXA(4)R because it has been shown to bind lipoxin A(4), we show that WKYMVm is about 300-fold more active at mobilizing intracellular calcium through FPRL1 than through FPR.	lipoxin A4	153-162	formyl peptide receptor 2	Homo sapiens	111-118
10688842-6	2000	Using transfected HL-60 cells expressing either the FPR or its neutrophil homologue FPRL1, also referred to as LXA(4)R because it has been shown to bind lipoxin A(4), we show that WKYMVm is about 300-fold more active at mobilizing intracellular calcium through FPRL1 than through FPR.	lipoxin A4	153-162	formyl peptide receptor 1	Homo sapiens	84-87
10590058-2	1999	Both LXA(4) analogs in nanomolar to micromolar concentrations prevented shedding of L-selectin and downregulated CD11/CD18 expression on resting neutrophils, monocytes, and lymphocytes.	lipoxin A4	5-11	selectin L	Homo sapiens	84-94
10679106-0	2000	Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases.	lipoxin A4	0-10	interleukin 1 beta	Homo sapiens	20-29
10679106-0	2000	Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases.	lipoxin A4	0-10	interleukin 6	Homo sapiens	38-42
10679106-0	2000	Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases.	lipoxin A4	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	44-48
10679106-6	2000	At nanomolar concentrations, LXA4 inhibited these IL-1 beta responses with reduction of IL-6 and IL-8 synthesis, by 45 +/- 7% and 75 +/- 11%, respectively, and prevented IL-1 beta-induced MMP-3 synthesis without significantly affecting MMP-1 levels.	lipoxin A4	29-33	interleukin 1 beta	Homo sapiens	50-59
10679106-6	2000	At nanomolar concentrations, LXA4 inhibited these IL-1 beta responses with reduction of IL-6 and IL-8 synthesis, by 45 +/- 7% and 75 +/- 11%, respectively, and prevented IL-1 beta-induced MMP-3 synthesis without significantly affecting MMP-1 levels.	lipoxin A4	29-33	interleukin 6	Homo sapiens	88-92
10679106-6	2000	At nanomolar concentrations, LXA4 inhibited these IL-1 beta responses with reduction of IL-6 and IL-8 synthesis, by 45 +/- 7% and 75 +/- 11%, respectively, and prevented IL-1 beta-induced MMP-3 synthesis without significantly affecting MMP-1 levels.	lipoxin A4	29-33	C-X-C motif chemokine ligand 8	Homo sapiens	97-101
10679106-6	2000	At nanomolar concentrations, LXA4 inhibited these IL-1 beta responses with reduction of IL-6 and IL-8 synthesis, by 45 +/- 7% and 75 +/- 11%, respectively, and prevented IL-1 beta-induced MMP-3 synthesis without significantly affecting MMP-1 levels.	lipoxin A4	29-33	interleukin 1 beta	Homo sapiens	170-179
10679106-6	2000	At nanomolar concentrations, LXA4 inhibited these IL-1 beta responses with reduction of IL-6 and IL-8 synthesis, by 45 +/- 7% and 75 +/- 11%, respectively, and prevented IL-1 beta-induced MMP-3 synthesis without significantly affecting MMP-1 levels.	lipoxin A4	29-33	matrix metallopeptidase 1	Homo sapiens	236-241
10679106-7	2000	Furthermore, LXA4 induced a 2-fold increase of tissue inhibitor of metalloproteinase (TIMP)-1 and a approximately 3-fold increase of TIMP-2 protein levels.	lipoxin A4	13-17	TIMP metallopeptidase inhibitor 1	Homo sapiens	47-93
10679106-7	2000	Furthermore, LXA4 induced a 2-fold increase of tissue inhibitor of metalloproteinase (TIMP)-1 and a approximately 3-fold increase of TIMP-2 protein levels.	lipoxin A4	13-17	TIMP metallopeptidase inhibitor 2	Homo sapiens	133-139
10590058-2	1999	Both LXA(4) analogs in nanomolar to micromolar concentrations prevented shedding of L-selectin and downregulated CD11/CD18 expression on resting neutrophils, monocytes, and lymphocytes.	lipoxin A4	5-11	lymphotoxin beta receptor	Homo sapiens	118-122
8037356-4	1994	Preincubation of eosinophils with increasing doses of LXA4 (10(-10)-10(-5) M) resulted in a concentration-dependent inhibition of cell migration induced by 10(-6) M formyl-methionyl-leucyl-phenylalanine (FMLP) and 10(-6) M PAF.	lipoxin A4	54-58	formyl peptide receptor 1	Homo sapiens	204-208
10685363-1	1999	The impact of lipoxin A4 (LXA4) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNF alpha)-initiated neutrophil (PMN) responses in vitro and in vivo using LX analogs that are metabolically more stable.	lipoxin A4	14-24	tumor necrosis factor	Homo sapiens	112-121
10377187-1	1999	The impact of lipoxin A4 (LXA4) and aspirin-triggered lipoxins (ATLs) was investigated in tumor necrosis factor (TNF)-alpha-initiated neutrophil (polymorphonuclear leukocyte) responses in vitro and in vivo using metabolically stable LX analogues.	lipoxin A4	14-24	tumor necrosis factor	Homo sapiens	90-123
10229829-8	1999	Although a lipid metabolite, lipoxin A4, was a high-affinity ligand for FPRL1, it was not reported to induce Ca2+ mobilization or chemotaxis in FPRL1-transfected cells.	lipoxin A4	29-39	formyl peptide receptor 2	Homo sapiens	72-77
9892621-20	1999	Here we demonstrate that SAA selectively induced Ca2+ mobilization and migration of HEK cells expressing FPRL1, a human seven-transmembrane domain phagocyte receptor with low affinity for fMLP, and high affinity for lipoxin A4.	lipoxin A4	216-226	serum amyloid A1 cluster	Homo sapiens	25-28
9892621-20	1999	Here we demonstrate that SAA selectively induced Ca2+ mobilization and migration of HEK cells expressing FPRL1, a human seven-transmembrane domain phagocyte receptor with low affinity for fMLP, and high affinity for lipoxin A4.	lipoxin A4	216-226	formyl peptide receptor 2	Homo sapiens	105-110
9729536-8	1998	However, the direct inhibition of 5-lipoxygenase by caffeic acid or lipoxin A4 resulted in a similar concentration-dependent attenuation of oxidase activity in both primed and unprimed cells.	lipoxin A4	68-78	arachidonate 5-lipoxygenase	Homo sapiens	34-48
8768752-6	1996	Lipoxin A4 (LXA4) interferes with binding of LTB4 to T lymphocytes or neutrophils by reducing LTB4 receptor density.	lipoxin A4	0-10	prostaglandin reductase 1	Cavia porcellus	45-49
8768752-6	1996	Lipoxin A4 (LXA4) interferes with binding of LTB4 to T lymphocytes or neutrophils by reducing LTB4 receptor density.	lipoxin A4	0-10	leukotriene B4 receptor 1	Cavia porcellus	94-107
8768752-6	1996	Lipoxin A4 (LXA4) interferes with binding of LTB4 to T lymphocytes or neutrophils by reducing LTB4 receptor density.	lipoxin A4	12-16	prostaglandin reductase 1	Cavia porcellus	45-49
8768752-6	1996	Lipoxin A4 (LXA4) interferes with binding of LTB4 to T lymphocytes or neutrophils by reducing LTB4 receptor density.	lipoxin A4	12-16	leukotriene B4 receptor 1	Cavia porcellus	94-107
8627545-0	1996	Identification and characterization of a high-affinity leukotriene B4 receptor on guinea pig T lymphocytes and its regulation by lipoxin A4.	lipoxin A4	129-139	leukotriene B4 receptor 1	Cavia porcellus	55-78
7572409-1	1995	In Figure 2, a schematic summary of current evidence implicates products of the 15-lipoxygenase pathway of arachidonic acid metabolism, principally 15-(S)-HETE and LXA4, as endogenous antagonists for the proinflammatory actions of leukotrienes.	lipoxin A4	164-168	arachidonate 15-lipoxygenase	Homo sapiens	80-95
7825843-1	1994	Figure 4 is a schematic summary of current evidence implicating products of the 15-lipoxygenase pathway of arachidonic acid metabolism, principally 15-S-HETE and LXA4, as endogenous antagonists for the proinflammatory actions of leukotrienes.	lipoxin A4	162-166	arachidonate 15-lipoxygenase	Homo sapiens	80-95
10360957-0	1999	Lipoxin A4: a new class of ligand for the Ah receptor.	lipoxin A4	0-10	aryl-hydrocarbon receptor	Mus musculus	42-53
10360957-3	1999	We have examined candidate endogenous lipophilic substances and report here the ability of the arachidonic acid metabolite, lipoxin A4, to bind to and activate the Ah receptor in Hepa-1 cells.	lipoxin A4	124-134	aryl-hydrocarbon receptor	Mus musculus	164-175
10360957-7	1999	Results of Ah receptor competitive binding experiments indicated that at a concentration of 100 nM, lipoxin A4 produced a half-maximum displacement (EC50) of [3H]TCDD binding.	lipoxin A4	100-110	aryl-hydrocarbon receptor	Mus musculus	11-22
10360957-8	1999	Results of Northern blot analyses indicated a transient increase in mRNA levels of the Ah receptor-responsive gene CYP1A1, which peaked at 4 h, consistent with the kinetics observed for lipoxin A4-induced CYP1A1 enzyme activity.	lipoxin A4	186-196	aryl-hydrocarbon receptor	Mus musculus	87-98
10360957-8	1999	Results of Northern blot analyses indicated a transient increase in mRNA levels of the Ah receptor-responsive gene CYP1A1, which peaked at 4 h, consistent with the kinetics observed for lipoxin A4-induced CYP1A1 enzyme activity.	lipoxin A4	186-196	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	115-121
10360957-8	1999	Results of Northern blot analyses indicated a transient increase in mRNA levels of the Ah receptor-responsive gene CYP1A1, which peaked at 4 h, consistent with the kinetics observed for lipoxin A4-induced CYP1A1 enzyme activity.	lipoxin A4	186-196	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	205-211
10360957-9	1999	Further, lipoxin A4 was found to be a competitive inhibitor for the CYP1A1 enzyme, with a calculated Ki = 1.1 microM.	lipoxin A4	9-19	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	68-74
10360957-10	1999	These results establish lipoxin A4 as a new class of Ah receptor ligand, one that differs dramatically from classical Ah receptor ligands.	lipoxin A4	24-34	aryl-hydrocarbon receptor	Mus musculus	53-64
10360957-10	1999	These results establish lipoxin A4 as a new class of Ah receptor ligand, one that differs dramatically from classical Ah receptor ligands.	lipoxin A4	24-34	aryl-hydrocarbon receptor	Mus musculus	118-129
9808710-5	1998	Formation of 15-epi-LXA4 was cell ratio-dependent during THP-1 (a monocytic leukemia cell line)-neutrophil interactions with ASA-treated cells, and 15-epi-LXA4 was not detected with either cell type alone.	lipoxin A4	13-24	GLI family zinc finger 2	Homo sapiens	57-62
9275235-0	1997	Lipoxin A4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: role of P-selectin.	lipoxin A4	0-10	selectin P	Rattus norvegicus	114-124
8757340-0	1996	Activation of human monocytes and the acute monocytic leukemia cell line (THP-1) by lipoxins involves unique signaling pathways for lipoxin A4 versus lipoxin B4: evidence for differential Ca2+ mobilization.	lipoxin A4	132-142	GLI family zinc finger 2	Homo sapiens	74-79
8757340-7	1996	LXA4 also induced a rise in [Ca2+]i in the monocytic leukemia cell line (time to reach maximum = 15.1 +/- 0.87 s), and both LXA4 and LXB4 stimulated a concentration-dependent THP-1 cell adherence to laminin with concentrations as low as 10(-10)M. In contrast to the findings with LXA4, exposure of THP-1 or PBM to LXB4 was not accompanied by mobilization of intracellular Ca2+.	lipoxin A4	0-4	GLI family zinc finger 2	Homo sapiens	175-180
8757340-7	1996	LXA4 also induced a rise in [Ca2+]i in the monocytic leukemia cell line (time to reach maximum = 15.1 +/- 0.87 s), and both LXA4 and LXB4 stimulated a concentration-dependent THP-1 cell adherence to laminin with concentrations as low as 10(-10)M. In contrast to the findings with LXA4, exposure of THP-1 or PBM to LXB4 was not accompanied by mobilization of intracellular Ca2+.	lipoxin A4	0-4	GLI family zinc finger 2	Homo sapiens	298-303
8757340-7	1996	LXA4 also induced a rise in [Ca2+]i in the monocytic leukemia cell line (time to reach maximum = 15.1 +/- 0.87 s), and both LXA4 and LXB4 stimulated a concentration-dependent THP-1 cell adherence to laminin with concentrations as low as 10(-10)M. In contrast to the findings with LXA4, exposure of THP-1 or PBM to LXB4 was not accompanied by mobilization of intracellular Ca2+.	lipoxin A4	124-128	GLI family zinc finger 2	Homo sapiens	175-180
8757340-7	1996	LXA4 also induced a rise in [Ca2+]i in the monocytic leukemia cell line (time to reach maximum = 15.1 +/- 0.87 s), and both LXA4 and LXB4 stimulated a concentration-dependent THP-1 cell adherence to laminin with concentrations as low as 10(-10)M. In contrast to the findings with LXA4, exposure of THP-1 or PBM to LXB4 was not accompanied by mobilization of intracellular Ca2+.	lipoxin A4	124-128	GLI family zinc finger 2	Homo sapiens	298-303
8731099-5	1996	Secondly, Lipoxin A4 (LXA4), an eicosanoid which inhibits leukocyte-endothelial adhesion in vitro, and is generated primarily by transcellular biosynthetic routes during P-selectin-mediated platelet-PMN interaction [1], was approximately 60% of wild type levels in nephritic kidneys of P-selectin-deficient mice.	lipoxin A4	10-20	selectin, platelet	Mus musculus	170-180
8731099-5	1996	Secondly, Lipoxin A4 (LXA4), an eicosanoid which inhibits leukocyte-endothelial adhesion in vitro, and is generated primarily by transcellular biosynthetic routes during P-selectin-mediated platelet-PMN interaction [1], was approximately 60% of wild type levels in nephritic kidneys of P-selectin-deficient mice.	lipoxin A4	10-20	tubulin-specific chaperone E	Mus musculus	199-202
8731099-5	1996	Secondly, Lipoxin A4 (LXA4), an eicosanoid which inhibits leukocyte-endothelial adhesion in vitro, and is generated primarily by transcellular biosynthetic routes during P-selectin-mediated platelet-PMN interaction [1], was approximately 60% of wild type levels in nephritic kidneys of P-selectin-deficient mice.	lipoxin A4	10-20	selectin, platelet	Mus musculus	286-296
8731099-5	1996	Secondly, Lipoxin A4 (LXA4), an eicosanoid which inhibits leukocyte-endothelial adhesion in vitro, and is generated primarily by transcellular biosynthetic routes during P-selectin-mediated platelet-PMN interaction [1], was approximately 60% of wild type levels in nephritic kidneys of P-selectin-deficient mice.	lipoxin A4	22-26	selectin, platelet	Mus musculus	170-180
8731099-5	1996	Secondly, Lipoxin A4 (LXA4), an eicosanoid which inhibits leukocyte-endothelial adhesion in vitro, and is generated primarily by transcellular biosynthetic routes during P-selectin-mediated platelet-PMN interaction [1], was approximately 60% of wild type levels in nephritic kidneys of P-selectin-deficient mice.	lipoxin A4	22-26	tubulin-specific chaperone E	Mus musculus	199-202
8731099-5	1996	Secondly, Lipoxin A4 (LXA4), an eicosanoid which inhibits leukocyte-endothelial adhesion in vitro, and is generated primarily by transcellular biosynthetic routes during P-selectin-mediated platelet-PMN interaction [1], was approximately 60% of wild type levels in nephritic kidneys of P-selectin-deficient mice.	lipoxin A4	22-26	selectin, platelet	Mus musculus	286-296
8777583-8	1995	Recently, a human cDNA encoding an orphan FMLP-related receptor cloned from HL60 cells of myeloid lineage was identified as the receptor for another eicosanoid, lipoxin A (Fiore et al., 1994).	lipoxin A4	161-170	formyl peptide receptor 1	Homo sapiens	42-46
7543622-9	1995	Prior treatment of animals with a blocking monoclonal antibody (mAb) against P-selectin (mAb CY1747), but not an isotype-matched non-blocking control mAb (mAb PNB1.6), caused striking inhibition of lipoxin A4 generation without attenuating neutrophil recruitment.	lipoxin A4	198-208	selectin P	Rattus norvegicus	77-87
7964131-5	1994	Pretreatment of HUVECs with PAF or lipoxin A4, but not LTB4, diminished a subsequent response to thrombin.	lipoxin A4	35-45	coagulation factor II, thrombin	Homo sapiens	97-105
8037356-5	1994	The concentration of LXA4 which produced 50% inhibition (IC50) of eosinophil migration was approximately 10(-6) M. LXA4 (10(-10)-10(-6) M) did not elicit ECP release or modulate ECP release induced by 10(-6) M FMLP.	lipoxin A4	21-25	formyl peptide receptor 1	Homo sapiens	210-214
34953854-3	2022	DHRS9/SDR9C4 is also active toward lipid inflammatory mediator di-hydroxylated Leukotriene B4 and pro-resolving mediators such as tri-hydroxylated Resolvin D1 and Lipoxin A4, although notably, with lack of activity on the 15-hydroxyl of prostaglandins.	lipoxin A4	163-173	dehydrogenase/reductase 9	Homo sapiens	0-5
33804219-7	2021	In general, bacterial and mitochondrial formylated peptides activate a proinflammatory cell response through FPR1, while Annexin A1 and Lipoxin A4 are anti-inflammatory FPR2 ligands.	lipoxin A4	136-146	formyl peptide receptor 2	Homo sapiens	169-173
8389617-13	1993	LXA4-induced phospholipase D (PLD) activation gave a biphasic concentration-dependent response comprised of at least two components: one phase being islet-activating protein (IAP)-sensitive (LXA4 10(-9) mol/L peak activity) and the other was staurosporine-sensitive (LXA4 10(-7) mol/L peak activity).	lipoxin A4	0-4	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	13-28
8389617-13	1993	LXA4-induced phospholipase D (PLD) activation gave a biphasic concentration-dependent response comprised of at least two components: one phase being islet-activating protein (IAP)-sensitive (LXA4 10(-9) mol/L peak activity) and the other was staurosporine-sensitive (LXA4 10(-7) mol/L peak activity).	lipoxin A4	0-4	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	30-33
1883860-6	1991	Whole blood incubated with either the ionophore of divalent cations (A23187), thrombin, or thrombin plus the chemotactic peptide formylmethionyl-leucine-phenylalanine generated both LXA4 and thromboxane, which were quantified by stable isotope dilution.	lipoxin A4	182-186	coagulation factor II, thrombin	Homo sapiens	78-86
1883860-6	1991	Whole blood incubated with either the ionophore of divalent cations (A23187), thrombin, or thrombin plus the chemotactic peptide formylmethionyl-leucine-phenylalanine generated both LXA4 and thromboxane, which were quantified by stable isotope dilution.	lipoxin A4	182-186	coagulation factor II, thrombin	Homo sapiens	91-99
2155925-4	1990	Simultaneous addition of FMLP and thrombin to coincubations of these cells led to formation of both lipoxin A4 and lipoxin B4, which were monitored by reversed-phase high pressure liquid chromatography.	lipoxin A4	100-110	formyl peptide receptor 1	Homo sapiens	25-29
2155925-4	1990	Simultaneous addition of FMLP and thrombin to coincubations of these cells led to formation of both lipoxin A4 and lipoxin B4, which were monitored by reversed-phase high pressure liquid chromatography.	lipoxin A4	100-110	coagulation factor II, thrombin	Homo sapiens	34-42
34953854-3	2022	DHRS9/SDR9C4 is also active toward lipid inflammatory mediator di-hydroxylated Leukotriene B4 and pro-resolving mediators such as tri-hydroxylated Resolvin D1 and Lipoxin A4, although notably, with lack of activity on the 15-hydroxyl of prostaglandins.	lipoxin A4	163-173	dehydrogenase/reductase 9	Homo sapiens	6-12
34532386-5	2021	Lipoxin A4 (LXA4), an endogenous anti-antioxidant lipid, plays a key role in multiple organs by binding to the formyl-peptide receptor-like 1 (FPRL1).	lipoxin A4	0-10	formyl peptide receptor 3	Mus musculus	111-141
34811702-7	2021	LXA4 promoted intracellular accumulation of lipid droplets of induced cells and increased UCP-1 expression in a dose- or time-dependent manner.	lipoxin A4	0-4	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	90-95
34537180-0	2021	Lipoxin A4 inhibits ovalbumin-induced airway inflammation and airway remodeling in a mouse model of asthma.	lipoxin A4	0-10	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	20-29
34537180-10	2021	In conclusion, these findings demonstrated that LXA4 alleviated allergic airway inflammation and remodeling in asthmatic mice, which may be related to the inhibition of STAT3 pathway.	lipoxin A4	48-52	signal transducer and activator of transcription 3	Mus musculus	169-174
34191664-2	2021	Inhibition of LTA4H not only prevents LTB4 biosynthesis but also induces a lipid mediator class-switch within the 5-lipoxygenase pathway, elevating biosynthesis of the anti-inflammatory lipid mediator Lipoxin A4.	lipoxin A4	201-211	leukotriene A4 hydrolase	Homo sapiens	14-19
34191664-2	2021	Inhibition of LTA4H not only prevents LTB4 biosynthesis but also induces a lipid mediator class-switch within the 5-lipoxygenase pathway, elevating biosynthesis of the anti-inflammatory lipid mediator Lipoxin A4.	lipoxin A4	201-211	arachidonate 5-lipoxygenase	Homo sapiens	114-128
34572022-3	2021	Among them, lipoxins (LXA4) and aspirin-triggered lipoxin A4 (AT-LXA4) mediate beneficial responses through the activation of N-formyl peptide receptor-2 (FPR2).	lipoxin A4	22-26	formyl peptide receptor 2	Rattus norvegicus	126-153
34572022-3	2021	Among them, lipoxins (LXA4) and aspirin-triggered lipoxin A4 (AT-LXA4) mediate beneficial responses through the activation of N-formyl peptide receptor-2 (FPR2).	lipoxin A4	22-26	formyl peptide receptor 2	Rattus norvegicus	155-159
34572022-3	2021	Among them, lipoxins (LXA4) and aspirin-triggered lipoxin A4 (AT-LXA4) mediate beneficial responses through the activation of N-formyl peptide receptor-2 (FPR2).	lipoxin A4	50-60	formyl peptide receptor 2	Rattus norvegicus	126-153
34572022-3	2021	Among them, lipoxins (LXA4) and aspirin-triggered lipoxin A4 (AT-LXA4) mediate beneficial responses through the activation of N-formyl peptide receptor-2 (FPR2).	lipoxin A4	50-60	formyl peptide receptor 2	Rattus norvegicus	155-159
34572022-11	2021	The favorable action of LXA4 and MR-39 was mediated through the inhibition of ERK1/2 phosphorylation.	lipoxin A4	24-28	mitogen activated protein kinase 3	Rattus norvegicus	78-84
34532386-5	2021	Lipoxin A4 (LXA4), an endogenous anti-antioxidant lipid, plays a key role in multiple organs by binding to the formyl-peptide receptor-like 1 (FPRL1).	lipoxin A4	0-10	formyl peptide receptor 3	Mus musculus	143-148
34532386-5	2021	Lipoxin A4 (LXA4), an endogenous anti-antioxidant lipid, plays a key role in multiple organs by binding to the formyl-peptide receptor-like 1 (FPRL1).	lipoxin A4	12-16	formyl peptide receptor 3	Mus musculus	111-141
34532386-5	2021	Lipoxin A4 (LXA4), an endogenous anti-antioxidant lipid, plays a key role in multiple organs by binding to the formyl-peptide receptor-like 1 (FPRL1).	lipoxin A4	12-16	formyl peptide receptor 3	Mus musculus	143-148
34162149-12	2021	CONCLUSION: LXA4 ameliorated inflammatory response by suppressing neutrophil infiltration, downregulating the expression of pro-inflammatory mediators and ROS production through ALX/FPR2 receptor in A. fumigatus keratitis.	lipoxin A4	12-16	formyl peptide receptor 3	Mus musculus	178-181
35228032-5	2022	In addition, our data demonstrated that prostate cancer cell-derived small lipid molecule lipoxin A4 (LXA4) activated STAT6 by inhibiting METTL3.	lipoxin A4	90-100	signal transducer and activator of transcription 6	Homo sapiens	118-123
35228032-5	2022	In addition, our data demonstrated that prostate cancer cell-derived small lipid molecule lipoxin A4 (LXA4) activated STAT6 by inhibiting METTL3.	lipoxin A4	90-100	methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit	Homo sapiens	138-144
34162149-0	2021	Lipoxin A4 activates ALX/FPR2 to attenuate inflammation in Aspergillus fumigatus keratitis.	lipoxin A4	0-10	formyl peptide receptor 3	Mus musculus	21-24
34162149-0	2021	Lipoxin A4 activates ALX/FPR2 to attenuate inflammation in Aspergillus fumigatus keratitis.	lipoxin A4	0-10	formyl peptide receptor 2	Mus musculus	25-29
34162149-12	2021	CONCLUSION: LXA4 ameliorated inflammatory response by suppressing neutrophil infiltration, downregulating the expression of pro-inflammatory mediators and ROS production through ALX/FPR2 receptor in A. fumigatus keratitis.	lipoxin A4	12-16	formyl peptide receptor 2	Mus musculus	182-186
35411569-0	2022	Combination of resolvin E1 and lipoxin A4 promotes the resolution of pulpitis by inhibiting NF-kappaB activation through upregulating sirtuin 7 in dental pulp fibroblasts.	lipoxin A4	31-41	nuclear factor kappa B subunit 1	Homo sapiens	92-101
35411569-0	2022	Combination of resolvin E1 and lipoxin A4 promotes the resolution of pulpitis by inhibiting NF-kappaB activation through upregulating sirtuin 7 in dental pulp fibroblasts.	lipoxin A4	31-41	sirtuin 7	Homo sapiens	134-143
35307625-12	2022	Lipoxin A4 treatment significantly reduced frequency of activated (CD8+CD69+) cytotoxic T cells.	lipoxin A4	0-10	CD69 antigen	Mus musculus	71-75
35228032-7	2022	Altogether, this work demonstrated that prostate cancer cells facilitate polarization of M2 like macrophages by releasing LXA4 via inhibiting METTL3.	lipoxin A4	122-126	methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit	Homo sapiens	142-148
35235107-4	2022	In cultured macrophages, LXA4 inhibited LPS-induced inflammatory polarization, thereby decreasing the release of proinflammatory cell factors (IL-1beta, IL-6, TNF-alpha) and increasing the release of anti-inflammatory cytokines (IL-4 and IL-10).	lipoxin A4	25-29	interleukin 1 alpha	Mus musculus	143-151
35235107-4	2022	In cultured macrophages, LXA4 inhibited LPS-induced inflammatory polarization, thereby decreasing the release of proinflammatory cell factors (IL-1beta, IL-6, TNF-alpha) and increasing the release of anti-inflammatory cytokines (IL-4 and IL-10).	lipoxin A4	25-29	interleukin 6	Mus musculus	153-157
35235107-4	2022	In cultured macrophages, LXA4 inhibited LPS-induced inflammatory polarization, thereby decreasing the release of proinflammatory cell factors (IL-1beta, IL-6, TNF-alpha) and increasing the release of anti-inflammatory cytokines (IL-4 and IL-10).	lipoxin A4	25-29	tumor necrosis factor	Mus musculus	159-168
35235107-4	2022	In cultured macrophages, LXA4 inhibited LPS-induced inflammatory polarization, thereby decreasing the release of proinflammatory cell factors (IL-1beta, IL-6, TNF-alpha) and increasing the release of anti-inflammatory cytokines (IL-4 and IL-10).	lipoxin A4	25-29	interleukin 4	Mus musculus	229-233
35235107-4	2022	In cultured macrophages, LXA4 inhibited LPS-induced inflammatory polarization, thereby decreasing the release of proinflammatory cell factors (IL-1beta, IL-6, TNF-alpha) and increasing the release of anti-inflammatory cytokines (IL-4 and IL-10).	lipoxin A4	25-29	interleukin 10	Mus musculus	238-243
35235107-6	2022	Moreover, LXA4 also induced the IL-4-induced polarization of M2 macrophages by promoting the FPR2/IRF4 signaling pathway.	lipoxin A4	10-14	interleukin 4	Mus musculus	32-36
35438373-8	2022	In addition, the effect of LXA4 on the function of neutrophils in ARDS rats is mediated by its receptor ALX.	lipoxin A4	27-31	formyl peptide receptor 2-like	Rattus norvegicus	104-107
35438373-9	2022	LXA4 can inhibit the release of NE and MPO from neutrophils, thereby reducing the production of NETs.	lipoxin A4	0-4	myeloperoxidase	Rattus norvegicus	39-42
35235107-6	2022	Moreover, LXA4 also induced the IL-4-induced polarization of M2 macrophages by promoting the FPR2/IRF4 signaling pathway.	lipoxin A4	10-14	formyl peptide receptor 2	Mus musculus	93-97
35235107-6	2022	Moreover, LXA4 also induced the IL-4-induced polarization of M2 macrophages by promoting the FPR2/IRF4 signaling pathway.	lipoxin A4	10-14	interferon regulatory factor 4	Mus musculus	98-102
35307625-14	2022	While expression levels of interferon gamma, tumor necrosis factor alpha, and interleukin-6 significantly reduced in the liver after lipoxin A4 treatment, an anti-inflammatory cytokine interleukin-10 expression was almost at similar levels in all experimental groups.	lipoxin A4	133-143	interleukin 6	Mus musculus	78-91
35017061-11	2022	COX2 modulated the production of efferocytosis-dependent lipid inflammatory mediators that include the eicosanoids PGI2, PGE2, LXA4 and 15d-PGJ2; and further affected secondary efferocytosis.	lipoxin A4	127-131	prostaglandin-endoperoxide synthase 2	Mus musculus	0-4
35215274-2	2022	Accordingly, children with ASD show decreased plasma levels of lipoxin A4 (LXA4), a mediator involved in the resolution of inflammation, which is the endogenous ligand of the formyl peptide receptor 2 (FPR2).	lipoxin A4	63-73	formyl peptide receptor 2	Homo sapiens	175-200
35215274-2	2022	Accordingly, children with ASD show decreased plasma levels of lipoxin A4 (LXA4), a mediator involved in the resolution of inflammation, which is the endogenous ligand of the formyl peptide receptor 2 (FPR2).	lipoxin A4	63-73	formyl peptide receptor 2	Homo sapiens	202-206
34048148-0	2021	Lipoxin A4 protects primary spinal cord neurons from Erastin-induced ferroptosis by activating the Akt/Nrf2/HO-1 signaling pathway.	lipoxin A4	0-10	AKT serine/threonine kinase 1	Homo sapiens	99-102
2503031-7	1989	Biologically derived LXA4 (3 nM) isolated from RBL-1 incubations contracted a rat tail artery preparation to 12% of the maximum induced by phenylephrine (0.125 microM), whereas LXA4 standard (3 nM) elicited 17.6% of the maximum contraction.	lipoxin A4	21-25	RB transcriptional corepressor like 1	Rattus norvegicus	47-52
2548801-11	1989	Preincubation of PMN with increasing concentrations of LXA4 induced a very similar dose- and time-dependent inhibition of the subsequent response to 10(-7) mol/l LTB4 or 10(-7) mol/l N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP).	lipoxin A4	55-59	formyl peptide receptor 1	Homo sapiens	230-234
2548801-14	1989	The (5S,6S,15S)-isomers of LXA4 and LXB4 were 5- and 100-fold less potent than LXA4, respectively, in suppressing LTB4- or FMLP-induced PMN migration.	lipoxin A4	27-31	formyl peptide receptor 1	Homo sapiens	123-127
2548801-16	1989	Preincubation of PMN with LXA4 led to a suppression of calcium mobilization, as assessed by Quin2-AM fluorescence, when the cells were subsequently stimulated under optimal conditions by LTB4 or FMLP.	lipoxin A4	26-30	formyl peptide receptor 1	Homo sapiens	195-199
3132921-0	1988	Soybean lipoxygenase-catalyzed formation of lipoxin A and lipoxin B isomers from arachidonic acid via 5,15-dihydroperoxyeicosatetraenoic acid.	lipoxin A4	44-53	linoleate 9S-lipoxygenase-4	Glycine max	8-20
34048148-0	2021	Lipoxin A4 protects primary spinal cord neurons from Erastin-induced ferroptosis by activating the Akt/Nrf2/HO-1 signaling pathway.	lipoxin A4	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	103-107
34048148-0	2021	Lipoxin A4 protects primary spinal cord neurons from Erastin-induced ferroptosis by activating the Akt/Nrf2/HO-1 signaling pathway.	lipoxin A4	0-10	heme oxygenase 1	Homo sapiens	108-112
34048148-11	2021	In conclusion, this work demonstrated that LXA4 exerted a neuroprotective effect in Erastin-induced ferroptosis of primary spinal cord neurons by activating Akt/Nrf2/HO-1 signaling pathway.	lipoxin A4	43-47	AKT serine/threonine kinase 1	Homo sapiens	157-160
34048148-11	2021	In conclusion, this work demonstrated that LXA4 exerted a neuroprotective effect in Erastin-induced ferroptosis of primary spinal cord neurons by activating Akt/Nrf2/HO-1 signaling pathway.	lipoxin A4	43-47	NFE2 like bZIP transcription factor 2	Homo sapiens	161-165
34048148-11	2021	In conclusion, this work demonstrated that LXA4 exerted a neuroprotective effect in Erastin-induced ferroptosis of primary spinal cord neurons by activating Akt/Nrf2/HO-1 signaling pathway.	lipoxin A4	43-47	heme oxygenase 1	Homo sapiens	166-170
33600815-8	2021	We found that LXA4 exerted protective effects on focal cerebral ischemia-reperfusion injury and reduced the expression of the pro-inflammatory cytokines IL-1beta and TNF-alpha.	lipoxin A4	14-18	interleukin 1 alpha	Rattus norvegicus	153-161
33600815-8	2021	We found that LXA4 exerted protective effects on focal cerebral ischemia-reperfusion injury and reduced the expression of the pro-inflammatory cytokines IL-1beta and TNF-alpha.	lipoxin A4	14-18	tumor necrosis factor	Rattus norvegicus	166-175
33600815-12	2021	These data suggest that LXA4 may regulate the polarization of microglia after cerebral ischemia-reperfusion injury through the Notch signaling pathway.	lipoxin A4	24-28	notch receptor 1	Rattus norvegicus	127-132
33922064-5	2021	Experimental and in vitro studies with Lipoxin A4 demonstrate a potential inhibitory effect on endometrial lesions" progression, attenuating pro-inflammatory and angiogenic signals, inhibiting proliferative and invasive action suppressing intracellular signaling induced by cytokines and estradiol, mainly through the FPR2/ALX.	lipoxin A4	39-49	formyl peptide receptor 2	Homo sapiens	318-322
33760150-0	2021	Lipoxin A4 protects against paraquat-induced acute lung injury by inhibiting the TLR4/MyD88-mediated activation of the NF-kappaB and PI3K/AKT pathways.	lipoxin A4	0-10	toll-like receptor 4	Rattus norvegicus	81-85
33760150-0	2021	Lipoxin A4 protects against paraquat-induced acute lung injury by inhibiting the TLR4/MyD88-mediated activation of the NF-kappaB and PI3K/AKT pathways.	lipoxin A4	0-10	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	86-91
33760150-0	2021	Lipoxin A4 protects against paraquat-induced acute lung injury by inhibiting the TLR4/MyD88-mediated activation of the NF-kappaB and PI3K/AKT pathways.	lipoxin A4	0-10	AKT serine/threonine kinase 1	Rattus norvegicus	138-141
33922064-5	2021	Experimental and in vitro studies with Lipoxin A4 demonstrate a potential inhibitory effect on endometrial lesions" progression, attenuating pro-inflammatory and angiogenic signals, inhibiting proliferative and invasive action suppressing intracellular signaling induced by cytokines and estradiol, mainly through the FPR2/ALX.	lipoxin A4	39-49	hematopoietic SH2 domain containing	Homo sapiens	323-326
33921615-12	2021	In addition, lipoxin A4 inhibited the infiltration of neutrophils and the production of cytokines and pro-inflammatory chemokines, such as interleukin (Il-1beta, Il-6, Il-8) and tumor necrosis factor-alpha (TNF-alpha).	lipoxin A4	13-23	interleukin 1 alpha	Homo sapiens	152-160
33921615-12	2021	In addition, lipoxin A4 inhibited the infiltration of neutrophils and the production of cytokines and pro-inflammatory chemokines, such as interleukin (Il-1beta, Il-6, Il-8) and tumor necrosis factor-alpha (TNF-alpha).	lipoxin A4	13-23	interleukin 6	Homo sapiens	162-166
33921615-12	2021	In addition, lipoxin A4 inhibited the infiltration of neutrophils and the production of cytokines and pro-inflammatory chemokines, such as interleukin (Il-1beta, Il-6, Il-8) and tumor necrosis factor-alpha (TNF-alpha).	lipoxin A4	13-23	C-X-C motif chemokine ligand 8	Homo sapiens	168-172
33921615-12	2021	In addition, lipoxin A4 inhibited the infiltration of neutrophils and the production of cytokines and pro-inflammatory chemokines, such as interleukin (Il-1beta, Il-6, Il-8) and tumor necrosis factor-alpha (TNF-alpha).	lipoxin A4	13-23	tumor necrosis factor	Homo sapiens	178-205
33921615-12	2021	In addition, lipoxin A4 inhibited the infiltration of neutrophils and the production of cytokines and pro-inflammatory chemokines, such as interleukin (Il-1beta, Il-6, Il-8) and tumor necrosis factor-alpha (TNF-alpha).	lipoxin A4	13-23	tumor necrosis factor	Homo sapiens	207-216
33936050-7	2021	Furthermore, LXA4 inhibited NF-kappaB-mediated inflammatory response and the p53/p21 senescence pathway in vivo and in vitro.	lipoxin A4	13-17	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	77-80
33936050-7	2021	Furthermore, LXA4 inhibited NF-kappaB-mediated inflammatory response and the p53/p21 senescence pathway in vivo and in vitro.	lipoxin A4	13-17	KRAS proto-oncogene, GTPase	Rattus norvegicus	81-84
33936050-9	2021	These results indicated that LXA4 exerted its renoprotective effects by blocking the crosstalk between inflammation and premature senescence in a PPAR-gamma-dependent manner.	lipoxin A4	29-33	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	146-156
33880053-4	2021	Methods: In vivo, LXA4 (0.1 microg/mouse) was injected intraperitoneally after intratracheal (1 mg/kg) lipopolysaccharide (LPS) administration; flow cytometry was used to measure peripheral blood monocyte derived recruited macrophage and neutrophil numbers; resident alveolar macrophage was depleted by liposome clodronate; CXCL2, CCL2, MMP9 level was detected by RT-PCR and ELISA.	lipoxin A4	18-22	chemokine (C-X-C motif) ligand 2	Mus musculus	324-329
33626375-2	2021	Lipoxin A4 (LXA4) can regulate transforming growth factor-beta (TGF-beta) pathway and alleviate tissue injury via binding to formyl peptide receptor 2 (FPR2).	lipoxin A4	0-10	transforming growth factor alpha	Sus scrofa	64-72
33880053-4	2021	Methods: In vivo, LXA4 (0.1 microg/mouse) was injected intraperitoneally after intratracheal (1 mg/kg) lipopolysaccharide (LPS) administration; flow cytometry was used to measure peripheral blood monocyte derived recruited macrophage and neutrophil numbers; resident alveolar macrophage was depleted by liposome clodronate; CXCL2, CCL2, MMP9 level was detected by RT-PCR and ELISA.	lipoxin A4	18-22	chemokine (C-C motif) ligand 2	Mus musculus	331-335
33880053-4	2021	Methods: In vivo, LXA4 (0.1 microg/mouse) was injected intraperitoneally after intratracheal (1 mg/kg) lipopolysaccharide (LPS) administration; flow cytometry was used to measure peripheral blood monocyte derived recruited macrophage and neutrophil numbers; resident alveolar macrophage was depleted by liposome clodronate; CXCL2, CCL2, MMP9 level was detected by RT-PCR and ELISA.	lipoxin A4	18-22	matrix metallopeptidase 9	Mus musculus	337-341
33880053-10	2021	Finally, LXA4"s beneficial effects were abrogated by BOC-2, an LXA4 receptor inhibitor.	lipoxin A4	9-13	formyl peptide receptor 3	Mus musculus	63-76
33221976-0	2021	Lipoxin A4-Mediated p38 MAPK Signaling Pathway Protects Mice Against Collagen-Induced Arthritis.	lipoxin A4	0-10	mitogen-activated protein kinase 14	Mus musculus	20-28
33760150-4	2021	LXA4 treatment attenuated PQ-induced lung injury, and this was accompanied by decreased tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta secretion levels, and reduced oxidative stress damage.	lipoxin A4	0-4	tumor necrosis factor	Rattus norvegicus	88-121
33760150-4	2021	LXA4 treatment attenuated PQ-induced lung injury, and this was accompanied by decreased tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta secretion levels, and reduced oxidative stress damage.	lipoxin A4	0-4	interleukin 1 alpha	Rattus norvegicus	126-148
33760150-5	2021	Additionally, LXA4 treatment inhibited the activation of the inflammation-related signaling molecules, Toll-like receptor 4 (TLR4), myeloid differentiation primary response 88 (MyD88), nuclear factor (NF)-kappaB p65, p-phosphoinositide 3-kinase (PI3K) and p-AKT.	lipoxin A4	14-18	toll-like receptor 4	Rattus norvegicus	103-123
33760150-5	2021	Additionally, LXA4 treatment inhibited the activation of the inflammation-related signaling molecules, Toll-like receptor 4 (TLR4), myeloid differentiation primary response 88 (MyD88), nuclear factor (NF)-kappaB p65, p-phosphoinositide 3-kinase (PI3K) and p-AKT.	lipoxin A4	14-18	toll-like receptor 4	Rattus norvegicus	125-129
33760150-5	2021	Additionally, LXA4 treatment inhibited the activation of the inflammation-related signaling molecules, Toll-like receptor 4 (TLR4), myeloid differentiation primary response 88 (MyD88), nuclear factor (NF)-kappaB p65, p-phosphoinositide 3-kinase (PI3K) and p-AKT.	lipoxin A4	14-18	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	132-175
33760150-5	2021	Additionally, LXA4 treatment inhibited the activation of the inflammation-related signaling molecules, Toll-like receptor 4 (TLR4), myeloid differentiation primary response 88 (MyD88), nuclear factor (NF)-kappaB p65, p-phosphoinositide 3-kinase (PI3K) and p-AKT.	lipoxin A4	14-18	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	177-182
33760150-5	2021	Additionally, LXA4 treatment inhibited the activation of the inflammation-related signaling molecules, Toll-like receptor 4 (TLR4), myeloid differentiation primary response 88 (MyD88), nuclear factor (NF)-kappaB p65, p-phosphoinositide 3-kinase (PI3K) and p-AKT.	lipoxin A4	14-18	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta	Rattus norvegicus	217-244
33760150-5	2021	Additionally, LXA4 treatment inhibited the activation of the inflammation-related signaling molecules, Toll-like receptor 4 (TLR4), myeloid differentiation primary response 88 (MyD88), nuclear factor (NF)-kappaB p65, p-phosphoinositide 3-kinase (PI3K) and p-AKT.	lipoxin A4	14-18	AKT serine/threonine kinase 1	Rattus norvegicus	258-261
33760150-6	2021	Furthermore, the in vitro experiments further confirmed that the beneficial effects of LXA4 on PQ-induced damage were TLR4-dependent.	lipoxin A4	87-91	toll-like receptor 4	Rattus norvegicus	118-122
33760150-7	2021	Hence, the present study demonstrated that LXA4 attenuated PQ-induced toxicity in lung tissue and RAW264.7 macrophages, and that this protective effect may be closely related to the mitigation of inflammatory responses, oxidative stress damage and the TLR4/MyD88-mediated activation of the PI3K/AKT/NF-kappaB pathway.	lipoxin A4	43-47	toll-like receptor 4	Rattus norvegicus	252-256
33760150-7	2021	Hence, the present study demonstrated that LXA4 attenuated PQ-induced toxicity in lung tissue and RAW264.7 macrophages, and that this protective effect may be closely related to the mitigation of inflammatory responses, oxidative stress damage and the TLR4/MyD88-mediated activation of the PI3K/AKT/NF-kappaB pathway.	lipoxin A4	43-47	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	257-262
33760150-7	2021	Hence, the present study demonstrated that LXA4 attenuated PQ-induced toxicity in lung tissue and RAW264.7 macrophages, and that this protective effect may be closely related to the mitigation of inflammatory responses, oxidative stress damage and the TLR4/MyD88-mediated activation of the PI3K/AKT/NF-kappaB pathway.	lipoxin A4	43-47	AKT serine/threonine kinase 1	Rattus norvegicus	295-298
32937208-10	2020	Gels loaded with LXA4 and/or DOX reduced the subgingival bacterial load and pro-inflammatory interleukin-8 level.	lipoxin A4	17-21	C-X-C motif chemokine ligand 8	Canis lupus familiaris	93-106
33221976-1	2021	The aim of the article was to study the mechanism of Lipoxin A4 (LXA4)-mediated p38 MAPK pathway protecting mice against collagen-induced arthritis (CIA).	lipoxin A4	53-63	mitogen-activated protein kinase 14	Mus musculus	80-88
33221976-1	2021	The aim of the article was to study the mechanism of Lipoxin A4 (LXA4)-mediated p38 MAPK pathway protecting mice against collagen-induced arthritis (CIA).	lipoxin A4	65-69	mitogen-activated protein kinase 14	Mus musculus	80-88
33221976-9	2021	CIA mice treated with LXA4 and SB203580 had lower levels of TNF-alpha, IL-6, IL-1beta, and IFN-gamma, accompanying decreased MDA as well as increased SOD, CAT,and GPx.	lipoxin A4	22-26	tumor necrosis factor	Mus musculus	60-69
33221976-9	2021	CIA mice treated with LXA4 and SB203580 had lower levels of TNF-alpha, IL-6, IL-1beta, and IFN-gamma, accompanying decreased MDA as well as increased SOD, CAT,and GPx.	lipoxin A4	22-26	interleukin 6	Mus musculus	71-75
33221976-9	2021	CIA mice treated with LXA4 and SB203580 had lower levels of TNF-alpha, IL-6, IL-1beta, and IFN-gamma, accompanying decreased MDA as well as increased SOD, CAT,and GPx.	lipoxin A4	22-26	interleukin 1 alpha	Mus musculus	77-85
33221976-9	2021	CIA mice treated with LXA4 and SB203580 had lower levels of TNF-alpha, IL-6, IL-1beta, and IFN-gamma, accompanying decreased MDA as well as increased SOD, CAT,and GPx.	lipoxin A4	22-26	interferon gamma	Mus musculus	91-100
33221976-9	2021	CIA mice treated with LXA4 and SB203580 had lower levels of TNF-alpha, IL-6, IL-1beta, and IFN-gamma, accompanying decreased MDA as well as increased SOD, CAT,and GPx.	lipoxin A4	22-26	catalase	Mus musculus	155-158
33221976-9	2021	CIA mice treated with LXA4 and SB203580 had lower levels of TNF-alpha, IL-6, IL-1beta, and IFN-gamma, accompanying decreased MDA as well as increased SOD, CAT,and GPx.	lipoxin A4	22-26	peroxiredoxin 6 pseudogene 2	Mus musculus	163-166
33221976-11	2021	LXA4 protected mice against collagen-induced arthritis via inhibiting p38 MAPK signaling pathway, which may be a potential new therapeutic target for rheumatoid arthritis.	lipoxin A4	0-4	mitogen-activated protein kinase 14	Mus musculus	70-78
33343231-8	2020	Results: The plasma level of BDNF negatively correlated with C22:1n9 13 erucic acid, C18:3n3 linolenic acid (ALA), and lipoxin A4 15-epi-LxA4.	lipoxin A4	119-129	brain derived neurotrophic factor	Homo sapiens	29-33
33343231-8	2020	Results: The plasma level of BDNF negatively correlated with C22:1n9 13 erucic acid, C18:3n3 linolenic acid (ALA), and lipoxin A4 15-epi-LxA4.	lipoxin A4	130-141	brain derived neurotrophic factor	Homo sapiens	29-33
32941865-7	2020	AHR is mainly involved in the resolution phase by induction of lipoxin A4 and Il-22.	lipoxin A4	63-73	aryl hydrocarbon receptor	Homo sapiens	0-3
33312119-0	2020	Corrigendum: Lipoxin A4 Inhibits NLRP3 Inflammasome Activation in Rats With Non-compressive Disc Herniation Through the JNK1/Beclin-1/PI3KC3 Pathway.	lipoxin A4	13-23	NLR family, pyrin domain containing 3	Rattus norvegicus	33-38
33312119-0	2020	Corrigendum: Lipoxin A4 Inhibits NLRP3 Inflammasome Activation in Rats With Non-compressive Disc Herniation Through the JNK1/Beclin-1/PI3KC3 Pathway.	lipoxin A4	13-23	beclin 1	Rattus norvegicus	125-133
32765680-0	2020	Lipoxin A4 attenuates uric acid-activated, NADPH oxidase-dependent oxidative stress by interfering with translocation of p47phox in human umbilical vein endothelial cells.	lipoxin A4	0-10	neutrophil cytosolic factor 1	Homo sapiens	121-128
32641387-5	2020	In contrast, the specialized proresolving mediator lipoxin A4 promoted NK cell LIMK expression, lytic granule polarization to the immune synapse and cytotoxicity.	lipoxin A4	51-61	LIM domain kinase 1	Homo sapiens	79-83
32641387-6	2020	Using a LIMK inhibitor, we show that LIMK activity is necessary for NK cell cytotoxicity, including lipoxin A4"s proresolving actions.	lipoxin A4	100-110	LIM domain kinase 1	Homo sapiens	8-12
32641387-6	2020	Using a LIMK inhibitor, we show that LIMK activity is necessary for NK cell cytotoxicity, including lipoxin A4"s proresolving actions.	lipoxin A4	100-110	LIM domain kinase 1	Homo sapiens	37-41
32070748-0	2020	Lipoxin A4 reduces house dust mite and TNFalpha-induced hyperreactivity in the mouse trachea.	lipoxin A4	0-10	tumor necrosis factor	Mus musculus	39-47
32070748-6	2020	TNFalpha-induced upregulation of 5-HT responses (Emax: 51.3 +- 1.2% versus control 13.9 +- 0.5%) was decreased by 10-1000 nM LXA4.	lipoxin A4	125-129	tumor necrosis factor	Mus musculus	0-8
32070748-8	2020	Overall, LXA4 was able to decrease airway hyperreactivity induced by both HDM and TNFalpha, thus having a sub-acute anti-inflammatory effect in airway inflammation.	lipoxin A4	9-13	tumor necrosis factor	Mus musculus	82-90
33071721-0	2020	Lipoxin A4 Inhibits NLRP3 Inflammasome Activation in Rats With Non-compressive Disc Herniation Through the JNK1/Beclin-1/PI3KC3 Pathway.	lipoxin A4	0-10	NLR family, pyrin domain containing 3	Rattus norvegicus	20-25
33071721-0	2020	Lipoxin A4 Inhibits NLRP3 Inflammasome Activation in Rats With Non-compressive Disc Herniation Through the JNK1/Beclin-1/PI3KC3 Pathway.	lipoxin A4	0-10	beclin 1	Rattus norvegicus	112-120
33071721-20	2020	Conclusions: These data suggested that LXA4 inhibited NLRP3 activation in rats with non-compressive disc herniation by regulating the JNK1/beclin-1/PI3KC3 pathway.	lipoxin A4	39-43	NLR family, pyrin domain containing 3	Rattus norvegicus	54-59
33071721-20	2020	Conclusions: These data suggested that LXA4 inhibited NLRP3 activation in rats with non-compressive disc herniation by regulating the JNK1/beclin-1/PI3KC3 pathway.	lipoxin A4	39-43	beclin 1	Rattus norvegicus	139-147
33145305-7	2020	Moreover, LXA4 treatment also reverses the increased expression of GRP78, p-PERK, p-eIF2alpha, ATF4, and CHOP induced by I/R injury.	lipoxin A4	10-14	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	67-72
33145305-7	2020	Moreover, LXA4 treatment also reverses the increased expression of GRP78, p-PERK, p-eIF2alpha, ATF4, and CHOP induced by I/R injury.	lipoxin A4	10-14	eukaryotic translation initiation factor 2A	Rattus norvegicus	84-93
33145305-7	2020	Moreover, LXA4 treatment also reverses the increased expression of GRP78, p-PERK, p-eIF2alpha, ATF4, and CHOP induced by I/R injury.	lipoxin A4	10-14	activating transcription factor 4	Rattus norvegicus	95-99
33145305-7	2020	Moreover, LXA4 treatment also reverses the increased expression of GRP78, p-PERK, p-eIF2alpha, ATF4, and CHOP induced by I/R injury.	lipoxin A4	10-14	DNA-damage inducible transcript 3	Rattus norvegicus	105-109
32765680-12	2020	Further experiments demonstrated that LXA4 interfered with the transfer of p47phox from the cytoplasm to the cell membrane.	lipoxin A4	38-42	neutrophil cytosolic factor 1	Homo sapiens	75-82
32657110-0	2020	Lipoxin A4 alleviates lung injury in sepsis rats through p38/MAPK signaling pathway.	lipoxin A4	0-10	mitogen activated protein kinase 14	Rattus norvegicus	57-60
32765941-5	2020	Since PGE2, LXA4 and their precursors AA (arachidonic acid), dihomo-gamma-linolenic acid (DGLA) and gamma-linolenic acid (GLA) inhibit the production of pro-inflammatory IL-6 and TNF-alpha, they could be employed to treat cytokine storm seen in COVID-19, immune check point inhibitory (ICI) therapy, sepsis and ARDS (acute respiratory disease).	lipoxin A4	12-16	interleukin 6	Homo sapiens	170-174
32765941-5	2020	Since PGE2, LXA4 and their precursors AA (arachidonic acid), dihomo-gamma-linolenic acid (DGLA) and gamma-linolenic acid (GLA) inhibit the production of pro-inflammatory IL-6 and TNF-alpha, they could be employed to treat cytokine storm seen in COVID-19, immune check point inhibitory (ICI) therapy, sepsis and ARDS (acute respiratory disease).	lipoxin A4	12-16	tumor necrosis factor	Homo sapiens	179-188
32760397-8	2020	injections of LXA4 significantly lowered transaminase levels only in Alox12/15-/- mice and reduced hepatic immune cell infiltration as well as systemic inflammatory cytokine expression in both genotypes, even though steatosis progressed.	lipoxin A4	14-18	arachidonate 12-lipoxygenase	Mus musculus	69-78
32760397-9	2020	Thus, while LXA4 injection attenuated selected parameters of disease progression in Alox12/15-/- mice, its beneficial impact on immunity was also apparent in Alox12/15+/+ mice.	lipoxin A4	12-16	arachidonate 12-lipoxygenase	Mus musculus	84-90
32848749-8	2020	Moreover, LXA4 could inhibit GC-mediated ALOX5 activation and LTB4 increase, and also suppress 11beta-HSD2 expression and corticosterone upregulation.	lipoxin A4	10-14	arachidonate 5-lipoxygenase	Homo sapiens	41-46
32848749-8	2020	Moreover, LXA4 could inhibit GC-mediated ALOX5 activation and LTB4 increase, and also suppress 11beta-HSD2 expression and corticosterone upregulation.	lipoxin A4	10-14	hydroxysteroid 11-beta dehydrogenase 2	Homo sapiens	95-106
32657110-0	2020	Lipoxin A4 alleviates lung injury in sepsis rats through p38/MAPK signaling pathway.	lipoxin A4	0-10	mitogen activated protein kinase 14	Rattus norvegicus	61-65
32657110-1	2020	The aim of the study was to explore the effect of lipoxin A4 (LXA4) on lung injury in sepsis rats through the p38/mitogen-activated protein kinase (MAPK) signaling pathway.	lipoxin A4	50-60	mitogen activated protein kinase 14	Rattus norvegicus	110-146
32657110-1	2020	The aim of the study was to explore the effect of lipoxin A4 (LXA4) on lung injury in sepsis rats through the p38/mitogen-activated protein kinase (MAPK) signaling pathway.	lipoxin A4	50-60	mitogen activated protein kinase 14	Rattus norvegicus	148-152
32657110-8	2020	The activity of myeloperoxidase (MPO) in lung tissue homogenate was evidently higher in the Sepsis group than that in The Control group, while it was notably lower in the Treatment group than that in the Sepsis group after LXA4 treatment (P<0.05).	lipoxin A4	223-227	myeloperoxidase	Rattus norvegicus	16-31
32657110-8	2020	The activity of myeloperoxidase (MPO) in lung tissue homogenate was evidently higher in the Sepsis group than that in The Control group, while it was notably lower in the Treatment group than that in the Sepsis group after LXA4 treatment (P<0.05).	lipoxin A4	223-227	myeloperoxidase	Rattus norvegicus	33-36
32657110-11	2020	LXA4 has an anti-inflammatory effect on sepsis rats with lung injury, and such effect is related to the p38/MAPK signaling pathway.	lipoxin A4	0-4	mitogen activated protein kinase 14	Rattus norvegicus	104-107
32657110-11	2020	LXA4 has an anti-inflammatory effect on sepsis rats with lung injury, and such effect is related to the p38/MAPK signaling pathway.	lipoxin A4	0-4	mitogen activated protein kinase 14	Rattus norvegicus	108-112
31814225-5	2020	In addition, the effects of LXA4 were analyzed on the TLR-MyD88-NF-kappaB (TMN)-mediated intracellular signal pathway using immunocytochemistry.	lipoxin A4	28-32	MYD88 innate immune signal transduction adaptor	Homo sapiens	58-63
32188695-9	2020	Targeted metabolomic experiments in the Fatp2 -/- liver revealed increases of total C16:0, C16:1, and C18:1 fatty acids; increases in lipoxin A4 and prostaglandin J2; and a decrease in 20-hydroxyeicosatetraenoic acid.	lipoxin A4	134-144	solute carrier family 27 (fatty acid transporter), member 2	Mus musculus	40-45
31814225-5	2020	In addition, the effects of LXA4 were analyzed on the TLR-MyD88-NF-kappaB (TMN)-mediated intracellular signal pathway using immunocytochemistry.	lipoxin A4	28-32	nuclear factor kappa B subunit 1	Homo sapiens	64-73
31698141-12	2020	(2) LXA4 inhibited LPS-induced Hyp production, meanwhile down-regulated LPS-induced Collagen I, Collagen III, MMP-2, and MMP-9 in HSC-T6 cells.	lipoxin A4	4-8	matrix metallopeptidase 2	Rattus norvegicus	110-115
32161582-4	2020	We report here that chronic ozone exposure activates AhR with increased tryptophan and lipoxin A4 production in mice.	lipoxin A4	87-97	aryl-hydrocarbon receptor	Mus musculus	53-56
31698141-12	2020	(2) LXA4 inhibited LPS-induced Hyp production, meanwhile down-regulated LPS-induced Collagen I, Collagen III, MMP-2, and MMP-9 in HSC-T6 cells.	lipoxin A4	4-8	matrix metallopeptidase 9	Rattus norvegicus	121-126
31764154-10	2020	Blockade of lipoxin A4 production in mesenchymal stromal cells, and of prostaglandin E2 synthesis in mesenchymal stromal cell/macrophage cocultures, prevented upregulation of heme oxygenase-1 in macrophages (from 9.6 +- 5.5-fold to 2.3 +- 1.3 and 2.4 +- 2.3 respectively, P = 0.004).	lipoxin A4	12-22	heme oxygenase 1	Homo sapiens	175-191
32001671-0	2020	Lipoxin A4 suppresses angiotensin II type 1 receptor autoantibody in preeclampsia via modulating caspase-1.	lipoxin A4	0-10	caspase 1	Homo sapiens	97-106
32001671-6	2020	Lipoxin A4 (LXA4), endogenous dual anti-inflammatory and proresolving lipid mediator, may inhibit AT1-AA production via modulating caspase-1.	lipoxin A4	0-10	caspase 1	Homo sapiens	131-140
32001671-6	2020	Lipoxin A4 (LXA4), endogenous dual anti-inflammatory and proresolving lipid mediator, may inhibit AT1-AA production via modulating caspase-1.	lipoxin A4	12-16	caspase 1	Homo sapiens	131-140
32001671-12	2020	These results suggest that caspase-1 promotes AT1-AA production via inducing trophoblast pyroptosis and AT1R exposure, while LXA4 suppresses AT1-AA production via modulating caspase-1, supporting caspase-1 serving as a therapeutic target for attenuating AT1-AA and LXA4 protecting patients from AT1-AA and PE.	lipoxin A4	125-129	caspase 1	Homo sapiens	174-183
32001671-12	2020	These results suggest that caspase-1 promotes AT1-AA production via inducing trophoblast pyroptosis and AT1R exposure, while LXA4 suppresses AT1-AA production via modulating caspase-1, supporting caspase-1 serving as a therapeutic target for attenuating AT1-AA and LXA4 protecting patients from AT1-AA and PE.	lipoxin A4	125-129	caspase 1	Homo sapiens	174-183
31746387-0	2020	Lipoxin A4 attenuates hyperoxia-induced lung epithelial cell injury via the upregulation of heme oxygenase-1 and inhibition of proinflammatory cytokines.	lipoxin A4	0-10	heme oxygenase 1	Mus musculus	92-108
31707382-10	2020	Additionally, NF-kappaB p65 inhibition led to an increase in the LXA4 concentration.	lipoxin A4	65-69	RELA proto-oncogene, NF-kB subunit	Homo sapiens	14-27
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	35-45	heme oxygenase 1	Mus musculus	81-85
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	35-45	interleukin 6	Mus musculus	118-131
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	35-45	interleukin 6	Mus musculus	133-137
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	35-45	chemokine (C-C motif) ligand 2	Mus musculus	143-173
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	35-45	chemokine (C-C motif) ligand 2	Mus musculus	175-180
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	35-45	interleukin 6	Mus musculus	356-360
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	35-45	chemokine (C-C motif) ligand 2	Mus musculus	365-370
31823816-8	2019	Sub-optimal doses of BDNF, LXA4, AA and EPA when used in combination protected against cytotoxic action of AL/STZ/DB/BP on RIN5F cells in vitro by restoring LXA4/BDNF levels and altered antioxidant/lipid peroxides/NO levels (P &lt; 0.01) to normal.	lipoxin A4	27-31	brain derived neurotrophic factor	Mus musculus	162-166
31746387-5	2020	ZnPP-IX, an inhibitor of HO-1, blocked LXA4-induced protection on cell viability in cells exposed to hyperoxia.	lipoxin A4	39-43	heme oxygenase 1	Mus musculus	25-29
31746387-8	2020	LXA4 inhibited the activation of p38 MAPK and ERK1/2 induced by hyperoxia, and increased the activation of the Akt signaling pathway, which was inhibited by hyperoxia.	lipoxin A4	0-4	mitogen-activated protein kinase 14	Mus musculus	33-36
31746387-8	2020	LXA4 inhibited the activation of p38 MAPK and ERK1/2 induced by hyperoxia, and increased the activation of the Akt signaling pathway, which was inhibited by hyperoxia.	lipoxin A4	0-4	mitogen-activated protein kinase 3	Mus musculus	46-52
31746387-8	2020	LXA4 inhibited the activation of p38 MAPK and ERK1/2 induced by hyperoxia, and increased the activation of the Akt signaling pathway, which was inhibited by hyperoxia.	lipoxin A4	0-4	thymoma viral proto-oncogene 1	Mus musculus	111-114
31746387-9	2020	Therefore, LXA4 attenuated hyperoxia-induced injury in MLE-12 cells via the upregulation of HO-1 expression.	lipoxin A4	11-15	heme oxygenase 1	Mus musculus	92-96
31746387-10	2020	The protection of LXA4 in hyperoxia-induced cell injury may be associated with the downregulation IL-6 and MCP-1 levels via the inhibition of the p38 MAPK and ERK1/2 signaling pathways.	lipoxin A4	18-22	interleukin 6	Mus musculus	98-102
31746387-10	2020	The protection of LXA4 in hyperoxia-induced cell injury may be associated with the downregulation IL-6 and MCP-1 levels via the inhibition of the p38 MAPK and ERK1/2 signaling pathways.	lipoxin A4	18-22	chemokine (C-C motif) ligand 2	Mus musculus	107-112
31746387-10	2020	The protection of LXA4 in hyperoxia-induced cell injury may be associated with the downregulation IL-6 and MCP-1 levels via the inhibition of the p38 MAPK and ERK1/2 signaling pathways.	lipoxin A4	18-22	mitogen-activated protein kinase 14	Mus musculus	146-154
31746387-10	2020	The protection of LXA4 in hyperoxia-induced cell injury may be associated with the downregulation IL-6 and MCP-1 levels via the inhibition of the p38 MAPK and ERK1/2 signaling pathways.	lipoxin A4	18-22	mitogen-activated protein kinase 3	Mus musculus	159-165
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	47-51	heme oxygenase 1	Mus musculus	81-85
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	47-51	interleukin 6	Mus musculus	118-131
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	47-51	interleukin 6	Mus musculus	133-137
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	47-51	chemokine (C-C motif) ligand 2	Mus musculus	143-173
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	47-51	chemokine (C-C motif) ligand 2	Mus musculus	175-180
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	47-51	interleukin 6	Mus musculus	356-360
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	47-51	chemokine (C-C motif) ligand 2	Mus musculus	365-370
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	185-189	chemokine (C-C motif) ligand 2	Mus musculus	143-173
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	185-189	chemokine (C-C motif) ligand 2	Mus musculus	175-180
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	185-189	chemokine (C-C motif) ligand 2	Mus musculus	143-173
31746387-1	2020	The present study examined whether lipoxin A4 (LXA4) increases the expression of HO-1, and inhibits the production of interleukin 6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) in LXA4-induced protection during hyperoxia-induced injury in murine lung epithelial cells (MLE-12) and what signal pathway may participate in the actions of LXA4 inhibiting IL-6 and MCP-1.	lipoxin A4	185-189	chemokine (C-C motif) ligand 2	Mus musculus	175-180
31746387-4	2020	LXA4 significantly increased the cell survival rates, cell viability, SOD levels and HO-1 expression, reduced the apoptosis rates, and inhibited the MCP-1 and IL-6 levels induced by hyperoxia in cells.	lipoxin A4	0-4	heme oxygenase 1	Mus musculus	85-89
31746387-4	2020	LXA4 significantly increased the cell survival rates, cell viability, SOD levels and HO-1 expression, reduced the apoptosis rates, and inhibited the MCP-1 and IL-6 levels induced by hyperoxia in cells.	lipoxin A4	0-4	chemokine (C-C motif) ligand 2	Mus musculus	149-154
31746387-4	2020	LXA4 significantly increased the cell survival rates, cell viability, SOD levels and HO-1 expression, reduced the apoptosis rates, and inhibited the MCP-1 and IL-6 levels induced by hyperoxia in cells.	lipoxin A4	0-4	interleukin 6	Mus musculus	159-163
31823816-14	2019	LXA4 seems to be the mediator of these cytoprotective actions of BDNF and PUFAs suggesting a close interaction exists among these molecules (BDNF, PUFAs and LXA4).	lipoxin A4	157-161	brain derived neurotrophic factor	Mus musculus	65-69
30773096-0	2019	Lipoxin A4 Suppresses IL-1beta-Induced Cyclooxygenase-2 Expression Through Inhibition of p38 MAPK Activation in Endometriosis.	lipoxin A4	0-10	interleukin 1 beta	Homo sapiens	22-30
30773096-0	2019	Lipoxin A4 Suppresses IL-1beta-Induced Cyclooxygenase-2 Expression Through Inhibition of p38 MAPK Activation in Endometriosis.	lipoxin A4	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	39-55
30773096-0	2019	Lipoxin A4 Suppresses IL-1beta-Induced Cyclooxygenase-2 Expression Through Inhibition of p38 MAPK Activation in Endometriosis.	lipoxin A4	0-10	mitogen-activated protein kinase 14	Homo sapiens	89-92
30773096-5	2019	Lipoxin A4 efficiently suppressed IL-1beta-induced COX-2 protein expression in ectopic endometriotic stromal cells (ESCs) via its receptor, formyl peptide receptor 2/lipoxin A4 receptor (FPR2/ALX).	lipoxin A4	0-10	interleukin 1 beta	Homo sapiens	34-42
30773096-5	2019	Lipoxin A4 efficiently suppressed IL-1beta-induced COX-2 protein expression in ectopic endometriotic stromal cells (ESCs) via its receptor, formyl peptide receptor 2/lipoxin A4 receptor (FPR2/ALX).	lipoxin A4	0-10	prostaglandin-endoperoxide synthase 2	Homo sapiens	51-56
30773096-5	2019	Lipoxin A4 efficiently suppressed IL-1beta-induced COX-2 protein expression in ectopic endometriotic stromal cells (ESCs) via its receptor, formyl peptide receptor 2/lipoxin A4 receptor (FPR2/ALX).	lipoxin A4	0-10	formyl peptide receptor 2	Homo sapiens	187-191
30773096-5	2019	Lipoxin A4 efficiently suppressed IL-1beta-induced COX-2 protein expression in ectopic endometriotic stromal cells (ESCs) via its receptor, formyl peptide receptor 2/lipoxin A4 receptor (FPR2/ALX).	lipoxin A4	0-10	hematopoietic SH2 domain containing	Homo sapiens	192-195
30773096-6	2019	Antagonism of FPR2/ALX eliminated the inhibitory effect by LXA4.	lipoxin A4	59-63	formyl peptide receptor 2	Homo sapiens	14-18
30773096-6	2019	Antagonism of FPR2/ALX eliminated the inhibitory effect by LXA4.	lipoxin A4	59-63	hematopoietic SH2 domain containing	Homo sapiens	19-22
30773096-8	2019	Pretreatment of ESCs with LXA4 inhibited the phosphorylation of p38 MAPK induced by IL-1beta.	lipoxin A4	26-30	mitogen-activated protein kinase 14	Homo sapiens	64-67
30773096-8	2019	Pretreatment of ESCs with LXA4 inhibited the phosphorylation of p38 MAPK induced by IL-1beta.	lipoxin A4	26-30	interleukin 1 beta	Homo sapiens	84-92
31781326-9	2019	Moreover, when Nrf2-knockout (Nrf2-/-) mice and cells were used to further assess the effect of the Nrf2/HO-1 pathway, we found that Nrf2 expression knockdown partially eliminated the effect of LXA4 on the reductions in inflammatory factor levels while abrogating the inhibitory effect of LXA4 on the ROS generation stimulated by AP-ALI.	lipoxin A4	194-198	nuclear factor, erythroid derived 2, like 2	Mus musculus	30-34
31781326-9	2019	Moreover, when Nrf2-knockout (Nrf2-/-) mice and cells were used to further assess the effect of the Nrf2/HO-1 pathway, we found that Nrf2 expression knockdown partially eliminated the effect of LXA4 on the reductions in inflammatory factor levels while abrogating the inhibitory effect of LXA4 on the ROS generation stimulated by AP-ALI.	lipoxin A4	194-198	heme oxygenase 1	Mus musculus	105-109
31781326-9	2019	Moreover, when Nrf2-knockout (Nrf2-/-) mice and cells were used to further assess the effect of the Nrf2/HO-1 pathway, we found that Nrf2 expression knockdown partially eliminated the effect of LXA4 on the reductions in inflammatory factor levels while abrogating the inhibitory effect of LXA4 on the ROS generation stimulated by AP-ALI.	lipoxin A4	194-198	nuclear factor, erythroid derived 2, like 2	Mus musculus	30-34
31781326-9	2019	Moreover, when Nrf2-knockout (Nrf2-/-) mice and cells were used to further assess the effect of the Nrf2/HO-1 pathway, we found that Nrf2 expression knockdown partially eliminated the effect of LXA4 on the reductions in inflammatory factor levels while abrogating the inhibitory effect of LXA4 on the ROS generation stimulated by AP-ALI.	lipoxin A4	289-293	heme oxygenase 1	Mus musculus	105-109
31781326-10	2019	Overall, LXA4 attenuated the resolution of AP-induced inflammation and ROS generation to mitigate ALI, perhaps by modulating the Nrf2/HO-1 pathway.	lipoxin A4	9-13	LIM homeobox protein 2	Mus musculus	43-45
31781326-10	2019	Overall, LXA4 attenuated the resolution of AP-induced inflammation and ROS generation to mitigate ALI, perhaps by modulating the Nrf2/HO-1 pathway.	lipoxin A4	9-13	nuclear factor, erythroid derived 2, like 2	Mus musculus	129-133
31781326-10	2019	Overall, LXA4 attenuated the resolution of AP-induced inflammation and ROS generation to mitigate ALI, perhaps by modulating the Nrf2/HO-1 pathway.	lipoxin A4	9-13	heme oxygenase 1	Mus musculus	134-138
31823816-8	2019	Sub-optimal doses of BDNF, LXA4, AA and EPA when used in combination protected against cytotoxic action of AL/STZ/DB/BP on RIN5F cells in vitro by restoring LXA4/BDNF levels and altered antioxidant/lipid peroxides/NO levels (P &lt; 0.01) to normal.	lipoxin A4	157-161	brain derived neurotrophic factor	Mus musculus	21-25
31823816-14	2019	LXA4 seems to be the mediator of these cytoprotective actions of BDNF and PUFAs suggesting a close interaction exists among these molecules (BDNF, PUFAs and LXA4).	lipoxin A4	0-4	brain derived neurotrophic factor	Mus musculus	65-69
31823816-14	2019	LXA4 seems to be the mediator of these cytoprotective actions of BDNF and PUFAs suggesting a close interaction exists among these molecules (BDNF, PUFAs and LXA4).	lipoxin A4	0-4	brain derived neurotrophic factor	Mus musculus	141-145
31200255-0	2019	15-epi-lipoxin A4 inhibits TNF-alpha-induced tissue factor expression via the PI3K/AKT/ NF-kappaB axis in human umbilical vein endothelial cells.	lipoxin A4	0-17	tumor necrosis factor	Homo sapiens	27-36
31781326-0	2019	Lipoxin A4 Ameliorates Acute Pancreatitis-Associated Acute Lung Injury through the Antioxidative and Anti-Inflammatory Effects of the Nrf2 Pathway.	lipoxin A4	0-10	nuclear factor, erythroid derived 2, like 2	Mus musculus	134-138
31781326-6	2019	Next, using ELISA, PCR, and fluorescence detection to evaluate different parameters, LXA4 was shown to reduce the inflammatory cytokine production induced by AP and block reactive oxygen species (ROS) generation in vivo and in vitro.	lipoxin A4	85-89	LIM homeobox protein 2	Mus musculus	158-160
31781326-9	2019	Moreover, when Nrf2-knockout (Nrf2-/-) mice and cells were used to further assess the effect of the Nrf2/HO-1 pathway, we found that Nrf2 expression knockdown partially eliminated the effect of LXA4 on the reductions in inflammatory factor levels while abrogating the inhibitory effect of LXA4 on the ROS generation stimulated by AP-ALI.	lipoxin A4	194-198	nuclear factor, erythroid derived 2, like 2	Mus musculus	30-34
31200255-0	2019	15-epi-lipoxin A4 inhibits TNF-alpha-induced tissue factor expression via the PI3K/AKT/ NF-kappaB axis in human umbilical vein endothelial cells.	lipoxin A4	0-17	coagulation factor III, tissue factor	Homo sapiens	45-58
31200255-0	2019	15-epi-lipoxin A4 inhibits TNF-alpha-induced tissue factor expression via the PI3K/AKT/ NF-kappaB axis in human umbilical vein endothelial cells.	lipoxin A4	0-17	AKT serine/threonine kinase 1	Homo sapiens	83-86
31438948-6	2019	RESULTS: In vivo, lipoxin A4 markedly promoted alveolar epithelial type II cells (AT II cells) proliferation, inhibited AT II cells apoptosis, reduced cleaved caspase-3 expression and epithelial-mesenchymal transition, with the outcome of attenuated LPS-induced lung injury.	lipoxin A4	18-28	caspase 3	Homo sapiens	159-168
31438948-9	2019	In addition, Smad3 inhibitor (Sis3) and PI3K inhibitor (LY294002) treatment abolished the inhibitory effects of lipoxinA4 on the epithelial mesenchymal transition of primary human AT II cells.	lipoxin A4	112-121	SMAD family member 3	Homo sapiens	13-18
31438948-10	2019	Lipoxin A4 significantly downregulated the expressions of p-AKT and p-Smad stimulated by TGF-beta1 in primary human AT II cells.	lipoxin A4	0-10	AKT serine/threonine kinase 1	Homo sapiens	60-63
31438948-10	2019	Lipoxin A4 significantly downregulated the expressions of p-AKT and p-Smad stimulated by TGF-beta1 in primary human AT II cells.	lipoxin A4	0-10	transforming growth factor beta 1	Homo sapiens	89-98
31059786-0	2019	Lipoxin A4 restores oxidative stress-induced vascular endothelial cell injury and thrombosis-related factor expression by its receptor-mediated activation of Nrf2-HO-1 axis.	lipoxin A4	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	158-162
31059786-0	2019	Lipoxin A4 restores oxidative stress-induced vascular endothelial cell injury and thrombosis-related factor expression by its receptor-mediated activation of Nrf2-HO-1 axis.	lipoxin A4	0-10	heme oxygenase 1	Homo sapiens	163-167
31059786-5	2019	In the present study, LXA4 supplementation dampened H2O2-evoked cytotoxic injury in human umbilical vein endothelial cells (HUVECs) by increasing cell viability, suppressing cell apoptosis and caspase-3 activity.	lipoxin A4	22-26	caspase 3	Homo sapiens	193-202
31059786-7	2019	Notably, LXA4 administration attenuated pro-vasoconstriction factor endothelin-1(ET-1) expression in HUVECs exposed to H2O2, but enhanced the productions of vasodilatation factor NO and prostacyclin (PGI2).	lipoxin A4	9-13	endothelin 1	Homo sapiens	68-80
31059786-7	2019	Notably, LXA4 administration attenuated pro-vasoconstriction factor endothelin-1(ET-1) expression in HUVECs exposed to H2O2, but enhanced the productions of vasodilatation factor NO and prostacyclin (PGI2).	lipoxin A4	9-13	endothelin 1	Homo sapiens	81-85
31059786-9	2019	Mechanism analysis substantiated that LXA4 further augmented activation of the Nrf2-HO-1 pathway.	lipoxin A4	38-42	NFE2 like bZIP transcription factor 2	Homo sapiens	79-83
31059786-9	2019	Mechanism analysis substantiated that LXA4 further augmented activation of the Nrf2-HO-1 pathway.	lipoxin A4	38-42	heme oxygenase 1	Homo sapiens	84-88
31059786-12	2019	Accordingly, this study suggests that LXA4 may ameliorate vascular endothelial cell oxidative stress injury and subsequent thrombotic response via LXA4 receptor-dependent activation of the Nrf2-HO-1 signaling, implying a promising strategy for DVT and its complication.	lipoxin A4	38-42	formyl peptide receptor 2	Homo sapiens	147-160
31059786-12	2019	Accordingly, this study suggests that LXA4 may ameliorate vascular endothelial cell oxidative stress injury and subsequent thrombotic response via LXA4 receptor-dependent activation of the Nrf2-HO-1 signaling, implying a promising strategy for DVT and its complication.	lipoxin A4	38-42	NFE2 like bZIP transcription factor 2	Homo sapiens	189-193
31059786-12	2019	Accordingly, this study suggests that LXA4 may ameliorate vascular endothelial cell oxidative stress injury and subsequent thrombotic response via LXA4 receptor-dependent activation of the Nrf2-HO-1 signaling, implying a promising strategy for DVT and its complication.	lipoxin A4	38-42	heme oxygenase 1	Homo sapiens	194-198
31152979-0	2019	Lipoxin A4 reduces hyperoxia-induced lung injury in neonatal rats through PINK1 signaling pathway.	lipoxin A4	0-10	PTEN induced kinase 1	Rattus norvegicus	74-79
31418419-3	2019	Because the regenerative capacity of hepatocytes in acute and chronic liver failure models of mouse increases by silencing MKK4, we aimed to investigate the effect of parenteral administration of LXA4 on the genes responsible for regeneration of liver, namely MKK4, MKK7, and ATF2, and visualize the therapeutic effects in an experimental model.	lipoxin A4	196-200	mitogen-activated protein kinase kinase 4	Mus musculus	260-264
31418419-13	2019	TGF-alpha and MKK4 expressions were significantly reduced in the LXA4-treated group.	lipoxin A4	65-69	transforming growth factor alpha	Mus musculus	0-9
31418419-13	2019	TGF-alpha and MKK4 expressions were significantly reduced in the LXA4-treated group.	lipoxin A4	65-69	mitogen-activated protein kinase kinase 4	Mus musculus	14-18
31418419-14	2019	Administration of LXA4 caused significant elevation of IL-10 in systemic circulation; however, that elevation was not detected in liver homogenates.	lipoxin A4	18-22	interleukin 10	Mus musculus	55-60
31200255-0	2019	15-epi-lipoxin A4 inhibits TNF-alpha-induced tissue factor expression via the PI3K/AKT/ NF-kappaB axis in human umbilical vein endothelial cells.	lipoxin A4	0-17	nuclear factor kappa B subunit 1	Homo sapiens	88-97
31559067-8	2019	Results: LXA4 treatment was found to inhibit AFC capacity, inflammatory cytokine release, partially, alleviate ALI severity, and restored AQP5 expression partially.	lipoxin A4	9-13	aquaporin 5	Homo sapiens	138-142
31200255-3	2019	This study aimed to demonstrate whether 15-epi-LXA4 could suppress the inflammatory factor tumor necrosis factor-alpha (TNF-alpha)-induced upregulation of tissue factor (TF), an important regulator of the blood coagulation cascade, and evaluated the possible underlying mechanisms.	lipoxin A4	40-51	tumor necrosis factor	Homo sapiens	91-118
31559067-9	2019	Additionally, we found that LXA4 played a protective role by the inhibition of the phosphorylation of p38 and JNK.	lipoxin A4	28-32	mitogen-activated protein kinase 14	Homo sapiens	102-105
31559067-9	2019	Additionally, we found that LXA4 played a protective role by the inhibition of the phosphorylation of p38 and JNK.	lipoxin A4	28-32	mitogen-activated protein kinase 8	Homo sapiens	110-113
31200255-3	2019	This study aimed to demonstrate whether 15-epi-LXA4 could suppress the inflammatory factor tumor necrosis factor-alpha (TNF-alpha)-induced upregulation of tissue factor (TF), an important regulator of the blood coagulation cascade, and evaluated the possible underlying mechanisms.	lipoxin A4	40-51	tumor necrosis factor	Homo sapiens	120-129
31559067-10	2019	Conclusions: In summary, our results suggest that LXA4 plays a protective role in lipopolysaccharide-induced ALI by restoring AFC capacity and upregulating AQP5 expression and inhibiting the phosphorylation of p38 and JNK.	lipoxin A4	50-54	aquaporin 5	Homo sapiens	156-160
31200255-3	2019	This study aimed to demonstrate whether 15-epi-LXA4 could suppress the inflammatory factor tumor necrosis factor-alpha (TNF-alpha)-induced upregulation of tissue factor (TF), an important regulator of the blood coagulation cascade, and evaluated the possible underlying mechanisms.	lipoxin A4	40-51	coagulation factor III, tissue factor	Homo sapiens	155-168
31559067-10	2019	Conclusions: In summary, our results suggest that LXA4 plays a protective role in lipopolysaccharide-induced ALI by restoring AFC capacity and upregulating AQP5 expression and inhibiting the phosphorylation of p38 and JNK.	lipoxin A4	50-54	mitogen-activated protein kinase 14	Homo sapiens	210-213
31559067-10	2019	Conclusions: In summary, our results suggest that LXA4 plays a protective role in lipopolysaccharide-induced ALI by restoring AFC capacity and upregulating AQP5 expression and inhibiting the phosphorylation of p38 and JNK.	lipoxin A4	50-54	mitogen-activated protein kinase 8	Homo sapiens	218-221
31200255-5	2019	In addition, 15-epi-LXA4 suppressed the activation of the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway, induced by TNF-alpha, in pc-HUVECs.	lipoxin A4	13-24	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	58-83
31200255-5	2019	In addition, 15-epi-LXA4 suppressed the activation of the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway, induced by TNF-alpha, in pc-HUVECs.	lipoxin A4	13-24	AKT serine/threonine kinase 1	Homo sapiens	91-94
31200255-5	2019	In addition, 15-epi-LXA4 suppressed the activation of the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway, induced by TNF-alpha, in pc-HUVECs.	lipoxin A4	13-24	tumor necrosis factor	Homo sapiens	125-134
31200255-6	2019	15-epi-LXA4 also inhibited the binding of NF-kappaB on the TF promoter, which is otherwise enhanced by TNF-alpha.	lipoxin A4	0-11	nuclear factor kappa B subunit 1	Homo sapiens	42-51
31200255-6	2019	15-epi-LXA4 also inhibited the binding of NF-kappaB on the TF promoter, which is otherwise enhanced by TNF-alpha.	lipoxin A4	0-11	tumor necrosis factor	Homo sapiens	103-112
31200255-7	2019	The role of 15-epi-LXA4 in regulating TNF-alpha-induced effects was enhanced by the PI3K inhibitor and prevented by the PI3K activator.	lipoxin A4	12-23	tumor necrosis factor	Homo sapiens	38-47
31200255-8	2019	In conclusion, 15-epi-LXA4 lowered the TNF-alpha-induced high TF expression and activity by suppressing PI3K/AKT signaling activation, thereby reducing the binding capacity of NF-kappaB on the TF promoter in pc-HUVECs.	lipoxin A4	15-26	tumor necrosis factor	Homo sapiens	39-48
31200255-8	2019	In conclusion, 15-epi-LXA4 lowered the TNF-alpha-induced high TF expression and activity by suppressing PI3K/AKT signaling activation, thereby reducing the binding capacity of NF-kappaB on the TF promoter in pc-HUVECs.	lipoxin A4	15-26	AKT serine/threonine kinase 1	Homo sapiens	109-112
31200255-8	2019	In conclusion, 15-epi-LXA4 lowered the TNF-alpha-induced high TF expression and activity by suppressing PI3K/AKT signaling activation, thereby reducing the binding capacity of NF-kappaB on the TF promoter in pc-HUVECs.	lipoxin A4	15-26	nuclear factor kappa B subunit 1	Homo sapiens	176-185
30340110-11	2018	Furthermore, LXA4 inhibited the oxLDL-activated c-Jun N-terminal kinase pathway and reduced oxLDL-induced macrophage apoptosis by inhibiting caspase-3 activation and restoring the mitochondrial membrane potential.	lipoxin A4	13-17	caspase-3	Oryctolagus cuniculus	141-150
31184596-4	2019	Cox2 MKO also reduced inflammation resolving lipoxin A4 (LXA4) in intestinal tissue, while administration of an LXA4 analog rescued disease in Cox2 MKO mice fed CCHF.	lipoxin A4	45-55	prostaglandin-endoperoxide synthase 2	Mus musculus	0-4
30118542-6	2019	The results indicate that LA4 markedly inhibits inflammatory cells infiltration, attenuates myeloperoxidase activity, and reduces the concentration of inflammatory mediators and Toll-like receptor 4 (TLR4) in RIR-induced ALI.	lipoxin A4	26-29	myeloperoxidase	Mus musculus	92-107
30118542-6	2019	The results indicate that LA4 markedly inhibits inflammatory cells infiltration, attenuates myeloperoxidase activity, and reduces the concentration of inflammatory mediators and Toll-like receptor 4 (TLR4) in RIR-induced ALI.	lipoxin A4	26-29	toll-like receptor 4	Mus musculus	178-198
30118542-6	2019	The results indicate that LA4 markedly inhibits inflammatory cells infiltration, attenuates myeloperoxidase activity, and reduces the concentration of inflammatory mediators and Toll-like receptor 4 (TLR4) in RIR-induced ALI.	lipoxin A4	26-29	toll-like receptor 4	Mus musculus	200-204
30118542-9	2019	These results indicate that LA4 exerts powerful anti-inflammatory functions in RIR-induced ALI by attenuating TLR4 expression via MAPK and NF-kappaB signalling.	lipoxin A4	28-31	toll-like receptor 4	Mus musculus	110-114
31023998-0	2019	Mesenchymal Stem Cells Reverse Diabetic Nephropathy Disease via Lipoxin A4 by Targeting Transforming Growth Factor beta (TGF-beta)/smad Pathway and Pro-Inflammatory Cytokines.	lipoxin A4	64-74	transforming growth factor, beta 1	Rattus norvegicus	121-129
31023998-10	2019	Intraperitoneal injection of LXA4 inhibited renal fibrosis by targeting TGF-ss/Smad signaling and downregulated serum TNF-alpha, IL-6, IL-8, and IFN-gamma in DN rats.	lipoxin A4	29-33	tumor necrosis factor	Rattus norvegicus	118-127
31023998-10	2019	Intraperitoneal injection of LXA4 inhibited renal fibrosis by targeting TGF-ss/Smad signaling and downregulated serum TNF-alpha, IL-6, IL-8, and IFN-gamma in DN rats.	lipoxin A4	29-33	interleukin 6	Rattus norvegicus	129-133
31023998-10	2019	Intraperitoneal injection of LXA4 inhibited renal fibrosis by targeting TGF-ss/Smad signaling and downregulated serum TNF-alpha, IL-6, IL-8, and IFN-gamma in DN rats.	lipoxin A4	29-33	interleukin 18	Rattus norvegicus	145-154
30778288-0	2019	Lipoxin A4 Regulates Lipopolysaccharide-Induced BV2 Microglial Activation and Differentiation via the Notch Signaling Pathway.	lipoxin A4	0-10	notch 1	Mus musculus	102-107
30407793-2	2018	5-LOX does not react with 5,15-diHpETE, although it can produce LXA4 when 15-HpETE is the substrate.	lipoxin A4	64-68	arachidonate 5-lipoxygenase	Homo sapiens	2-5
30556891-2	2018	The transporter multidrug resistance-associated protein 4 (MRP4/ABCC4) is expressed in human endometrial tissue; it is overexpressed in ectopic endometrial tissue, and is modulated by the anti-inflammatory lipid Lipoxin A4 (LXA4).	lipoxin A4	212-222	ATP binding cassette subfamily C member 4	Homo sapiens	16-57
30556891-2	2018	The transporter multidrug resistance-associated protein 4 (MRP4/ABCC4) is expressed in human endometrial tissue; it is overexpressed in ectopic endometrial tissue, and is modulated by the anti-inflammatory lipid Lipoxin A4 (LXA4).	lipoxin A4	212-222	ATP binding cassette subfamily C member 4	Homo sapiens	59-63
30556891-2	2018	The transporter multidrug resistance-associated protein 4 (MRP4/ABCC4) is expressed in human endometrial tissue; it is overexpressed in ectopic endometrial tissue, and is modulated by the anti-inflammatory lipid Lipoxin A4 (LXA4).	lipoxin A4	212-222	ATP binding cassette subfamily C member 4	Homo sapiens	64-69
29948727-12	2018	This might be due to an effect of FPR2 in mediating arachidonic acid/LXA4 or DHA/RvD1-induced axonal or dendritic outgrowth.	lipoxin A4	69-73	formyl peptide receptor 2	Rattus norvegicus	34-38
30138965-0	2018	[Lipoxin A4 inhibits the invasion and migration of endometrial stromal cells by down-regulating NF-kappaB signaling-mediated autophagy].	lipoxin A4	1-11	nuclear factor kappa B subunit 1	Homo sapiens	96-105
30138965-12	2018	There was a significant negative correlation between LXA4 concentration and relative expression of LC3-II in ectopic lesions (r= -0.780, P=0.002) .	lipoxin A4	53-57	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	99-102
30219663-0	2018	LipoxinA4 attenuates acute pancreatitis-associated acute lung injury by regulating AQP-5 and MMP-9 expression, anti-apoptosis and PKC/SSeCKS-mediated F-actin activation.	lipoxin A4	0-9	aquaporin 5	Mus musculus	83-88
30219663-0	2018	LipoxinA4 attenuates acute pancreatitis-associated acute lung injury by regulating AQP-5 and MMP-9 expression, anti-apoptosis and PKC/SSeCKS-mediated F-actin activation.	lipoxin A4	0-9	matrix metallopeptidase 9	Mus musculus	93-98
30219663-0	2018	LipoxinA4 attenuates acute pancreatitis-associated acute lung injury by regulating AQP-5 and MMP-9 expression, anti-apoptosis and PKC/SSeCKS-mediated F-actin activation.	lipoxin A4	0-9	A kinase (PRKA) anchor protein (gravin) 12	Mus musculus	134-140
30219663-3	2018	In previous studies, we found that Lipoxin A4 (LXA4) reduced AP-induced pulmonary oedema and TNF-alpha production in lung.	lipoxin A4	35-45	tumor necrosis factor	Mus musculus	93-102
29684359-1	2018	Lipoxin receptor (ALX)/N-formyl peptide receptor (FPR)-2 is a G-protein-coupled receptor that has multiple binding partners, including the endogenous lipid mediators resolvin D1, lipoxin A4, and the Ca2+-dependent phospholipid-binding protein annexin A1.	lipoxin A4	179-189	formyl peptide receptor 3	Mus musculus	18-21
29969931-0	2018	Lipoxin A4 attenuates LPS-induced acute lung injury via activation of the ACE2-Ang-(1-7)-Mas axis.	lipoxin A4	0-10	angiotensin I converting enzyme (peptidyl-dipeptidase A) 2	Mus musculus	74-78
29969931-7	2018	Fourth, LXA4 inhibited the activation of the NF-kappaB signal pathway and repressed the degradation of inhibitor of NF-kappaB, the phosphorylation of NF-kappaB, and the translocation of NF-kappaB.	lipoxin A4	8-12	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	45-54
29969931-7	2018	Fourth, LXA4 inhibited the activation of the NF-kappaB signal pathway and repressed the degradation of inhibitor of NF-kappaB, the phosphorylation of NF-kappaB, and the translocation of NF-kappaB.	lipoxin A4	8-12	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	116-125
29969931-7	2018	Fourth, LXA4 inhibited the activation of the NF-kappaB signal pathway and repressed the degradation of inhibitor of NF-kappaB, the phosphorylation of NF-kappaB, and the translocation of NF-kappaB.	lipoxin A4	8-12	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	116-125
29969931-7	2018	Fourth, LXA4 inhibited the activation of the NF-kappaB signal pathway and repressed the degradation of inhibitor of NF-kappaB, the phosphorylation of NF-kappaB, and the translocation of NF-kappaB.	lipoxin A4	8-12	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	116-125
30022762-0	2018	[Effect of lipoxin A4 on the expression of Toll-like receptor 4 and TNF receptor-associated factor 6 in the liver of obese rats with sepsis].	lipoxin A4	11-21	toll-like receptor 4	Rattus norvegicus	43-63
30022762-0	2018	[Effect of lipoxin A4 on the expression of Toll-like receptor 4 and TNF receptor-associated factor 6 in the liver of obese rats with sepsis].	lipoxin A4	11-21	TNF receptor associated factor 6	Rattus norvegicus	68-100
30022762-1	2018	OBJECTIVE: To study the protective effect of lipoxin A4 (LXA4) against sepsis induced by lipopolysaccharide (LPS) in rats with obesity and its effect on the expression of Toll-like receptor 4 (TLR4) and TNF receptor-associated factor 6 (TRAF6) in the liver.	lipoxin A4	45-55	toll-like receptor 4	Rattus norvegicus	171-191
30022762-1	2018	OBJECTIVE: To study the protective effect of lipoxin A4 (LXA4) against sepsis induced by lipopolysaccharide (LPS) in rats with obesity and its effect on the expression of Toll-like receptor 4 (TLR4) and TNF receptor-associated factor 6 (TRAF6) in the liver.	lipoxin A4	57-61	toll-like receptor 4	Rattus norvegicus	171-191
29786049-0	2018	Lipoxin A4 Ameliorates Lipopolysaccharide-Induced A549 Cell Injury through Upregulation of N-myc Downstream-Regulated Gene-1.	lipoxin A4	0-10	N-myc downstream regulated 1	Homo sapiens	91-124
29787808-0	2018	Lipoxin A4 and its analog suppress hepatocarcinoma cell epithelial-mesenchymal transition, migration and metastasis via regulating integrin-linked kinase axis.	lipoxin A4	0-10	integrin linked kinase	Homo sapiens	131-153
29892010-0	2018	Lipoxin A4 Attenuates the Inflammatory Response in Stem Cells of the Apical Papilla via ALX/FPR2.	lipoxin A4	0-10	hematopoietic SH2 domain containing	Homo sapiens	88-91
29892010-0	2018	Lipoxin A4 Attenuates the Inflammatory Response in Stem Cells of the Apical Papilla via ALX/FPR2.	lipoxin A4	0-10	formyl peptide receptor 2	Homo sapiens	92-96
29684359-1	2018	Lipoxin receptor (ALX)/N-formyl peptide receptor (FPR)-2 is a G-protein-coupled receptor that has multiple binding partners, including the endogenous lipid mediators resolvin D1, lipoxin A4, and the Ca2+-dependent phospholipid-binding protein annexin A1.	lipoxin A4	179-189	formyl peptide receptor 2	Mus musculus	23-56
29499280-0	2018	Lipoxin A4 may attenuate the progression of obesity-related glomerulopathy by inhibiting NF-kappaB and ERK/p38 MAPK-dependent inflammation.	lipoxin A4	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	89-98
31938370-0	2018	Aspirin-triggered lipoxin A4 attenuates lipopolysaccharide-induced acute lung injury by inhibiting activation of mitogen-activated protein kinases and NF-kappaB in mice.	lipoxin A4	18-28	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	151-160
29523657-0	2018	15-epi-Lipoxin A4, Resolvin D2, and Resolvin D3 Induce NF-kappaB Regulators in Bacterial Pneumonia.	lipoxin A4	0-17	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	55-64
29523657-5	2018	Of interest, 15-epi-LXA4 induced A20 and SIGIRR in an lipoxin A4 receptor/formyl peptide receptor 2 (ALX/FPR2) receptor-dependent manner in epithelial cells and in murine pneumonia.	lipoxin A4	13-24	tumor necrosis factor, alpha-induced protein 3	Mus musculus	33-36
29523657-5	2018	Of interest, 15-epi-LXA4 induced A20 and SIGIRR in an lipoxin A4 receptor/formyl peptide receptor 2 (ALX/FPR2) receptor-dependent manner in epithelial cells and in murine pneumonia.	lipoxin A4	13-24	single immunoglobulin and toll-interleukin 1 receptor (TIR) domain	Mus musculus	41-47
29523657-5	2018	Of interest, 15-epi-LXA4 induced A20 and SIGIRR in an lipoxin A4 receptor/formyl peptide receptor 2 (ALX/FPR2) receptor-dependent manner in epithelial cells and in murine pneumonia.	lipoxin A4	13-24	formyl peptide receptor 3	Mus musculus	101-104
29523657-5	2018	Of interest, 15-epi-LXA4 induced A20 and SIGIRR in an lipoxin A4 receptor/formyl peptide receptor 2 (ALX/FPR2) receptor-dependent manner in epithelial cells and in murine pneumonia.	lipoxin A4	13-24	formyl peptide receptor 2	Mus musculus	105-109
28869373-0	2018	Lipoxin A4 alleviates cerebral ischemia-reperfusion injury through up-regulating Nrf2.	lipoxin A4	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	81-85
29499280-0	2018	Lipoxin A4 may attenuate the progression of obesity-related glomerulopathy by inhibiting NF-kappaB and ERK/p38 MAPK-dependent inflammation.	lipoxin A4	0-10	mitogen-activated protein kinase 1	Mus musculus	103-106
29499280-0	2018	Lipoxin A4 may attenuate the progression of obesity-related glomerulopathy by inhibiting NF-kappaB and ERK/p38 MAPK-dependent inflammation.	lipoxin A4	0-10	mitogen-activated protein kinase 14	Mus musculus	107-115
29707294-0	2018	Lipoxin A4 regulates PM2.5-induced severe allergic asthma in mice via the Th1/Th2 balance of group 2 innate lymphoid cells.	lipoxin A4	0-10	negative elongation factor complex member C/D, Th1l	Mus musculus	74-77
28691579-0	2018	Lipoxin A4 Suppresses Estrogen-Induced Epithelial-Mesenchymal Transition via ALXR-Dependent Manner in Endometriosis.	lipoxin A4	0-10	formyl peptide receptor 2	Homo sapiens	77-81
28691579-10	2018	Lipoxin A4 reduced E2-induced ZEB1 promoter activity.	lipoxin A4	0-10	zinc finger E-box binding homeobox 1	Homo sapiens	30-34
28691579-11	2018	Lipoxin A4 also attenuated the phosphorylation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase induced by E2.	lipoxin A4	0-10	mitogen-activated protein kinase 14	Homo sapiens	92-95
28691579-15	2018	CONCLUSION: Lipoxin A4 suppresses E2-induced EMT via ALXR-dependent manner in eutopic EECs, which reveals a novel biological effect of LXA4 in EM.	lipoxin A4	12-22	formyl peptide receptor 2	Homo sapiens	53-57
28691579-15	2018	CONCLUSION: Lipoxin A4 suppresses E2-induced EMT via ALXR-dependent manner in eutopic EECs, which reveals a novel biological effect of LXA4 in EM.	lipoxin A4	135-139	formyl peptide receptor 2	Homo sapiens	53-57
29136768-0	2018	Lipoxin A4 protects against spinal cord injury via regulating Akt/nuclear factor (erythroid-derived 2)-like 2/heme oxygenase-1 signaling.	lipoxin A4	0-10	AKT serine/threonine kinase 1	Rattus norvegicus	62-65
29136768-0	2018	Lipoxin A4 protects against spinal cord injury via regulating Akt/nuclear factor (erythroid-derived 2)-like 2/heme oxygenase-1 signaling.	lipoxin A4	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	66-109
29136768-0	2018	Lipoxin A4 protects against spinal cord injury via regulating Akt/nuclear factor (erythroid-derived 2)-like 2/heme oxygenase-1 signaling.	lipoxin A4	0-10	heme oxygenase 1	Rattus norvegicus	110-126
29136768-12	2018	shNrf2 and ZnPP prohibited LXA4-induced increase of BBB scores, and PWT and PWL, decrease of lesion volume of spinal cord, reduction of Bax expression and increase of Bcl-2 expression.	lipoxin A4	27-31	BCL2 associated X, apoptosis regulator	Rattus norvegicus	136-139
29136768-12	2018	shNrf2 and ZnPP prohibited LXA4-induced increase of BBB scores, and PWT and PWL, decrease of lesion volume of spinal cord, reduction of Bax expression and increase of Bcl-2 expression.	lipoxin A4	27-31	BCL2, apoptosis regulator	Rattus norvegicus	167-172
29228980-0	2017	Lipoxin A4 reverses mesenchymal phenotypes to attenuate invasion and metastasis via the inhibition of autocrine TGF-beta1 signaling in pancreatic cancer.	lipoxin A4	0-10	transforming growth factor beta 1	Homo sapiens	112-121
29228980-2	2017	Lipoxin A4 (LXA4) is one of the metabolites that is derived from arachidonic acid and that is catalyzed by 15-lipoxygenase (15-LOX), and it has recently been reported to exhibit anti-cancer effects.	lipoxin A4	0-10	arachidonate 15-lipoxygenase	Homo sapiens	107-122
29228980-2	2017	Lipoxin A4 (LXA4) is one of the metabolites that is derived from arachidonic acid and that is catalyzed by 15-lipoxygenase (15-LOX), and it has recently been reported to exhibit anti-cancer effects.	lipoxin A4	0-10	arachidonate 15-lipoxygenase	Homo sapiens	124-130
29228980-2	2017	Lipoxin A4 (LXA4) is one of the metabolites that is derived from arachidonic acid and that is catalyzed by 15-lipoxygenase (15-LOX), and it has recently been reported to exhibit anti-cancer effects.	lipoxin A4	12-16	arachidonate 15-lipoxygenase	Homo sapiens	107-122
29228980-2	2017	Lipoxin A4 (LXA4) is one of the metabolites that is derived from arachidonic acid and that is catalyzed by 15-lipoxygenase (15-LOX), and it has recently been reported to exhibit anti-cancer effects.	lipoxin A4	12-16	arachidonate 15-lipoxygenase	Homo sapiens	124-130
29185103-2	2017	Statins and ticagrelor increase the production of 15-epi-lipoxin A4 via cyclooxygenase-2.	lipoxin A4	50-67	prostaglandin-endoperoxide synthase 2	Mus musculus	72-88
28724795-8	2017	SAA and aliquots of LXA4loSAAhi BAL fluid induced IL-8 production by lung epithelial cells expressing ALX receptors, which was inhibited by coincubation with 15-epi-LXA4.	lipoxin A4	158-169	serum amyloid A1 cluster	Homo sapiens	0-3
28071789-0	2017	Aspirin-triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E-/- mice.	lipoxin A4	18-28	apolipoprotein E	Mus musculus	69-85
28694081-11	2017	Treatment of cartilage explants with 12/15-LOX metabolites, suppressed IL-1alpha-induced production of MMP-13, NO and PGE2, with LXA4 being the most potent.	lipoxin A4	129-133	arachidonate 15-lipoxygenase	Mus musculus	37-46
28694081-11	2017	Treatment of cartilage explants with 12/15-LOX metabolites, suppressed IL-1alpha-induced production of MMP-13, NO and PGE2, with LXA4 being the most potent.	lipoxin A4	129-133	interleukin 1 alpha	Mus musculus	71-80
28887458-7	2017	Inhibition of 15-PGDH using either indomethacin or SW033291 significantly reduced the further conversion of 15-epi-LXA4 and MaR1 and regulated expression of IL-6, PDPN and STAT-1.	lipoxin A4	108-119	15-hydroxyprostaglandin dehydrogenase	Homo sapiens	14-21
28855632-9	2017	During the resolving phase-(d5), 15-epi-LXA4 initiated rapid neutrophils clearance with persistent activation of FPR2 in LV.	lipoxin A4	33-44	formyl peptide receptor 2	Mus musculus	113-117
28769106-0	2017	Lipoxin A4 and its analog suppress inflammation by modulating HMGB1 translocation and expression in psoriasis.	lipoxin A4	0-10	high mobility group box 1	Mus musculus	62-67
28724795-8	2017	SAA and aliquots of LXA4loSAAhi BAL fluid induced IL-8 production by lung epithelial cells expressing ALX receptors, which was inhibited by coincubation with 15-epi-LXA4.	lipoxin A4	158-169	C-X-C motif chemokine ligand 8	Homo sapiens	50-54
28724795-8	2017	SAA and aliquots of LXA4loSAAhi BAL fluid induced IL-8 production by lung epithelial cells expressing ALX receptors, which was inhibited by coincubation with 15-epi-LXA4.	lipoxin A4	158-169	hematopoietic SH2 domain containing	Homo sapiens	102-105
27993857-5	2017	Here, the action of simvastatin in a murine model of chronic Chagas cardiomyopathy and the link with the production of the proresolving eicosanoid 15-epi-lipoxin A4, produced by 5-lipoxygenase, are evaluated.	lipoxin A4	147-164	arachidonate 5-lipoxygenase	Mus musculus	178-192
28259922-15	2017	Therefore, LXA4-induced renoprotection is associated with activation of the p38 MAPK/PPARgamma/Nrf2-ARE/HO-1 pathway.	lipoxin A4	11-15	mitogen-activated protein kinase 14	Homo sapiens	76-84
28259922-15	2017	Therefore, LXA4-induced renoprotection is associated with activation of the p38 MAPK/PPARgamma/Nrf2-ARE/HO-1 pathway.	lipoxin A4	11-15	peroxisome proliferator activated receptor gamma	Homo sapiens	85-94
28259922-15	2017	Therefore, LXA4-induced renoprotection is associated with activation of the p38 MAPK/PPARgamma/Nrf2-ARE/HO-1 pathway.	lipoxin A4	11-15	NFE2 like bZIP transcription factor 2	Homo sapiens	95-99
28259922-15	2017	Therefore, LXA4-induced renoprotection is associated with activation of the p38 MAPK/PPARgamma/Nrf2-ARE/HO-1 pathway.	lipoxin A4	11-15	heme oxygenase 1	Homo sapiens	104-108
27615282-4	2017	This study tested the hypothesis that ATL-1, a synthetic analogue of 15-epi-lipoxin A4 , could modulate TAM activity profile.	lipoxin A4	69-86	atlastin GTPase 1	Homo sapiens	38-43
28100645-0	2017	Lipoxin A4 stimulates endothelial miR-126-5p expression and its transfer via microvesicles.	lipoxin A4	0-10	microRNA 1265	Homo sapiens	34-44
28485793-0	2017	Lipoxin A4 mitigates experimental autoimmune myocarditis by regulating inflammatory response, NF-kappaB and PI3K/Akt signaling pathway in mice.	lipoxin A4	0-10	thymoma viral proto-oncogene 1	Mus musculus	113-116
28485793-11	2017	Furthermore, LXA4 administration effectively inhibited NF-kappaB nuclear translocation and deactivated PI3K/Akt pathway.	lipoxin A4	13-17	thymoma viral proto-oncogene 1	Mus musculus	108-111
28259922-8	2017	Preincubation of cells with LXA4 exposed to H/R injury led to a decreased production of inducible nitrogen oxide synthase, malondialdehyde, gamma-glutamyl transpeptidase, leucine aminopeptidase and N-acetyl-beta-glucosaminidase.	lipoxin A4	28-32	inactive glutathione hydrolase 2	Homo sapiens	140-169
28259922-8	2017	Preincubation of cells with LXA4 exposed to H/R injury led to a decreased production of inducible nitrogen oxide synthase, malondialdehyde, gamma-glutamyl transpeptidase, leucine aminopeptidase and N-acetyl-beta-glucosaminidase.	lipoxin A4	28-32	O-GlcNAcase	Homo sapiens	198-227
28492741-0	2017	Effect of Alox-15 Polymorphism on GCF Levels of Lipoxin-A4 in Chronic Periodontitis: A Preliminary Study.	lipoxin A4	48-58	arachidonate 15-lipoxygenase	Homo sapiens	10-17
27887602-1	2016	It has been suggested that aspirin may be of benefit in treating sepsis and ARDS in view of its ability to block cyclo-oxygenase-1 (COX-1) and COX-2 activities; inhibit nuclear factor kappa B (NF-kappaB); enhance the production of endothelial nitric oxide (eNO) and lipoxin A4 (LXA4).	lipoxin A4	266-276	nuclear factor kappa B subunit 1	Homo sapiens	193-202
27072607-0	2017	Lipoxin A4 activates ALX/FPR2 receptor to regulate conjunctival goblet cell secretion.	lipoxin A4	0-10	formyl peptide receptor 2-like	Rattus norvegicus	21-24
27072607-0	2017	Lipoxin A4 activates ALX/FPR2 receptor to regulate conjunctival goblet cell secretion.	lipoxin A4	0-10	formyl peptide receptor 2	Rattus norvegicus	25-29
27064029-1	2016	Activation of the G-protein coupled formyl peptide receptor 2 (ALX/FPR2) by the lipid mediators lipoxin A4 and resolvin D1 (RvD1) promotes resolution of inflammation.	lipoxin A4	96-106	formyl peptide receptor 3	Mus musculus	63-66
27742828-8	2016	We also examined the effect of lipoxin A4 on PP5 activation by IL-2 plus IL-4.	lipoxin A4	31-41	protein phosphatase 5 catalytic subunit	Homo sapiens	45-48
27742828-9	2016	Similar to PP5 small interfering RNA inhibition, pretreatment of eosinophils with lipoxin A4 restored GCR phosphorylation and the proaptoptotic function of GCs.	lipoxin A4	82-92	protein phosphatase 5 catalytic subunit	Homo sapiens	11-14
27742828-9	2016	Similar to PP5 small interfering RNA inhibition, pretreatment of eosinophils with lipoxin A4 restored GCR phosphorylation and the proaptoptotic function of GCs.	lipoxin A4	82-92	nuclear receptor subfamily 3 group C member 1	Homo sapiens	102-105
27957484-4	2016	Lipoxin A4 promoted type II cell wound repair and proliferation, blocked the negative effects of soluble Fas ligand/tumour necrosis factor alpha upon cell proliferation, viability and apoptosis, and augmented the epithelial cell proliferative response to bronchoaveolar lavage fluid (BALF) from acute respiratory distress syndrome (ARDS).	lipoxin A4	0-10	Fas ligand	Homo sapiens	105-115
27154726-5	2016	Moreover, aspirin-triggered lipoxin A4 activation of neutrophil Fpr2/3 regulated neutrophil-platelet aggregate formation in the brain and inhibited the reactivity of the cerebral microvasculature.	lipoxin A4	28-38	formyl peptide receptor 2	Homo sapiens	64-68
27824117-6	2016	LXA4 inhibited histamine-stimulated increases in mucin secretion, [Ca2+]i, and ERK1/2 activation through activation of beta-adrenergic receptor kinase 1.	lipoxin A4	0-4	LOC100508689	Homo sapiens	49-54
27824117-6	2016	LXA4 inhibited histamine-stimulated increases in mucin secretion, [Ca2+]i, and ERK1/2 activation through activation of beta-adrenergic receptor kinase 1.	lipoxin A4	0-4	mitogen-activated protein kinase 3	Homo sapiens	79-85
27824117-6	2016	LXA4 inhibited histamine-stimulated increases in mucin secretion, [Ca2+]i, and ERK1/2 activation through activation of beta-adrenergic receptor kinase 1.	lipoxin A4	0-4	G protein-coupled receptor kinase 2	Homo sapiens	119-152
27424221-1	2016	Lipoxin (LX) A4, a main stop signal of inflammation, exerts potent bioactions by activating a specific G protein-coupled receptor, termed formyl peptide receptor 2 and recently renamed ALX/FPR2.	lipoxin A4	0-15	hematopoietic SH2 domain containing	Homo sapiens	185-188
27424221-1	2016	Lipoxin (LX) A4, a main stop signal of inflammation, exerts potent bioactions by activating a specific G protein-coupled receptor, termed formyl peptide receptor 2 and recently renamed ALX/FPR2.	lipoxin A4	0-15	formyl peptide receptor 2	Homo sapiens	189-193
27424221-7	2016	In both cells types, changes in the histone acetylation/methylation status enhanced ALX/FPR2 signaling in response to LXA4.	lipoxin A4	118-122	hematopoietic SH2 domain containing	Homo sapiens	84-87
27424221-7	2016	In both cells types, changes in the histone acetylation/methylation status enhanced ALX/FPR2 signaling in response to LXA4.	lipoxin A4	118-122	formyl peptide receptor 2	Homo sapiens	88-92
28191524-8	2016	Thus, it is proposed that Angiotensin-II receptor blockers and angiotensin-converting enzymes and angiotensin-II antagonists may have the ability to augment LXA4 synthesis and thus bring about their beneficial actions.	lipoxin A4	157-161	angiotensinogen	Homo sapiens	26-40
28191524-8	2016	Thus, it is proposed that Angiotensin-II receptor blockers and angiotensin-converting enzymes and angiotensin-II antagonists may have the ability to augment LXA4 synthesis and thus bring about their beneficial actions.	lipoxin A4	157-161	angiotensinogen	Homo sapiens	98-112
27064029-1	2016	Activation of the G-protein coupled formyl peptide receptor 2 (ALX/FPR2) by the lipid mediators lipoxin A4 and resolvin D1 (RvD1) promotes resolution of inflammation.	lipoxin A4	96-106	formyl peptide receptor 2	Mus musculus	67-71
26845617-7	2016	To further assess whether and how NF-E2-related factor 2 (Nrf2) was involved in the protective effect of LXA4, fluorescence resonance energy transfer (FRET) analysis was employed in human epithelial cell line (16HBE), to determine the relative distance between Nrf2 and its negative regulator or cytosolic inhibitor, Kelch-like ECH-associated protein 1 (Keap1).	lipoxin A4	105-109	NFE2 like bZIP transcription factor 2	Homo sapiens	34-56
26845617-7	2016	To further assess whether and how NF-E2-related factor 2 (Nrf2) was involved in the protective effect of LXA4, fluorescence resonance energy transfer (FRET) analysis was employed in human epithelial cell line (16HBE), to determine the relative distance between Nrf2 and its negative regulator or cytosolic inhibitor, Kelch-like ECH-associated protein 1 (Keap1).	lipoxin A4	105-109	NFE2 like bZIP transcription factor 2	Homo sapiens	58-62
26845617-11	2016	These results provide a new mechanism by which LXA4 inhibits LPS-induced ALI through Nrf2-mediated E-cadherin expression.	lipoxin A4	47-51	nuclear factor, erythroid derived 2, like 2	Mus musculus	85-89
26845617-11	2016	These results provide a new mechanism by which LXA4 inhibits LPS-induced ALI through Nrf2-mediated E-cadherin expression.	lipoxin A4	47-51	cadherin 1	Mus musculus	99-109
26779118-4	2015	Our previous studies showed that the anti-inflammatory lipid Lipoxin A4 (LXA4) acts as an estrogen receptor-alpha agonist in endometrial epithelial cells, inhibiting certain E2-mediated effects.	lipoxin A4	61-71	estrogen receptor 1	Homo sapiens	90-113
26706021-8	2016	We also observed that BDNF levels are low in type 2 diabetes mellitus and that BDNF enhances production of antiinflammatory lipid, lipoxin A4, whose levels are low in diabetes mellitus.	lipoxin A4	131-141	brain derived neurotrophic factor	Homo sapiens	79-83
26732571-0	2016	Lipoxin A4 Reduces Inflammation Through Formyl Peptide Receptor 2/p38 MAPK Signaling Pathway in Subarachnoid Hemorrhage Rats.	lipoxin A4	0-10	formyl peptide receptor 2	Rattus norvegicus	40-65
26732571-0	2016	Lipoxin A4 Reduces Inflammation Through Formyl Peptide Receptor 2/p38 MAPK Signaling Pathway in Subarachnoid Hemorrhage Rats.	lipoxin A4	0-10	mitogen activated protein kinase 14	Rattus norvegicus	66-69
26732571-12	2016	These effects of LXA4 were abolished by FPR2 siRNA.	lipoxin A4	17-21	formyl peptide receptor 2	Rattus norvegicus	40-44
26779118-4	2015	Our previous studies showed that the anti-inflammatory lipid Lipoxin A4 (LXA4) acts as an estrogen receptor-alpha agonist in endometrial epithelial cells, inhibiting certain E2-mediated effects.	lipoxin A4	73-77	estrogen receptor 1	Homo sapiens	90-113
28861476-5	2016	Thus, the therapeutic neuroprotection application of lipoxin A4, an arachidonic acid derivative, as an allosteric enhancer of CB1R activity has been confirmed in vivo.	lipoxin A4	53-63	cannabinoid receptor 1	Homo sapiens	126-130
27375835-0	2016	Lipoxin A4 Preconditioning Attenuates Intestinal Ischemia Reperfusion Injury through Keap1/Nrf2 Pathway in a Lipoxin A4 Receptor Independent Manner.	lipoxin A4	0-10	Kelch-like ECH-associated protein 1	Rattus norvegicus	85-90
26649143-0	2016	Lipoxin A4 Attenuates Cell Invasion by Inhibiting ROS/ERK/MMP Pathway in Pancreatic Cancer.	lipoxin A4	0-10	mitogen-activated protein kinase 1	Homo sapiens	54-57
27375835-0	2016	Lipoxin A4 Preconditioning Attenuates Intestinal Ischemia Reperfusion Injury through Keap1/Nrf2 Pathway in a Lipoxin A4 Receptor Independent Manner.	lipoxin A4	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	91-95
27375835-0	2016	Lipoxin A4 Preconditioning Attenuates Intestinal Ischemia Reperfusion Injury through Keap1/Nrf2 Pathway in a Lipoxin A4 Receptor Independent Manner.	lipoxin A4	0-10	formyl peptide receptor 2-like	Rattus norvegicus	109-128
27375835-8	2016	Meanwhile, LXA4 pretreatment upregulated nuclear Nrf2 level and reduced hypoxia/reoxygenation-induced IEC-6 cell damage and Nrf2 siRNA reversed this protective effect of LXA4 in vitro.	lipoxin A4	11-15	NFE2 like bZIP transcription factor 2	Rattus norvegicus	49-53
27375835-8	2016	Meanwhile, LXA4 pretreatment upregulated nuclear Nrf2 level and reduced hypoxia/reoxygenation-induced IEC-6 cell damage and Nrf2 siRNA reversed this protective effect of LXA4 in vitro.	lipoxin A4	11-15	NFE2 like bZIP transcription factor 2	Rattus norvegicus	124-128
26302186-0	2015	Lipoxin A4 activates alveolar epithelial sodium channel gamma via the microRNA-21/PTEN/AKT pathway in lipopolysaccharide-induced inflammatory lung injury.	lipoxin A4	0-10	microRNA 21	Homo sapiens	70-81
26004392-11	2015	In vitro studies showed that both LXA4 (10 nmol/L) and BDNF (500 pg) decreased the IL-6 levels (p=0.036, 0.0002), in LPS induced pro-inflammatory condition in ARPE 19 cells, thereby their anti-inflammatory effect.	lipoxin A4	34-38	interleukin 6	Homo sapiens	83-87
26302186-0	2015	Lipoxin A4 activates alveolar epithelial sodium channel gamma via the microRNA-21/PTEN/AKT pathway in lipopolysaccharide-induced inflammatory lung injury.	lipoxin A4	0-10	phosphatase and tensin homolog	Homo sapiens	82-86
26302186-0	2015	Lipoxin A4 activates alveolar epithelial sodium channel gamma via the microRNA-21/PTEN/AKT pathway in lipopolysaccharide-induced inflammatory lung injury.	lipoxin A4	0-10	AKT serine/threonine kinase 1	Homo sapiens	87-90
26302186-9	2015	In addition, an miR-21 inhibitor mimicked the effects of LXA4; overexpression of miR-21 abolished the protective effects of LXA4.	lipoxin A4	57-61	microRNA 21	Homo sapiens	16-22
26302186-12	2015	In summary, LXA4 activates ENaC-gamma in part via the miR-21/PTEN/AKT signaling pathway.	lipoxin A4	12-16	sodium channel epithelial 1 subunit gamma	Homo sapiens	27-37
26302186-12	2015	In summary, LXA4 activates ENaC-gamma in part via the miR-21/PTEN/AKT signaling pathway.	lipoxin A4	12-16	microRNA 21	Homo sapiens	54-60
26302186-12	2015	In summary, LXA4 activates ENaC-gamma in part via the miR-21/PTEN/AKT signaling pathway.	lipoxin A4	12-16	phosphatase and tensin homolog	Homo sapiens	61-65
26302186-12	2015	In summary, LXA4 activates ENaC-gamma in part via the miR-21/PTEN/AKT signaling pathway.	lipoxin A4	12-16	AKT serine/threonine kinase 1	Homo sapiens	66-69
26283693-9	2015	In coincubations of platelets and polymorphonuclear leukocytes, inhibition of LTC4S led to shunting of LTA4 toward anti-inflammatory lipoxin A4, which was significantly enhanced by simultaneous inhibition of LTA4H.	lipoxin A4	133-143	leukotriene C4 synthase	Homo sapiens	78-83
26283693-9	2015	In coincubations of platelets and polymorphonuclear leukocytes, inhibition of LTC4S led to shunting of LTA4 toward anti-inflammatory lipoxin A4, which was significantly enhanced by simultaneous inhibition of LTA4H.	lipoxin A4	133-143	leukotriene A4 hydrolase	Homo sapiens	208-213
25702137-0	2015	Lipoxin A4 Activates Nrf2 Pathway and Ameliorates Cell Damage in Cultured Cortical Astrocytes Exposed to Oxygen-Glucose Deprivation/Reperfusion Insults.	lipoxin A4	0-10	NFE2 like bZIP transcription factor 2	Homo sapiens	21-25
26211948-10	2015	The reported NAMs pregnenolone and hemopressin as well as the reported PAM lipoxin A4 are without effect in this model of endocannabinoid signaling.	lipoxin A4	75-85	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	71-74
25943485-0	2015	Lipoxin A4 attenuates radicular pain possibly by inhibiting spinal ERK, JNK and NF-kappaB/p65 and cytokine signals, but not p38, in a rat model of non-compressive lumbar disc herniation.	lipoxin A4	0-10	Eph receptor B1	Rattus norvegicus	67-70
25943485-0	2015	Lipoxin A4 attenuates radicular pain possibly by inhibiting spinal ERK, JNK and NF-kappaB/p65 and cytokine signals, but not p38, in a rat model of non-compressive lumbar disc herniation.	lipoxin A4	0-10	mitogen-activated protein kinase 8	Rattus norvegicus	72-75
25943485-0	2015	Lipoxin A4 attenuates radicular pain possibly by inhibiting spinal ERK, JNK and NF-kappaB/p65 and cytokine signals, but not p38, in a rat model of non-compressive lumbar disc herniation.	lipoxin A4	0-10	synaptotagmin 1	Rattus norvegicus	90-93
25702137-13	2015	Moreover, LXA4 induced the excess p62 accumulation.	lipoxin A4	10-14	nucleoporin 62	Homo sapiens	34-37
25847211-0	2015	Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes associated with the ERK1/2 and NF-kappaB pathways.	lipoxin A4	0-10	mitogen-activated protein kinase 3	Homo sapiens	134-140
25814167-6	2015	Treatment with LXA4 or 15-epi-LXA4 effectively reduced the levels of COX-2, 5-LO proteins, and secretion of PGE2 and LTB4 in KS-IMM cells.	lipoxin A4	15-19	prostaglandin-endoperoxide synthase 2	Homo sapiens	69-74
25814167-6	2015	Treatment with LXA4 or 15-epi-LXA4 effectively reduced the levels of COX-2, 5-LO proteins, and secretion of PGE2 and LTB4 in KS-IMM cells.	lipoxin A4	23-34	prostaglandin-endoperoxide synthase 2	Homo sapiens	69-74
25760938-2	2015	It has remained elusive whether the toll-like receptors (TLR2)/mycloid differentiation factor 88 (MyD88)/nuclear factor (NF)-kappaB signaling pathway is involved in lipoxin A4 (LXA4)-induced protection against asthma.	lipoxin A4	165-175	toll-like receptor 2	Mus musculus	57-61
25760938-2	2015	It has remained elusive whether the toll-like receptors (TLR2)/mycloid differentiation factor 88 (MyD88)/nuclear factor (NF)-kappaB signaling pathway is involved in lipoxin A4 (LXA4)-induced protection against asthma.	lipoxin A4	165-175	myeloid differentiation primary response gene 88	Mus musculus	98-103
26261553-0	2015	Lipoxin A4 promotes ABCA1 expression and cholesterol efflux through the LXRalpha signaling pathway in THP-1 macrophage-derived foam cells.	lipoxin A4	0-10	ATP binding cassette subfamily A member 1	Homo sapiens	20-25
26261553-0	2015	Lipoxin A4 promotes ABCA1 expression and cholesterol efflux through the LXRalpha signaling pathway in THP-1 macrophage-derived foam cells.	lipoxin A4	0-10	nuclear receptor subfamily 1 group H member 3	Homo sapiens	72-80
25847211-11	2015	The ERK1/2 phosphorylation and NF-kappaB-p65 nuclear translocation of NHEKs were both suppressed by LXA4.	lipoxin A4	100-104	mitogen-activated protein kinase 3	Homo sapiens	4-10
25847211-11	2015	The ERK1/2 phosphorylation and NF-kappaB-p65 nuclear translocation of NHEKs were both suppressed by LXA4.	lipoxin A4	100-104	RELA proto-oncogene, NF-kB subunit	Homo sapiens	31-44
25567326-8	2015	Quantitative real-time (QRT)-PCR analysis of utero-placental tissues harvested 6 h post-treatment demonstrated that 15-epi-lipoxin A4 treatment increased Ptgs2 expression in the uterus, placenta and fetal membranes (P &lt; 0.05) and decreased 15-Hpgd expression (P &lt; 0.05) in the placenta and uterus, suggesting that 15-epi-lipoxin A4 may regulate the local production and activity of prostaglandins.	lipoxin A4	116-133	prostaglandin-endoperoxide synthase 2	Mus musculus	154-159
26072084-0	2015	Lipoxin A4 inhibits lipopolysaccharide-induced production of inflammatory cytokines in keratinocytes by up-regulating SOCS2 and down-regulating TRAF6.	lipoxin A4	0-10	suppressor of cytokine signaling 2	Homo sapiens	118-123
26072084-0	2015	Lipoxin A4 inhibits lipopolysaccharide-induced production of inflammatory cytokines in keratinocytes by up-regulating SOCS2 and down-regulating TRAF6.	lipoxin A4	0-10	TNF receptor associated factor 6	Homo sapiens	144-149
26072084-10	2015	It was concluded that LXA4 inhibits the LPS-induced production of TNF-alpha and IL-1beta in NHEKs by up-regulating SOCS2 and down-regulating TRAF6.	lipoxin A4	22-26	tumor necrosis factor	Homo sapiens	66-75
26072084-10	2015	It was concluded that LXA4 inhibits the LPS-induced production of TNF-alpha and IL-1beta in NHEKs by up-regulating SOCS2 and down-regulating TRAF6.	lipoxin A4	22-26	interleukin 1 beta	Homo sapiens	80-88
26072084-10	2015	It was concluded that LXA4 inhibits the LPS-induced production of TNF-alpha and IL-1beta in NHEKs by up-regulating SOCS2 and down-regulating TRAF6.	lipoxin A4	22-26	suppressor of cytokine signaling 2	Homo sapiens	115-120
26072084-10	2015	It was concluded that LXA4 inhibits the LPS-induced production of TNF-alpha and IL-1beta in NHEKs by up-regulating SOCS2 and down-regulating TRAF6.	lipoxin A4	22-26	TNF receptor associated factor 6	Homo sapiens	141-146
25978361-14	2015	In conclusion, Simvastatin and benznidazole prevent endothelial activation induced by T. cruzi infection, and the effect of simvastatin is mediated by the inhibition of the NFkappaB pathway by inducing 15-epi-LXA4 production.	lipoxin A4	202-213	nuclear factor kappa B subunit 1	Homo sapiens	173-181
25567326-8	2015	Quantitative real-time (QRT)-PCR analysis of utero-placental tissues harvested 6 h post-treatment demonstrated that 15-epi-lipoxin A4 treatment increased Ptgs2 expression in the uterus, placenta and fetal membranes (P &lt; 0.05) and decreased 15-Hpgd expression (P &lt; 0.05) in the placenta and uterus, suggesting that 15-epi-lipoxin A4 may regulate the local production and activity of prostaglandins.	lipoxin A4	116-133	hydroxyprostaglandin dehydrogenase 15 (NAD)	Mus musculus	246-250
25583526-7	2015	Moreover, this pathogen upregulated the production of the lipid mediators leukotriene B4 and lipoxin A4 in a 5-LO-dependent manner.	lipoxin A4	93-103	arachidonate 5-lipoxygenase	Mus musculus	109-113
25137396-6	2015	The levels of the anti-inflammatory lipoxin, lipoxin A4, were reduced by threefold along with cyclo-oxygenase (COX)-2 and microsomal prostaglandin E synthase (mPGES)-1 in airway epithelial cells and PGE2 levels in the bronchoalveolar lavage of CW compared with CS mice.	lipoxin A4	45-55	cytochrome c oxidase II, mitochondrial	Mus musculus	94-117
24129401-0	2014	LipoxinA4 attenuates myocardial ischemia reperfusion injury via a mechanism related to downregulation of GRP-78 and caspase-12 in rats.	lipoxin A4	0-9	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	105-111
24923883-0	2014	Lipoxin A4 suppresses the development of endometriosis in an ALX receptor-dependent manner via the p38 MAPK pathway.	lipoxin A4	0-10	formyl peptide receptor 3	Mus musculus	61-64
24923883-0	2014	Lipoxin A4 suppresses the development of endometriosis in an ALX receptor-dependent manner via the p38 MAPK pathway.	lipoxin A4	0-10	mitogen-activated protein kinase 14	Mus musculus	99-102
25162465-8	2014	LXA4 and 15-epi-LXA4 levels were inversely related to sEH activity in sputum supernatants and sEHIs significantly increased 14,15-epoxy-eicosatrienoic acid and 15-epi-LXA4 generation by severe asthma whole blood and bronchoalveolar lavage fluid cells.	lipoxin A4	9-20	epoxide hydrolase 2	Homo sapiens	54-57
25162465-8	2014	LXA4 and 15-epi-LXA4 levels were inversely related to sEH activity in sputum supernatants and sEHIs significantly increased 14,15-epoxy-eicosatrienoic acid and 15-epi-LXA4 generation by severe asthma whole blood and bronchoalveolar lavage fluid cells.	lipoxin A4	160-171	epoxide hydrolase 2	Homo sapiens	54-57
24129401-0	2014	LipoxinA4 attenuates myocardial ischemia reperfusion injury via a mechanism related to downregulation of GRP-78 and caspase-12 in rats.	lipoxin A4	0-9	caspase 12	Rattus norvegicus	116-126
24887589-2	2014	ATL-1, a synthetic analog of 15-epi-LXA4, inhibits various actions stimulated by vascular endothelial growth factor (VEGF).	lipoxin A4	29-40	atlastin GTPase 1	Homo sapiens	0-5
24909072-9	2014	In addition, LXA4 ME significantly elevated the ratio of Bcl-2/Bax and decreased cleaved caspase-3 expression in the hippocampus.	lipoxin A4	13-17	BCL2, apoptosis regulator	Rattus norvegicus	57-62
24909072-9	2014	In addition, LXA4 ME significantly elevated the ratio of Bcl-2/Bax and decreased cleaved caspase-3 expression in the hippocampus.	lipoxin A4	13-17	BCL2 associated X, apoptosis regulator	Rattus norvegicus	63-66
24887589-2	2014	ATL-1, a synthetic analog of 15-epi-LXA4, inhibits various actions stimulated by vascular endothelial growth factor (VEGF).	lipoxin A4	29-40	vascular endothelial growth factor A	Homo sapiens	81-115
24887589-2	2014	ATL-1, a synthetic analog of 15-epi-LXA4, inhibits various actions stimulated by vascular endothelial growth factor (VEGF).	lipoxin A4	29-40	vascular endothelial growth factor A	Homo sapiens	117-121
24588705-0	2014	Activation of P2RY11 and ATP release by lipoxin A4 restores the airway surface liquid layer and epithelial repair in cystic fibrosis.	lipoxin A4	40-50	purinergic receptor P2Y11	Homo sapiens	14-20
25107986-6	2014	These ion transport and ASLh responses to LXA4 were blocked by Boc-2 an inhibitor of the specific LXA4 receptor ALX/FPR2.	lipoxin A4	42-46	hematopoietic SH2 domain containing	Homo sapiens	112-115
25107986-6	2014	These ion transport and ASLh responses to LXA4 were blocked by Boc-2 an inhibitor of the specific LXA4 receptor ALX/FPR2.	lipoxin A4	42-46	formyl peptide receptor 2	Homo sapiens	116-120
24588705-6	2014	The ATP release induced by LXA4 was completely inhibited by antagonists of the ALX/FPR2 receptor and Pannexin-1 channels.	lipoxin A4	27-31	hematopoietic SH2 domain containing	Homo sapiens	79-82
24588705-6	2014	The ATP release induced by LXA4 was completely inhibited by antagonists of the ALX/FPR2 receptor and Pannexin-1 channels.	lipoxin A4	27-31	pannexin 1	Homo sapiens	101-111
24588705-7	2014	LXA4 induced an increase in intracellular cAMP and calcium, which were abolished by the selective inhibition of the P2RY11 purinoreceptor.	lipoxin A4	0-4	purinergic receptor P2Y11	Homo sapiens	116-122
24836854-1	2014	Aspirin-triggered Lipoxin A4 (ATL), as a Lipoxin A4 (LXA4) epimer, is endogenously produced by aspirin-acetylated cycloxygenase-2 (COX-2) and plays a vital role in endogenous anti-inflammation via the LXA4 receptor (ALX).	lipoxin A4	18-28	formyl peptide receptor 2-like	Rattus norvegicus	216-219
24522831-0	2014	Lipoxin A4 inhibits NF-kappaB activation and cell cycle progression in RAW264.7 cells.	lipoxin A4	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	20-29
24522831-7	2014	The data suggested that LXA4 inhibited LPS-induced proliferation through the G0/G1 phase arrest in RAW264.7 macrophages, and the inhibitory effect might depend on NF-kappaB signaling transduction pathway.	lipoxin A4	24-28	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	163-172
24892762-10	2014	Treatment with Lipoxin A4 also led to a reduction of CXCL2 (2.4 fold) while selectively increasing TGFbeta2 (2.1 fold) and Smad3 (1.58 fold).	lipoxin A4	15-25	chemokine (C-X-C motif) ligand 2	Mus musculus	53-58
24835059-0	2014	Lipoxin A4 regulates expression of the estrogen receptor and inhibits 17beta-estradiol induced p38 mitogen-activated protein kinase phosphorylation in human endometriotic stromal cells.	lipoxin A4	0-10	estrogen receptor 1	Homo sapiens	39-56
24835059-0	2014	Lipoxin A4 regulates expression of the estrogen receptor and inhibits 17beta-estradiol induced p38 mitogen-activated protein kinase phosphorylation in human endometriotic stromal cells.	lipoxin A4	0-10	mitogen-activated protein kinase 14	Homo sapiens	95-131
24835059-9	2014	Moreover, administering LXA4 could augment ERbeta expression in ESCs and inhibit the 17beta-estradiol-induced phosphorylation of p38 MAPK very likely through ERbeta.	lipoxin A4	24-28	estrogen receptor 2	Homo sapiens	43-49
24835059-9	2014	Moreover, administering LXA4 could augment ERbeta expression in ESCs and inhibit the 17beta-estradiol-induced phosphorylation of p38 MAPK very likely through ERbeta.	lipoxin A4	24-28	mitogen-activated protein kinase 14	Homo sapiens	129-137
24835059-9	2014	Moreover, administering LXA4 could augment ERbeta expression in ESCs and inhibit the 17beta-estradiol-induced phosphorylation of p38 MAPK very likely through ERbeta.	lipoxin A4	24-28	estrogen receptor 2	Homo sapiens	158-164
24892762-10	2014	Treatment with Lipoxin A4 also led to a reduction of CXCL2 (2.4 fold) while selectively increasing TGFbeta2 (2.1 fold) and Smad3 (1.58 fold).	lipoxin A4	15-25	transforming growth factor, beta 2	Mus musculus	99-107
24892762-10	2014	Treatment with Lipoxin A4 also led to a reduction of CXCL2 (2.4 fold) while selectively increasing TGFbeta2 (2.1 fold) and Smad3 (1.58 fold).	lipoxin A4	15-25	SMAD family member 3	Mus musculus	123-128
24746836-6	2014	Decreased selenoprotein activity resulted in the accumulation of reactive oxygen species, enhanced cyclooxygenase and lipoxygenase expression and decreased oxylipids with known anti-inflammatory properties such as arachidonic acid-derived lipoxin A4 (LXA4) and linoleic acid-derived 9-oxo-octadecadienoic acid (9-oxoODE).	lipoxin A4	251-255	selenoprotein F	Mus musculus	10-23
24395886-10	2014	15-epi-lipoxin-A4 was identified in exhaled breath condensate from LAM subjects and was increased by aspirin treatment, indicative of functional COX-2 expression in the LAM airway.	lipoxin A4	0-17	prostaglandin-endoperoxide synthase 2	Homo sapiens	145-150
24671173-4	2014	In vitro, inhibition of CFTR promotes MIP-2 production in LPS-stimulated neutrophils; however, lipoxin A4 could dose-dependently suppress this effect.	lipoxin A4	95-105	cystic fibrosis transmembrane conductance regulator	Mus musculus	24-28
24571985-7	2014	Moreover, LXA4 supplementation dampened Dex-potentiated placental inflammation and suppressed Dex-mediated ALOX5 activation in vivo and in vitro.	lipoxin A4	10-14	arachidonate 5-lipoxygenase	Rattus norvegicus	107-112
24463858-13	2014	15-Epi-lipoxin A4 also attenuated the production of interleukin-6 and tumor necrosis factor-alpha by lipopolysaccharide- or CpG DNA-stimulated peritoneal macrophages.	lipoxin A4	0-17	interleukin 6	Mus musculus	52-97
24463858-14	2014	Furthermore, 15-epi-lipoxin A4 combined with antibiotics synergistically reduced the production of interleukin-6 and tumor necrosis factor-alpha by peritoneal macrophages stimulated with live E. coli.	lipoxin A4	13-30	interleukin 6	Mus musculus	99-144
24463858-16	2014	The reduced production of interleukin-6 and tumor necrosis factor-alpha by peritoneal macrophages suggested that 15-epi-lipoxin A4 blocked the initial proinflammatory response.	lipoxin A4	113-130	interleukin 6	Mus musculus	26-71
24225006-2	2014	Lipoxin A4 (LXA4 ) is an anti-inflammatory, pro-resolution lipid mediator with high affinity binding to ALX, the lipoxin A4 receptor.	lipoxin A4	0-10	formyl peptide receptor 2-like	Rattus norvegicus	104-107
24225006-2	2014	Lipoxin A4 (LXA4 ) is an anti-inflammatory, pro-resolution lipid mediator with high affinity binding to ALX, the lipoxin A4 receptor.	lipoxin A4	0-10	formyl peptide receptor 2-like	Rattus norvegicus	113-132
24525704-3	2014	A relationship has been reported between asthma and anti-inflammatory mediators such as lipoxin A4 and annexin A1.	lipoxin A4	88-98	annexin A1	Homo sapiens	103-113
25612650-0	2014	Lipoxin A4 mediates aortic contraction via RHOA/RHO kinase, endothelial dysfunction and reactive oxygen species.	lipoxin A4	0-10	ras homolog family member A	Homo sapiens	43-47
24000382-7	2013	In conclusion, the protective effects of LXA4 to ALI may be executed through inhibition inflammation pathways of NF-kappaB and p38 MAPK and up-regulation of cytoprotective HO-1.	lipoxin A4	41-45	nuclear factor kappa B subunit 1	Homo sapiens	113-122
25612650-8	2014	RESULTS: LXA4 induced concentration-dependent contractions via formyl peptide receptor-2 activation and both RhoA/Rho kinase inhibitor and ROS scavenger decreased this contraction.	lipoxin A4	9-13	ras homolog family member A	Homo sapiens	109-113
25612650-9	2014	Also, endothelium removal, and COX-2 and NAD(P)H oxidase inhibitors attenuate the LXA4-induced contraction.	lipoxin A4	82-86	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	31-36
24249731-8	2013	Treatment of BMDM with e-LXA4 inhibited LPS-dependent activation of NF-kappaB and IkappaB kinase beta activity, protected against LPS activation-dependent apoptosis, and enhanced the accumulation of the Nrf-2 transcription factor.	lipoxin A4	23-29	inhibitor of kappaB kinase beta	Mus musculus	82-101
24249731-8	2013	Treatment of BMDM with e-LXA4 inhibited LPS-dependent activation of NF-kappaB and IkappaB kinase beta activity, protected against LPS activation-dependent apoptosis, and enhanced the accumulation of the Nrf-2 transcription factor.	lipoxin A4	23-29	nuclear factor, erythroid derived 2, like 2	Mus musculus	203-208
24000382-7	2013	In conclusion, the protective effects of LXA4 to ALI may be executed through inhibition inflammation pathways of NF-kappaB and p38 MAPK and up-regulation of cytoprotective HO-1.	lipoxin A4	41-45	mitogen-activated protein kinase 14	Homo sapiens	127-135
23880501-0	2013	Lipoxin A4 ameliorates cerebral ischaemia/reperfusion injury through upregulation of nuclear factor erythroid 2-related factor 2.	lipoxin A4	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	85-128
23851615-8	2013	In LXA4-treated groups, the expression of TNF-alpha was significantly lower than those in PCM and NAC groups (p &lt; 0.05).	lipoxin A4	3-7	tumor necrosis factor	Oryctolagus cuniculus	42-51
24358628-13	2013	Lipoxin A4 inhibited tumor necrosis factor alpha-induced interleukin 8 release from airway epithelial cells via its receptor FPRL-1.	lipoxin A4	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	57-70
24358628-13	2013	Lipoxin A4 inhibited tumor necrosis factor alpha-induced interleukin 8 release from airway epithelial cells via its receptor FPRL-1.	lipoxin A4	0-10	formyl peptide receptor 2	Homo sapiens	125-131
23880501-12	2013	Lipoxin A4 induced Nrf2 expression and its nuclear translocation, as well as HO-1 expression and GSH synthesis; Boc2 did not block these effects.	lipoxin A4	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	19-23
23607720-6	2013	In our study, a FPR2/ALX synthetic peptide (WKYMVm) and a small molecule FPR2/ALX agonist (compound 43) induced FPR2/ALX-mediated signalling, enhancing guanosine triphosphate-gamma (GTPgamma) binding and decreasing cyclic adenosine monophosphate (cAMP) levels, whereas 15-epi-LXA4 was inactive.	lipoxin A4	269-280	formyl peptide receptor 2	Homo sapiens	16-20
23792301-3	2013	When acetylated by aspirin, however, COX-2 (but not COX-1) can form 15(R)-HETE, which is metabolized to aspirin-triggered lipoxin (ATL), 15-epi-lipoxin A4.	lipoxin A4	137-154	cytochrome c oxidase II, mitochondrial	Mus musculus	37-42
23607720-6	2013	In our study, a FPR2/ALX synthetic peptide (WKYMVm) and a small molecule FPR2/ALX agonist (compound 43) induced FPR2/ALX-mediated signalling, enhancing guanosine triphosphate-gamma (GTPgamma) binding and decreasing cyclic adenosine monophosphate (cAMP) levels, whereas 15-epi-LXA4 was inactive.	lipoxin A4	269-280	hematopoietic SH2 domain containing	Homo sapiens	21-24
23607720-6	2013	In our study, a FPR2/ALX synthetic peptide (WKYMVm) and a small molecule FPR2/ALX agonist (compound 43) induced FPR2/ALX-mediated signalling, enhancing guanosine triphosphate-gamma (GTPgamma) binding and decreasing cyclic adenosine monophosphate (cAMP) levels, whereas 15-epi-LXA4 was inactive.	lipoxin A4	269-280	formyl peptide receptor 2	Homo sapiens	73-77
23607720-6	2013	In our study, a FPR2/ALX synthetic peptide (WKYMVm) and a small molecule FPR2/ALX agonist (compound 43) induced FPR2/ALX-mediated signalling, enhancing guanosine triphosphate-gamma (GTPgamma) binding and decreasing cyclic adenosine monophosphate (cAMP) levels, whereas 15-epi-LXA4 was inactive.	lipoxin A4	269-280	hematopoietic SH2 domain containing	Homo sapiens	78-81
23607720-6	2013	In our study, a FPR2/ALX synthetic peptide (WKYMVm) and a small molecule FPR2/ALX agonist (compound 43) induced FPR2/ALX-mediated signalling, enhancing guanosine triphosphate-gamma (GTPgamma) binding and decreasing cyclic adenosine monophosphate (cAMP) levels, whereas 15-epi-LXA4 was inactive.	lipoxin A4	269-280	formyl peptide receptor 2	Homo sapiens	73-77
23607720-6	2013	In our study, a FPR2/ALX synthetic peptide (WKYMVm) and a small molecule FPR2/ALX agonist (compound 43) induced FPR2/ALX-mediated signalling, enhancing guanosine triphosphate-gamma (GTPgamma) binding and decreasing cyclic adenosine monophosphate (cAMP) levels, whereas 15-epi-LXA4 was inactive.	lipoxin A4	269-280	hematopoietic SH2 domain containing	Homo sapiens	78-81
23889245-0	2013	Apolipoprotein A1 potentiates lipoxin A4 synthesis and recovery of allergen-induced disrupted tight junctions in the airway epithelium.	lipoxin A4	30-40	apolipoprotein A-I	Mus musculus	0-17
23889245-11	2013	ApoA1-induced increases in the TJ proteins were dependent on increased production of lipoxin A4 (LX A4).	lipoxin A4	85-95	apolipoprotein A-I	Mus musculus	0-5
23889245-11	2013	ApoA1-induced increases in the TJ proteins were dependent on increased production of lipoxin A4 (LX A4).	lipoxin A4	97-102	apolipoprotein A-I	Mus musculus	0-5
23607720-8	2013	In neutrophils, 15-epi-LXA4 showed a moderate reduction of interleukin (IL)-8-mediated neutrophil chemotaxis but no effect on neutrophil survival was observed.	lipoxin A4	22-27	C-X-C motif chemokine ligand 8	Homo sapiens	59-77
23607720-10	2013	In conclusion, 15-epi-LXA4 is not a functional agonist or an antagonist of FPR2/ALX or CysLT1, shows no effect on IL-8-induced neutrophil survival and produces only moderate inhibition in IL-8-mediated neutrophil migration.	lipoxin A4	15-26	C-X-C motif chemokine ligand 8	Homo sapiens	188-192
23733341-3	2013	Analysis of endogenous agonists for Fpr2/3 revealed that lipoxin A4 (LXA4) was generated by platelet/neutrophil aggregates during ischemia: this cellular response was attenuated in Fpr2/3(-/-) mice; hence, LXA4 levels were lower after 30 minutes" ischemia, and associated with augmented vascular inflammation in the reperfusion (45-180 minutes) phase.	lipoxin A4	57-67	formyl peptide receptor 2	Mus musculus	36-40
23733341-3	2013	Analysis of endogenous agonists for Fpr2/3 revealed that lipoxin A4 (LXA4) was generated by platelet/neutrophil aggregates during ischemia: this cellular response was attenuated in Fpr2/3(-/-) mice; hence, LXA4 levels were lower after 30 minutes" ischemia, and associated with augmented vascular inflammation in the reperfusion (45-180 minutes) phase.	lipoxin A4	57-67	formyl peptide receptor 2	Mus musculus	181-185
23733341-5	2013	Such LXA4-based circuit could be activated by aspirin (30-100 mg/kg), which triggered formation of 15-epi-LXA4 in wild-type mice, yet it was effective in Fpr2/3(-/-) mice.	lipoxin A4	5-9	formyl peptide receptor 2	Mus musculus	154-158
23686859-10	2013	Finally, both LXA4 and pinacidil stimulated ERK-MAP kinase phosphorylation, whereas the effect of LXA4 on ERK phosphorylation was inhibited by glibenclamide.	lipoxin A4	14-18	mitogen-activated protein kinase 1	Homo sapiens	44-47
23627303-8	2013	SAA predominately promoted expression of the TH17 polarizing cytokine IL-6, which was opposed by 15-epi-lipoxin A4, a counter-regulatory mediator, and ALX/FPR2 ligand.	lipoxin A4	97-114	serum amyloid A1 cluster	Homo sapiens	0-3
23627303-8	2013	SAA predominately promoted expression of the TH17 polarizing cytokine IL-6, which was opposed by 15-epi-lipoxin A4, a counter-regulatory mediator, and ALX/FPR2 ligand.	lipoxin A4	97-114	interleukin 6	Homo sapiens	70-74
23686859-10	2013	Finally, both LXA4 and pinacidil stimulated ERK-MAP kinase phosphorylation, whereas the effect of LXA4 on ERK phosphorylation was inhibited by glibenclamide.	lipoxin A4	98-102	mitogen-activated protein kinase 1	Homo sapiens	106-109
23826208-0	2013	Lipoxin A4-induced heme oxygenase-1 protects cardiomyocytes against hypoxia/reoxygenation injury via p38 MAPK activation and Nrf2/ARE complex.	lipoxin A4	0-10	heme oxygenase 1	Rattus norvegicus	19-35
23607720-3	2013	However, it has been reported that 15-epi-LXA4 analogues can also bind to cysteinyl leukotriene receptor 1 (CysLT1) and that the CysLT1 antagonist MK-571 binds to FPR2/ALX, so cross-reactivity between FPR2/ALX and CysLT1 ligands cannot be discarded.	lipoxin A4	35-46	cysteinyl leukotriene receptor 1	Homo sapiens	74-106
23607720-3	2013	However, it has been reported that 15-epi-LXA4 analogues can also bind to cysteinyl leukotriene receptor 1 (CysLT1) and that the CysLT1 antagonist MK-571 binds to FPR2/ALX, so cross-reactivity between FPR2/ALX and CysLT1 ligands cannot be discarded.	lipoxin A4	35-46	cysteinyl leukotriene receptor 1	Homo sapiens	108-114
23826208-0	2013	Lipoxin A4-induced heme oxygenase-1 protects cardiomyocytes against hypoxia/reoxygenation injury via p38 MAPK activation and Nrf2/ARE complex.	lipoxin A4	0-10	mitogen activated protein kinase 14	Rattus norvegicus	101-109
23826208-0	2013	Lipoxin A4-induced heme oxygenase-1 protects cardiomyocytes against hypoxia/reoxygenation injury via p38 MAPK activation and Nrf2/ARE complex.	lipoxin A4	0-10	NFE2 like bZIP transcription factor 2	Rattus norvegicus	125-129
23643932-1	2013	Lipoxin A4 (LXA4) has been described as an anti-inflammatory mediator, which exerts its effects through the formyl peptide receptor FPR2, also known as ALX.	lipoxin A4	0-10	hematopoietic SH2 domain containing	Homo sapiens	152-155
23602847-8	2013	However, the protective effects of LXA4 were completely blocked by transfection of the cells with HO-1 siRNA, and were partially but significantly blocked by pretreatment of the cells with various blockers of K(+) channels.	lipoxin A4	35-39	heme oxygenase 1	Homo sapiens	98-102
23643932-1	2013	Lipoxin A4 (LXA4) has been described as an anti-inflammatory mediator, which exerts its effects through the formyl peptide receptor FPR2, also known as ALX.	lipoxin A4	0-10	formyl peptide receptor 2	Homo sapiens	132-136
23470626-4	2013	Lipoxin A4 and 5(S), 6(R)-7-trihydroxymethyl 17 heptanoate not only up-regulated the ENaC alpha and ENaC gamma subunits protein expression, but also increased Na,K-ATPase alpha1 subunit protein expression and Na,K-ATPase activity in lung tissues.	lipoxin A4	0-10	sodium channel epithelial 1 subunit alpha	Rattus norvegicus	85-95
23470626-7	2013	The beneficial effects of lipoxin A4 were abrogated by butoxycarbonyl-Phe-Leu-Phe-Leu-Ph (lipoxin A4 receptor antagonist) in OA-induced lung injury.	lipoxin A4	26-36	formyl peptide receptor 2-like	Rattus norvegicus	90-109
23602847-9	2013	The LXA4-induced expressions of HO-1 in the cells were also inhibited by HO-1 siRNA and various blockers of K(+) channels.	lipoxin A4	4-8	heme oxygenase 1	Homo sapiens	32-36
23602847-9	2013	The LXA4-induced expressions of HO-1 in the cells were also inhibited by HO-1 siRNA and various blockers of K(+) channels.	lipoxin A4	4-8	heme oxygenase 1	Homo sapiens	73-77
23602847-10	2013	The inhibitory effects of LXA4 on enhanced TNF-alpha levels induced by H/R injury were abolished by transfection of the cells with HO-1 siRNA.	lipoxin A4	26-30	tumor necrosis factor	Homo sapiens	43-52
23602847-10	2013	The inhibitory effects of LXA4 on enhanced TNF-alpha levels induced by H/R injury were abolished by transfection of the cells with HO-1 siRNA.	lipoxin A4	26-30	heme oxygenase 1	Homo sapiens	131-135
23613965-0	2013	Lipoxin A4 and 15-epi-lipoxin A4 protect against experimental cerebral malaria by inhibiting IL-12/IFN-gamma in the brain.	lipoxin A4	0-10	interferon gamma	Homo sapiens	99-108
23638194-9	2013	We explored whether this observation was related to the metabolic shift toward the production of 5-lipoxygenase derivatives, and although we did not observe an increase in LTB4 production in infected RAW cells and mice infected, we did find an increase in 15-epi-LXA4 (an ASA-triggered lipoxin).	lipoxin A4	256-267	arachidonate 5-lipoxygenase	Mus musculus	97-111
23613965-0	2013	Lipoxin A4 and 15-epi-lipoxin A4 protect against experimental cerebral malaria by inhibiting IL-12/IFN-gamma in the brain.	lipoxin A4	15-32	interferon gamma	Homo sapiens	99-108
23508943-7	2013	Mac-1 signaling is also target for the anti-inflammatory, pro-resolving mediators, including lipoxin A4, aspirin-triggered lipoxin A4, and resolvin E1.	lipoxin A4	93-103	integrin subunit beta 2	Homo sapiens	0-5
23426803-0	2013	Lipoxin A4 blocks embryo implantation by controlling estrogen receptor alpha activity.	lipoxin A4	0-10	estrogen receptor 1 (alpha)	Mus musculus	53-76
23426803-2	2013	Lipoxin A4 (LXA4), a biologically active eicosanoid with specific anti-inflammatory and pro-resolving properties, was recently found to be a novel modulator of estrogen receptor alpha (ERalpha).	lipoxin A4	0-10	estrogen receptor 1 (alpha)	Mus musculus	160-183
23426803-2	2013	Lipoxin A4 (LXA4), a biologically active eicosanoid with specific anti-inflammatory and pro-resolving properties, was recently found to be a novel modulator of estrogen receptor alpha (ERalpha).	lipoxin A4	0-10	estrogen receptor 1 (alpha)	Mus musculus	185-192
23426803-2	2013	Lipoxin A4 (LXA4), a biologically active eicosanoid with specific anti-inflammatory and pro-resolving properties, was recently found to be a novel modulator of estrogen receptor alpha (ERalpha).	lipoxin A4	12-16	estrogen receptor 1 (alpha)	Mus musculus	160-183
23426803-2	2013	Lipoxin A4 (LXA4), a biologically active eicosanoid with specific anti-inflammatory and pro-resolving properties, was recently found to be a novel modulator of estrogen receptor alpha (ERalpha).	lipoxin A4	12-16	estrogen receptor 1 (alpha)	Mus musculus	185-192
23114480-4	2013	Lipoxin A4 inhibits the expression of IL-1beta, IL-6, and TNF-alpha, the values of the infarct ratios, apoptotic index, the level of serum cTnI and NF-kappaB p65.	lipoxin A4	0-10	interleukin-1 beta	Oryctolagus cuniculus	38-46
23114480-4	2013	Lipoxin A4 inhibits the expression of IL-1beta, IL-6, and TNF-alpha, the values of the infarct ratios, apoptotic index, the level of serum cTnI and NF-kappaB p65.	lipoxin A4	0-10	interleukin-6	Oryctolagus cuniculus	48-52
23114480-4	2013	Lipoxin A4 inhibits the expression of IL-1beta, IL-6, and TNF-alpha, the values of the infarct ratios, apoptotic index, the level of serum cTnI and NF-kappaB p65.	lipoxin A4	0-10	tumor necrosis factor	Oryctolagus cuniculus	58-67
23766562-4	2013	In addition, lipoxin A4 increased alveolar fluid clearance (AFC) and the effect of lipoxin A4 on AFC was abolished by CFTRinh-172 (a specific inhibitor of CFTR).	lipoxin A4	83-93	CF transmembrane conductance regulator	Rattus norvegicus	118-122
23520204-8	2013	Overexpression of let-7c mimicked the antifibrotic effects of LXA4 in renal epithelia; conversely, anti-miR directed against let-7c attenuated the effects of LXA4.	lipoxin A4	62-66	microRNA let-7c	Homo sapiens	18-24
23447017-7	2013	Lipoxin A4, a natural pro-resolving ligand for ALX/FPR2 receptors, significantly increased NK cell-mediated eosinophil apoptosis and decreased IL-13 release by ILC2s.	lipoxin A4	0-10	hematopoietic SH2 domain containing	Homo sapiens	47-50
23447017-7	2013	Lipoxin A4, a natural pro-resolving ligand for ALX/FPR2 receptors, significantly increased NK cell-mediated eosinophil apoptosis and decreased IL-13 release by ILC2s.	lipoxin A4	0-10	formyl peptide receptor 2	Homo sapiens	51-55
23447017-7	2013	Lipoxin A4, a natural pro-resolving ligand for ALX/FPR2 receptors, significantly increased NK cell-mediated eosinophil apoptosis and decreased IL-13 release by ILC2s.	lipoxin A4	0-10	interleukin 13	Homo sapiens	143-148
23766562-7	2013	These results showed that lipoxin A4 enhanced CFTR protein expression and increased AFC via PI3K/Akt pathway.	lipoxin A4	26-36	CF transmembrane conductance regulator	Rattus norvegicus	46-50
23766562-7	2013	These results showed that lipoxin A4 enhanced CFTR protein expression and increased AFC via PI3K/Akt pathway.	lipoxin A4	26-36	AKT serine/threonine kinase 1	Rattus norvegicus	97-100
23204441-0	2012	Lipoxin A4 is an allosteric endocannabinoid that strengthens anandamide-induced CB1 receptor activation.	lipoxin A4	0-10	cannabinoid receptor 1	Homo sapiens	80-83
23818745-8	2013	In accordance, application of lipoxin A4 (LXA4, a product of ALOX15) obtained a proresolution effect similar to neutralization of IFN-gamma.	lipoxin A4	30-40	arachidonate 15-lipoxygenase	Homo sapiens	61-67
23063943-5	2012	LXA(4) also inhibited LPS-triggered apoptosis, activation of NF-kappaB, TNF-alpha and IL-8 mRNA and protein expression in TEV-1 cells.	lipoxin A4	0-5	tumor necrosis factor	Rattus norvegicus	72-81
23766562-5	2013	Moreover, lipoxin A4 could increase cystic fibrosis transmembrane conductance regulator (CFTR) protein expression in vitro and in vivo.	lipoxin A4	10-20	CF transmembrane conductance regulator	Rattus norvegicus	36-87
23766562-5	2013	Moreover, lipoxin A4 could increase cystic fibrosis transmembrane conductance regulator (CFTR) protein expression in vitro and in vivo.	lipoxin A4	10-20	CF transmembrane conductance regulator	Rattus norvegicus	89-93
22828048-0	2012	Lipoxin A4 inhibits platelet-activating factor inflammatory response and stimulates corneal wound healing of injuries that compromise the stroma.	lipoxin A4	0-10	patchy fur	Mus musculus	20-46
22828048-11	2012	The strong stromal cell infiltration and MPO activity stimulated by PAF was also decreased with LXA(4) treatment.	lipoxin A4	96-102	myeloperoxidase	Mus musculus	41-44
22828048-11	2012	The strong stromal cell infiltration and MPO activity stimulated by PAF was also decreased with LXA(4) treatment.	lipoxin A4	96-102	patchy fur	Mus musculus	68-71
22828048-13	2012	The PAF actions were reverted by LXA(4) treatment.	lipoxin A4	33-39	patchy fur	Mus musculus	4-7
21845429-0	2012	A lipoxin A4 analog ameliorates blood-brain barrier dysfunction and reduces MMP-9 expression in a rat model of focal cerebral ischemia-reperfusion injury.	lipoxin A4	2-12	matrix metallopeptidase 9	Rattus norvegicus	76-81
22516296-4	2012	The S663D enzyme exhibits robust 15-LOX activity, as determined by spectrophotometric and HPLC analyses, with only traces of 5-LOX activity remaining; synthesis of the anti-inflammatory lipoxin A(4) from arachidonic acid is also detected.	lipoxin A4	186-195	arachidonate 15-lipoxygenase	Homo sapiens	33-39
22516296-4	2012	The S663D enzyme exhibits robust 15-LOX activity, as determined by spectrophotometric and HPLC analyses, with only traces of 5-LOX activity remaining; synthesis of the anti-inflammatory lipoxin A(4) from arachidonic acid is also detected.	lipoxin A4	186-195	arachidonate 5-lipoxygenase	Homo sapiens	34-39
22205391-2	2012	Native lipoxin A(4) (LXA(4)) binds to the G protein-coupled lipoxin receptors formyl peptide receptor 2 (FPR2)/ALX and CysLT1.	lipoxin A4	7-16	formyl peptide receptor 2	Homo sapiens	105-109
22205391-2	2012	Native lipoxin A(4) (LXA(4)) binds to the G protein-coupled lipoxin receptors formyl peptide receptor 2 (FPR2)/ALX and CysLT1.	lipoxin A4	7-16	hematopoietic SH2 domain containing	Homo sapiens	111-114
22205391-2	2012	Native lipoxin A(4) (LXA(4)) binds to the G protein-coupled lipoxin receptors formyl peptide receptor 2 (FPR2)/ALX and CysLT1.	lipoxin A4	7-16	cysteinyl leukotriene receptor 1	Homo sapiens	119-125
22205391-10	2012	Furthermore, LXA(4) preincubation with human submandibular gland cell line (HSG) also blocked TNF-alpha-mediated upregulation of vascular cell adhesion molecule-1 (VCAM-1) in these cells, and it reduced lymphocyte adhesion.	lipoxin A4	13-19	tumor necrosis factor	Homo sapiens	94-103
22205391-10	2012	Furthermore, LXA(4) preincubation with human submandibular gland cell line (HSG) also blocked TNF-alpha-mediated upregulation of vascular cell adhesion molecule-1 (VCAM-1) in these cells, and it reduced lymphocyte adhesion.	lipoxin A4	13-19	vascular cell adhesion molecule 1	Homo sapiens	129-162
22205391-10	2012	Furthermore, LXA(4) preincubation with human submandibular gland cell line (HSG) also blocked TNF-alpha-mediated upregulation of vascular cell adhesion molecule-1 (VCAM-1) in these cells, and it reduced lymphocyte adhesion.	lipoxin A4	13-19	vascular cell adhesion molecule 1	Homo sapiens	164-170
22943296-4	2012	RESULTS: Inferring from molecular docking studies, lipoxin A4 (LXA4), and a known anti-inflammatory bioactive metabolite derived from PUFAs, with a binding energy of -3.98 Kcal/mol and dissociation constant of 1.2 mM showed highest binding affinity for BDNF in comparison to other PUFAs and metabolites considered in the study.	lipoxin A4	51-61	brain derived neurotrophic factor	Homo sapiens	253-257
22661361-0	2012	Lipoxin A4 inhibits 5-lipoxygenase translocation and leukotrienes biosynthesis to exert a neuroprotective effect in cerebral ischemia/reperfusion injury.	lipoxin A4	0-10	arachidonate 5-lipoxygenase	Rattus norvegicus	20-34
21944479-0	2012	Protective role of cyclooxygenase (COX)-2 in experimental lung injury: evidence of a lipoxin A4-mediated effect.	lipoxin A4	85-95	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	19-41
22662206-7	2012	In non-CF and CF bronchial epithelia, LXA(4) stimulated whole-cell Cl(-) currents which were inhibited by NPPB (calcium-activated Cl(-) channel inhibitor), BAPTA-AM (chelator of intracellular Ca(2+)) but not by CFTRinh-172 (CFTR inhibitor).	lipoxin A4	38-44	natriuretic peptide B	Homo sapiens	106-110
22662206-7	2012	In non-CF and CF bronchial epithelia, LXA(4) stimulated whole-cell Cl(-) currents which were inhibited by NPPB (calcium-activated Cl(-) channel inhibitor), BAPTA-AM (chelator of intracellular Ca(2+)) but not by CFTRinh-172 (CFTR inhibitor).	lipoxin A4	38-44	CF transmembrane conductance regulator	Homo sapiens	211-215
22215599-7	2012	Lipoxin A(4) (LXA(4)) can also interact with ALX/FPR2 receptors and lead to allosteric inhibition of SAA-initiated epithelial responses (pA(2) 13 nM).	lipoxin A4	0-9	hematopoietic SH2 domain containing	Homo sapiens	45-48
22215599-7	2012	Lipoxin A(4) (LXA(4)) can also interact with ALX/FPR2 receptors and lead to allosteric inhibition of SAA-initiated epithelial responses (pA(2) 13 nM).	lipoxin A4	0-9	formyl peptide receptor 2	Homo sapiens	49-53
22215599-7	2012	Lipoxin A(4) (LXA(4)) can also interact with ALX/FPR2 receptors and lead to allosteric inhibition of SAA-initiated epithelial responses (pA(2) 13 nM).	lipoxin A4	0-9	serum amyloid A1 cluster	Homo sapiens	101-104
21671842-7	2011	In a final regression model, serum lipoxin A(4) levels were positively correlated with age, female gender, white blood cell counts, and interleukin-5 levels in all patients, while asthma patients had lower serum lipoxin A(4) levels compared to the other two groups.	lipoxin A4	35-44	interleukin 5	Homo sapiens	136-149
21885654-3	2011	In the present study, we investigated the role of lipoxin A(4) (LXA(4)) in the endometrium and demonstrated that 15-LOX-2, an enzyme necessary for LX biosynthesis, is expressed in this tissue.	lipoxin A4	50-62	arachidonate 15-lipoxygenase type B	Homo sapiens	113-121
21885654-3	2011	In the present study, we investigated the role of lipoxin A(4) (LXA(4)) in the endometrium and demonstrated that 15-LOX-2, an enzyme necessary for LX biosynthesis, is expressed in this tissue.	lipoxin A4	64-70	arachidonate 15-lipoxygenase type B	Homo sapiens	113-121
21307335-0	2011	Leukotriene B4/antimicrobial peptide LL-37 proinflammatory circuits are mediated by BLT1 and FPR2/ALX and are counterregulated by lipoxin A4 and resolvin E1.	lipoxin A4	130-140	cathelicidin antimicrobial peptide	Homo sapiens	37-42
21555360-7	2011	Finally, we have shown that lipoxin A(4) can suppress phorbol myristate acetate-induced expression of the inflammatory cytokines interleukin 6 and 8 in human endometrium and decidua tissue.	lipoxin A4	28-37	interleukin 6	Homo sapiens	129-148
21552771-2	2011	Lipoxin A4 (LXA4) strongly attenuated lipopolysaccharide (LPS)-induced hyperpermeability through maintaining the normal expression of VE-cadherin and a-catenin.	lipoxin A4	0-10	cadherin 5	Homo sapiens	134-145
21552771-2	2011	Lipoxin A4 (LXA4) strongly attenuated lipopolysaccharide (LPS)-induced hyperpermeability through maintaining the normal expression of VE-cadherin and a-catenin.	lipoxin A4	12-16	cadherin 5	Homo sapiens	134-145
21555360-1	2011	Lipoxin A(4) is a lipid mediator that elicits anti-inflammatory and pro-resolution actions via its receptor, formyl peptide receptor 2 (FPR2/ALX).	lipoxin A4	0-9	formyl peptide receptor 2	Homo sapiens	136-140
21555360-1	2011	Lipoxin A(4) is a lipid mediator that elicits anti-inflammatory and pro-resolution actions via its receptor, formyl peptide receptor 2 (FPR2/ALX).	lipoxin A4	0-9	hematopoietic SH2 domain containing	Homo sapiens	141-144
21555360-6	2011	We found that lipoxin A(4) was regulated by human chorionic gonadotrophin (hCG) during early pregnancy, because treatment of human decidua tissue with hCG increased lipoxin A(4) release (P&lt;0.01).	lipoxin A4	14-23	hypertrichosis 2 (generalised, congenital)	Homo sapiens	75-78
21555360-6	2011	We found that lipoxin A(4) was regulated by human chorionic gonadotrophin (hCG) during early pregnancy, because treatment of human decidua tissue with hCG increased lipoxin A(4) release (P&lt;0.01).	lipoxin A4	14-23	hypertrichosis 2 (generalised, congenital)	Homo sapiens	151-154
21555360-6	2011	We found that lipoxin A(4) was regulated by human chorionic gonadotrophin (hCG) during early pregnancy, because treatment of human decidua tissue with hCG increased lipoxin A(4) release (P&lt;0.01).	lipoxin A4	165-174	hypertrichosis 2 (generalised, congenital)	Homo sapiens	75-78
21555360-6	2011	We found that lipoxin A(4) was regulated by human chorionic gonadotrophin (hCG) during early pregnancy, because treatment of human decidua tissue with hCG increased lipoxin A(4) release (P&lt;0.01).	lipoxin A4	165-174	hypertrichosis 2 (generalised, congenital)	Homo sapiens	151-154
21501589-3	2011	In this study, we investigated the inhibitory effect and the molecular mechanism of the lipoxin A(4) (LXA(4)) on the production of interleukin-1beta (IL-1beta) and tumor necrosis factoralpha (TNFalpha) induced by beta-amyloid in the cortex and hippocampus of mice, and in Abeta-stimulated BV2 cells, a mouse microglial cell line.	lipoxin A4	88-97	interleukin 1 beta	Mus musculus	131-148
21501589-3	2011	In this study, we investigated the inhibitory effect and the molecular mechanism of the lipoxin A(4) (LXA(4)) on the production of interleukin-1beta (IL-1beta) and tumor necrosis factoralpha (TNFalpha) induced by beta-amyloid in the cortex and hippocampus of mice, and in Abeta-stimulated BV2 cells, a mouse microglial cell line.	lipoxin A4	88-97	interleukin 1 alpha	Mus musculus	150-158
21501589-3	2011	In this study, we investigated the inhibitory effect and the molecular mechanism of the lipoxin A(4) (LXA(4)) on the production of interleukin-1beta (IL-1beta) and tumor necrosis factoralpha (TNFalpha) induced by beta-amyloid in the cortex and hippocampus of mice, and in Abeta-stimulated BV2 cells, a mouse microglial cell line.	lipoxin A4	88-97	tumor necrosis factor	Mus musculus	192-200
21501589-3	2011	In this study, we investigated the inhibitory effect and the molecular mechanism of the lipoxin A(4) (LXA(4)) on the production of interleukin-1beta (IL-1beta) and tumor necrosis factoralpha (TNFalpha) induced by beta-amyloid in the cortex and hippocampus of mice, and in Abeta-stimulated BV2 cells, a mouse microglial cell line.	lipoxin A4	88-97	amyloid beta (A4) precursor protein	Mus musculus	272-277
21501589-5	2011	Our findings suggest that LXA(4) inhibits the production of IL-1beta and TNFalpha induced by beta-amyloid in the cortex and hippocampus of mice, and in BV2 microglial cells via the NF-kappaB signal pathway.	lipoxin A4	26-32	interleukin 1 alpha	Mus musculus	60-68
21501589-5	2011	Our findings suggest that LXA(4) inhibits the production of IL-1beta and TNFalpha induced by beta-amyloid in the cortex and hippocampus of mice, and in BV2 microglial cells via the NF-kappaB signal pathway.	lipoxin A4	26-32	tumor necrosis factor	Mus musculus	73-81
21501589-5	2011	Our findings suggest that LXA(4) inhibits the production of IL-1beta and TNFalpha induced by beta-amyloid in the cortex and hippocampus of mice, and in BV2 microglial cells via the NF-kappaB signal pathway.	lipoxin A4	26-32	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	181-190
21398608-3	2011	Addition of LXA(4) to human polymorphonuclear leukocytes (PMNs) provoked a concentration- and time-dependent mobilization of AnxA1 onto the plasma membrane, as determined by Western blotting and flow cytometry analyses.	lipoxin A4	12-18	annexin A1	Homo sapiens	125-130
21220563-0	2011	EGF stimulates lipoxin A4 synthesis and modulates repair in corneal epithelial cells through ERK and p38 activation.	lipoxin A4	15-25	pro-epidermal growth factor	Oryctolagus cuniculus	0-3
21330635-10	2011	In the fat-1-treated mice, proinflammatory arachidonic-derived mediators as prostaglandin E2 and 12-hydroxyeicosatetraenoic acid were decreased and the anti-inflammatory lipoxin A4 was detected.	lipoxin A4	170-180	FAT atypical cadherin 1	Mus musculus	7-12
21575454-11	2011	CONCLUSION: Our findings demonstrated that LXA(4) could prevent the endothelial cell hyperpermeability induced by LPS in HUVEC under which the possible mechanism was through inhibiting the expression of NF-kappaB and its related cytokines through receptor-dependent.	lipoxin A4	43-49	nuclear factor kappa B subunit 1	Homo sapiens	203-212
21181369-0	2010	Effect of lipoxin A4 on IL-1beta production of monocytes and its possible mechanism in severe preeclampsia.	lipoxin A4	10-20	interleukin 1 beta	Homo sapiens	24-32
21181369-1	2010	This study examined in vitro effect of lipoxin A(4) (LXA(4)) on interleukin-1beta (IL-1beta) production of monocytes and its possible mechanism in severe preeclampsia (PE).	lipoxin A4	39-48	interleukin 1 beta	Homo sapiens	64-81
21181369-1	2010	This study examined in vitro effect of lipoxin A(4) (LXA(4)) on interleukin-1beta (IL-1beta) production of monocytes and its possible mechanism in severe preeclampsia (PE).	lipoxin A4	39-48	interleukin 1 beta	Homo sapiens	83-91
21181369-8	2010	It was concluded that LXA(4) may inhibit the IL-1beta production of monocytes from severe preeclampsia women by inhibiting extracellular calcium influx.	lipoxin A4	22-28	interleukin 1 beta	Homo sapiens	45-53
20930115-6	2011	Increases in cyclin D1 protein induced by FCS or LXA(4) were blocked by the PI3 kinase inhibitor, LY294002, and attenuated by FPR2 antagonism using Boc2.	lipoxin A4	49-55	cyclin D1	Homo sapiens	13-22